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ABSTRACT
Murine models of infection with the protozoan parasite Leishmania major 
cause either a local, healing cutaneous lesion or a fatal, disseminated disease depending 
on the strain of the mouse. This is due to the preferential development of T helper 1 
(Thl) response in the resistant mice and of T helper 2 (Th2) response in the susceptible 
mice. It has been shown, however, that upon injection with a low dose of the parasite, 
susceptible mice are capable of developing protective immunity by favouring a Thl 
response. Moreover, the subcutaneous injection of high doses of Leishmania major in 
the hind paw of susceptible mice leads to an obvious hyperalgesia even before the 
appearance of the lesion (which is accompanied by the up-regulation of some pro- 
inflammatory cytokines such as IL-ip and IL-6).
On the other hand, IL-10 and IL-13, produced mainly by Th2 cells, have been 
shown to have hypoalgesic effects in other models. This thesis investigates the effect of 
IL-10 and IL-13 on the L. major-inàwcQd inflammation in mice with respect to 
hyperalgesia and course and outcome of infection. We demonstrate that the injection of 
susceptible mice (BALB/c mice) with a low dose of L. major causes a state of 
hyperalgesia during early infection accompanied by an up-regulation of IL-lp and a 
short burst of IL-6. This low pain threshold and the high level of IL-lp are reversed 
within two weeks of infection.
We also demonstrate that IL-10 and IL-13 are able to reduce this evoked 
hyperalgesia in both, the high and the low dose models. However, the early presence of 
the hypoalgesic doses of those two cytokines leads to a prolonged hyperalgesia and 
inhibits the suspected Th2/Thl switch in the low dose model.
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CHAPTER 1 
INTRODUCTION
1.1. Leishmania major
1.1. L General Description
Leishamania major is an obligate intracellular parasitic protozoan of 
mononuclear phagocytes (Grimaldi Jr, 1982; Marzochi and Marzochi, 1994) that 
belongs to the kingdom Protista, phylum Sarcomastigophora, subphylum mastigophora, 
class Zoomastigophora, order Kinetoplastida, suborder Trypanosomatina, family 
Tiypanosomidae, genus Leishmania (Molyneux and Ashford, 1983).
The taxonomy of this genus is complex and often confusing since the 
differentiation is not based on the morphology of the organism but on the pathology and 
symptoms of the disease, site of infection, vector species and reservoir hosts. In 
addition, biochemical and serological factors are also used for characterization of the 
species complex. There are five principal species complexes, three “old world” and 2 
“new world”. There are two distinct types of diseases caused by the different species of 
Leishamania: visceral leishmaniasis (Kala Azar) and cutaneous leishmaniasis. The 
visceral leishmaniasis is caused by Leishmania donovani (old world) and it affects 
mainly males and children up to 10 years. Cutaneous leishmaniasis: occurs in two 
distinct forms both in the old world and in the new world. These are described below. 
New World:
• Leishmania mexicana: causes a single painless lesion that heals within few
months.
• Leishmania braziliensis: causes single or multiple ulcers that seldom heal
spontaneously.
Old World;
• Leishmania tropica: causes a disease characterized by a dry cutaneous lesion 
which ulcerates but eventually heals leaving disfiguring scars (Ebrahimzadeh and 
Thomas., 1983).
• Leishmania major: causes a disease characterized by a moist lesion (usually 
on the limbs) that ulcerates early. The lesions are slow to heal and they leave large 
disfiguring scars (Le blancq et al, 1986).
Leishmania major occurs in two distinct forms, the flagellated promastigote 
(which is also the infective stage) and the non-flagellated, amastigote, which is the 
intracellular stage, residing and multiplying within the macrophages of mammalian 
hosts (Molyneux and Ashford, 1983). The amastigotes are spherical or ovoid in shape, 
about 2.5 to 5pm in diameter, and are contained within a parasitophorous vacuole in the 
macrophage. There is a prominent nucleus and kinetoplast with a non-emergent 
flagellum. The cytoplasm is vacuolated and contains lysosomes. The amastigotes 
contain exclusively megalysosomes, which are thick, membraneous organelles 
containing digestive enzymes (Coombs et a l, 1986) (Figure 1.1). Under the light 
microscope the promastigotes (14-20pm in size) appear fusiform with a long flagellum 
and a pointed posterior end, with the obvious presence of a nucleus and kinetoplast. 
Moreover, the mitochondria are quite abundant in the promastigote. Both forms 
multiply by binary fission (Gamham, 1971) (Figure 1.2).
Figure 1.1. Leishmania tropica amastigotes in a still intact macrophage practically filled with 
amastigotes, several of which have clearly visible a nucleus and a kinetoplast. WHO/Pasteur
%
S .
Figure 1.2. Stained Leishmania donovani promastigotes from a culture show a long slim body, a 
central nucleus, a kinetoplast with a long anterior flagellum. WHO
1.1.2. Life Cycle
The promastigote form is injected under the skin of the host by a blood sucking 
sandfly vector (Behin and Louis, 1984). Once within the host, the parasite is 
phagocytozed by a macrophage and transforms to the non-flagellated amastigote form 
by undergoing many physiological and morphological changes (Denny et al., 2005). 
The amastigotes next replicate within the macrophage by binary fission until the host 
cell ruptures liberating the amastigotes that are taken-up in turn by other macrophages. 
This reproductive cycle is repeated many times. The amastigotes within the 
macrophages are ingested by female sandflies when they take a blood meal from 
infected margin of ulcers. Once inside the midgut of the sandfly, the amastigotes are 
freed from host cells by digestion. The parasites then transform into promastigotes, the 
infective stage of mammalian hosts. Promastigotes undergo several cycles of division 
by binary fission and they travel to the foregut and esophagus, where they reach the 
sandfly’s saliva and become ready to be injected during the next blood meal. During 
this time the saliva promotes survival and development of the promastigotes (Ghosh and 
Mukhopadhyay, 1998) (Figure 1.3).
1.1.3. Clinical Description
Leishmaniasis threatens 350 million people in 88 countries of four continents. 
The incidence of new cases is estimated between 1.5 and 2 million each year (Desjeux, 
1999). Visceral Leishmaniasis, the most acute form of the disease, is considered a 
poverty illness. Individuals suffering from malnutrition are the most susceptible to the 
severe form of the disease, while healthy individuals are hardly ever infected (Cerf et 
al., 1987; Fargeas et al., 1996). Visceral Leishmaniasis is also observed as an 
opportunistic disease in AIDS patients (Alvar, 1994; Rosenthal et al, 1995). New
disease symptoms have immerged, such as viseerotropic Leishmaniasis caused by 
Leishmania tropica observed in veterans o f Operation Desert Storm (Magill, 1993; 
Dillon, 1995; Magill, 1995).
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Figure 1.3. Leishmania life cycle. CDC DPDx Parasite Image Library
Leishmania major causes a zoonotic or rural cutaneous leishmaniasis. It 
involves wild and domestic animals as reservoir hosts, with man being an accidental 
host (Ashford, 1996). Most o f the reservoir hosts are adapted to Leishmania and are 
weakly infected, and the infection can persist for many years. A notable exception is the 
dog, which develops a generalized and lethal disease (Dedet, 2002).
Leishmania major causes a wet and ulcerative lesion which is normally self- 
limiting. Healing, which occurs after several months, is accompanied by infiltration by 
lymphocytes and plasma cells and the complete elimination o f the parasite (Zuckerman,
1975). The initial lesion begins as a small erythematous papule, which appears at the 
site of promastigote inoculation. It increases slowly and the papule breaks down and 
becomes crusted. The ulcer is usually shallow and circular with raised borders. This 
type has a brief incubation period. Ulcers heal spontaneously in an interval of time 
ranging from 6 to 12 months leaving a depressed, atrophic, depigmented scar (Pearson 
and De Queiroz Sousa, 1995). The size and duration of the lesion in mice depends on 
the infecting dose (Preston and Dumonde, 1976; Preston et al., 1978) and on the genetic 
predisposition of the strain, e.g. CBA are highly resistant to L. major whilst BALB/c are 
extremely susceptible (Howard et al., 1980).
1.2. Leishmaniasis Immunology
1.2.1. Introduction
Parasites, like other micro-organisms, stimulate the immune response and elicit 
antibody production or cell mediated immunity. There are essentially three aspects to 
be considered in the immunological relationship between mammals and their parasites: 
(a) The way the parasite presents itself to its host's immune system; (b) the way the host 
responds to this exposure; (c) and the way the parasite responds to the mechanisms the 
host brings to bear against it.
When a pathogen is encountered, an animal generally responds with a humoral 
or a cellular response (Parish, 1972; Katssura, 1977; Scott et al., 1989; Muller et al., 
1989). However, Leishmania escapes from the humoral response by hiding as an 
amastigote inside the phagolysosomes of the host macrophage. Since the intracellular 
parasite is not exposed to the host’s humoral response, circulating antibodies have no 
effect on the infection. Thus, immunity is mainly cell-mediated and this is based on the 
following observations: (1) depletion of B-cells in animals has no effect on the course
of infection (2) suppression of antibodies with anti-IgM has no effect (3) high levels of 
IgM and IgG are found, hut these do not protect against infection (Fiorentino et al.,
1989).
A possible reason why either the cellular or the humoral immune responses 
prevails in leishmaniasis has emerged from studies of T helper cells showing that two 
mouse CD4^ cell subsets designated as Thl and Th2 can he distinguished on the basis 
of their pattern of cytokine secretion (Romagnani, 1991; Street and Mosmann, 1991). In 
the murine model of leishmaniasis, the outcome of infection depends on the activation 
of one of the two subsets of CD4^ T cells (Reiner and Locksley, 1995; Bogdan et al., 
1996).
1.2.2. Leishmanial Antigens
After developing in the sandfly vector to a promastigote stage, the parasite 
displays a major glycoprotein of 62 - 65 Kilodaltons termed gp63 or leishmanolysin, 
which is encoded by 7 genes. This protein is inserted into the parasite membrane via a 
glycosylphosphatidilinonsital (GPI) anchor (Glaser et al, 1991; Zufferey and Mamoun, 
2005). Gp63 is expressed in 500 000 copies on each promastigote constituting about 1% 
of the total cell protein. Gp63 is a zinc-dependent endopeptidase, which can be inhibited 
by heavy metal ions. This leishmanial antigen is an active protease (Etges et al., 1986). 
It enables the promastigotes, released from the sandfly, to counteract humoral responses 
until they complete their entry into the host macrophage and start the intracellular phase 
of the life cycle. In addition, this same surface glycoprotein is involved in binding the 
host serum complement C3 in order to be phagocytosed by the macrophages through 
binding of the C3 receptor (Blackwell et al., 1986).
Gp63 is one of the parasite virulence factors due to the following: (1) it aids in
the binding of the parasite to the macrophage (Russell and Wilhelm, 1986), (2) it can 
degrade lysosomal enzymes and thereby protect the parasites from being digested and 
(3) treatment of infective promastigotes with anti-gp63 monoclonal antibodies inhibits 
intracellular parasite survival (Bouvier et al., 1989; Joshi et al., 2002). Purified gp63 
reconstituted into liposomes produced protective immunity in both resistant and 
susceptible mice (Russell and Alexander, 1988) although the protection in BALB/c 
mice was less complete. Moreover, in contrast to subcutaneous injection of gp63, which 
failed to induce immunity, significant protection was achieved if the gp63 was 
administered intravenously (Kahl et al., 1989; Theodos et al., 2004).
Lipophosphoglycan (LPG) is present on all Leishmania species. It is a complex 
phosphorylated oligosaccharide, which also has a glycosylphosphatidilinonsital (GPI) 
anchor. It is a relatively small molecule (9 Kilodaltons) with a repeating phosphorylated 
oligosaccharide structure and an unusual heptasaccharide leading to the fatty acid 
terminus, which is readily secreted by parasites in culture. The LPG has a bifunctional 
interaction with the host immune system (Turco, 1988). When the intact LPG is 
purified, it will elicit a protective immune response on vaccination; however, LPG can 
enhance the survival of the parasite within the macrophage which might be due to a 
number of mechanisms including scavenging free oxygen radicals (Chan et al., 1989; 
Spath et al., 2000), inhibition of monocyte and neutrophil activity (Frankenburg et al.,
1990) and inhibition of protein kinase C (McNeely and Turco, 1987) and signal 
transduction in macrophages (Descoteaux et al., 1991). However, cleavage of the lipid 
produces a carbohydrate group with a potent suppressive effect on the immune response 
and is capable of enhancing pathology when included in a vaccine. For this reason it is 
termed a disease promoting antigen (Mitchell and Handman, 1986). Glaser et al. (1991) 
have shown that LPG on the surface of the amastigote of Leishmania major is
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antigenically and biochemically distinct from promastigote LPG.
Apart from LPG and gp63, the only other characterized surface molecules of 
Leishmania include gp46, several transporter-like molecules such as an ATP-ase and a 
newly discovered family of surface glycoproteins termed the promastigote surface 
antigen-2 (PSA-2) complex. As with LPG and gp63, the PSA-2 proteins are linked to 
the parasite surface membrane via a glycosylphosphatidilinonsital (GPI) linkage 
(Murray and Spichill, 1991). Handman et al. (1995) have identified three polypeptides 
of Leishmania major belonging to the PSA-2 family. The three polypeptides with 
approximate molecular weights of 96, 80 and 50 Kilodaltons are products of different 
genes with similar, but distinct amino-acid terminal sequences (Symons et al., 1994). 
The deduced amino-acid sequences of Leishmania major PSA-2 genes cloned to date 
show significant homology throughout the molecule and are identical at the carboxyl - 
terminal end. Although PSA-2 polypeptides were thought initially to occur in 
promastigotes only (Murray and Spichill, 1991), other researchers have obtained clear 
evidence that some, but not all, PSA-2 polypeptides are also present in amastigotes 
(Handman et al., 1995). Peripheral blood mononuclear cells activated by PSA-2 
produced high amounts of interferon-y and tumour necrosis factor-)!, and little 
interleukin-4, thereby showing a Thl cytokine pattern (Kemp et al., 1998).
1.2.3. Innate Immunity
1.2.3.1. Introduction
Directly after infection by the parasites, a local inflammatory response is 
initiated to remove damaged tissue and to heal the wound. First, neutrophilic and 
eosinophilic granulocytes infiltrate the wound (Muller et al., 2001), then an invasion of 
inflammatory macrophages occurs and dominates the infected area. At this early stage
lymphocytes are barely detected (Beil et al., 1992; Sunderkotter et al., 1993). Before 
the invasion of the macrophages, most of the promastigotes are either dead or have 
penetrated local cells (Mirkovich etal., 1986; Greil etal., 1988).
1.2.3.2. Entrance and Survival of the Parasite
Once injected, the promastigotes activate the complement system through the 
classical pathway leading to the fixation of the C3 fragment on the leishmanial plasma 
membrane and then its cleavage into C3b which can bind to LPG or gp63. This process 
can lead to the destruction of the parasite through the formation of the complex C5b-9 
(Sacks and Perkins, 1984; Filippi et al., 2001). However, gp63 catalyses the conversion 
of C3 into the inactive protein C3bi. Furthermore, the promastigotes have on their 
plasma membrane protein kinases which can inactivate C3 and C3b by phosphorylating 
them. Finally, LPG can prevent the attachment of C5b-9 on the plasma membrane of the 
promastigotes (Filippi et al, 2001). The promastigotes can then be attacked by 
neutrophils which, although in their absence lesions and the parasite burden are 
exacerbated, are not necessary for resistance since the lesion will ultimately heal (in 
resistant mice) (Tacchini-Cottier et al, 2000). Furthermore, macrophages were shown 
to phagocytose apoptotic neutrophils which have already ingested the parasite. 
Leishmania internalized by this indirect way can survive and multiply in macrophages 
which will secrete the anti-inflammatory cytokine tumor growth factor-p (TGF-p) (van 
Zandbergen et al, 2004). Natural Killer (NK) cells also appear at the site of infection 24 
hours after infection and this migration seems to correlate with the expression of the NK 
cell-activating chemokine IP-10 in resistant mice. Treatment of BALB/c mice with 
recombinant mouse IP-10 increases NK cell cytotoxicity in the draining lymph nodes 
(Muller e ta l, 2001).
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The internalisation of the parasites by macrophages is thought to be through 
receptor-mediated phagocytosis (Handman, 1999). The entry of promastigotes into 
macrophages involves a number of receptors including the mannose-fructose receptor, 
the fibronectin receptor, the Fc receptor and the complement receptors CRl and CR3 
(also called CD lib ) (Alexander et al., 1999). Then the promastigotes are taken inside 
the phagocytes by either “coiling phagocytosis” or “zipperlike” interactions (Rittig et 
a\., 1998a; Rittig et al, 1998b) and they fuse with lysosomal vacuoles to form the 
phagolysosomes or parasitophorous vacuoles (PV) where the promastigotes are 
converted into amastigotes and where they reside and multiply (Antoine et al, 1998). 
Despite the importance of the amastigotes in leishmaniasis, little is known about the 
molecules involved in their entry into macrophages (Henri et al, 2002). However, 
studies on L. major have have shown that the amastigotes can use a lectin like receptor 
that recognizes LPG (Kelleher et al, 1995) and CR3, indicating also a major role for 
opsonisation with immunogloulin and entry into macrophage using their Fc receptor 
(Guy and Belosevic, 1993). Thus, the parasite makes positive use of an element of the 
host's defensive mechanisms to secure entry into the macrophage (Blackwell et al., 
1986). However, this is a very hostile environment where cells taken up by the 
macrophages are normally destroyed by several mechanisms:
• Oxidative burst: phagocytosis of a foreign body activates an NAD(P)H 
oxidase in the plasma membrane which transfers protons to molecular oxygen forming 
reactive oxygen intermediates (ROI) such as superoxide anion (O2)' and hydrogen 
peroxide and hydroxyls radicals. These will react with the pathogen’s phospholipid 
membrane and also with its macromolecules. Thus, they are the major killing 
mechanisms (Hughes, 1988). Furthermore, hydrogen peroxide (H2O2) has been shown 
to be leishmanicidal with the promastigotes being more susceptible than the amastigotes
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(Pearson et al., 1983). This correlates with the ability of amastigotes to stimulate less 
release of H2O2 from mononuclear cells than the promastigote and produces their own 
superoxide dismutase (Spath et al, 2000) which are able to generate reduced 
glutathione, a free radical scavenger. These may provide an important defence against 
free radicals generated by the macrophage (Channon and Blackwell, 1985).
• Acidification: after fusion of the phagosome with the endosome, the vesicle 
is acidified by a proton ATPase. The low pH causes dénaturation of proteins that then 
become susceptible to acid hydrolases (Zilberstein and Shapira, 1994; Saar et al., 1998). 
It has been suggested that the amastigote membranes possess a proton pump, which 
actively translocates protons from the parasite's cytoplasm into the lysosomal vacuole. 
This establishes an electrochemical gradient, which drives the uptake of glucose and 
amino acids by the parasite. The effect of this pump may be also to lower the pH of the 
lysosomal contents and impair the activity of the lysosomal enzymes. Thus, the 
amastigotes are known to be acidophiles having their optimal metabolism at pH 4. An 
alternative view is that lysosomal-like organelles found within the amastigotes, may 
play a role in parasite survival by modulating the phagolysosomal environment. Their 
effect may be to produce ammonia which raises the pH of the lysosomal vacuole and 
inhibits lysosomal enzymes (Scott, 1985).
• Digestion: the endosome fuses with primary lysosomes, and acid hydrolases 
are released which degrade DNA, RNA, proteins and carbohydrate. However, many 
mechanisms have also been suggested through which the parasites evade this defence 
strategy; there are the so-called "excreted factors" which are negatively charged 
carbohydrates that may have an inhibitory effect on lysosomal enzymes. Furthermore, 
the surface properties of the amastigote may resist enzyme degradation, as the 
transformation from promastigote to amastigote following phagocytosis is accompanied
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by the acquisition of resistance to the digestive capacity of the macrophage (Mitchell, 
1982). This is done primarily by masking the surface proteins by the glyco-inositol- 
phospholipids (Filippi eta l, 2001).
In contrast to promastigotes, the killing of intracellular amastigotes is by non- 
oxidative mechanisms, namely nitric oxide (NO). The macrophages have another 
protective system in which IFN-y, TNF-a, migration inhibitory factor (MIF), IL-1, IL- 
1 2  and possibly other cytokines, occupying their respective receptors on the 
macrophage, send a series of signals which, in the presence of LPS, lead to the 
production of nitric oxide synthase (NOS) leading to the synthesis of nitric oxide (NO). 
This substance is derived from a reaction with the terminal guanidine nitrogen of the 
amino acid L-arginine and molecular oxygen in the presence of the enzyme nitric oxide 
synthase (NOS). NO reacts with itself, water and oxygen to generate nitrogen dioxide 
(NO2) and then nitrite (NO2 ) and nitrate (NO3 ). Those products are collectively known 
as reactive nitrogen intermediates (RNI) (Liew and O’Donnell, 1993). Birkland et a l 
(1992) described a mechanism of macrophage activation for antimicrobial defence that 
involves direct cell contact between CD4^ (T-helper) lymphocytes and Leishmania- 
infected macrophages. The mechanism is distinctive since it does not involve secretion 
of lymphokines but is apparently mediated by the membrane-bound form of tumor 
necrosis factor (mTNF-a, 50-60 kd) present on the surface of the effector T- 
lymphocytes and its expression is antigen - specific and genetically restricted. These 
studies indicate that the Te/s/zwanzfl-specific cloned T-lymphocytes that express 
membrane bound TNF but does not secrete TNF or other macrophage activators, can 
activate anti-leishmanial defense inflammatoiy macrophages, whereas soluble TNF 
(sTNF) alone is unable to do so. On the other hand, both kinds of cells can act 
synergistically with IFN- y (a known macrophage - activating factor) in activating
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antimicrobial defence and NO2' release. All these effects have been shown to be 
arginine-dependent (Birkland et al., 1992). In contrast to IFN-y, TNF-a, (MIF), IL-1, 
IL-12 which in the presence of LPS lead to the induction of nitric oxide synthase 
(NOS), other cytokines such as IL-3, IL-4, transforming growth factor (TGF-P), IL-10 
and IL-13 send a series of signals which act in the opposite direction, inhibiting the 
expression of nitric oxide synthase (NOS) (Liew et al., 1991; Weiss et al, 1997). As to 
MIF, it was shown that its effect on the activation of the leishmanicidal activity of 
macrophages depends on TNF-a produced endogenously by those cells, because the 
administration of anti-TNF-a antiserum significantly reduced the MIF effect. This 
effect seems also to involve iNOS since macrophages form iNOS-deficient mice don’t 
respond to MIF (Juttner et a l, 1998; Satoskar et al, 2001). The mechanism by which 
the parasites are killed seems to involve the covalent bond between NO and iron leading 
to the inactivation of many enzymes of the mitochondrial electron transport chain 
(Lancaster and Hibbs, 1990). However, the amastigotes are able to limit the production 
of those toxic substances (RIO and NO) especially by LPG and gp63 which inhibit their 
synthesis by acting on protein kinases (Turco, 1999) or by degrading its protein 
substrate, marcks Related Protein (MRP). Also, as mentioned the glyco-inositol- 
phospholipids of the Leishmania plasma membrane inhibit NO production. Finally, the 
macrophages infected with Leishmania produce little (if any) IL-12, an important 
cytokine in activating a protective immune response (Belkaid et al., 1998).
1.2.3.3. Factors Involved In the Spreading or Containment of the Parasite
After 2-5 hours injection of 2 x 10^  of L. major promastigotes into the hind 
footpad of BALB/c mice, parasites were found in the draining lymph nodes. 10-24 
hours later, parasites were found in the para-aortic lymph nodes, the spleen, the liver,
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the bone marrow, and, sometimes, the kidney (Laskay et al., 1995). In other mouse 
strains with a resistant phenotype like C57BL/6, CBA/J, and C3H/HeJ, the parasites did 
not spread and remained in the footpad and in the draining popliteal lymph node for 5 
days or more (Laskay et a l ,  1995).
In SCID mice, which lack functional T and B cells but have high potential o f  
functional NK cells, spreading o f the parasite did not occur (Kumar et al., 1989). This 
proposes a key role for NK cells in regulating the spreading o f parasites. In fact, treating 
resistant C57BL/6 mice with anti-NK cell antibody, led to rapid parasite spreading 
(Solbach and Laskay, 1998). Study o f the causal mechanism showed that NK cells 
quickly produced IFN-y after activation by both parasite antigens and IL-12, which in 
turn prevented parasite dissemination (See Figure 1.4) (Laskay et al., 1995).
■ ) IFNyRr
STAT1
IL-12R62
iFNy Fig-
Infected macrophage
OD 
oO OO oO
pSSOQ p40*
IL-12  heterodim er
IL-1201)1"
T cell/natural killer ce ll
Figure 1.4. Overview of the roles of interleukin 12 (IL-12) and interferon y (IFN-y) in 
mycobacterial immunity. IL-12 is a heterodimeric cytokine released by infected macrophages. 
IL-12 consists o f two subunits p35 and p40. IL-12p70 is the biologically active fonn o f IL-12 
and it is formed by the two subunits molecule. IL-12p70 binds with high-affmity to IL-12R on 
natural killer (NK) cells, CD4^ T helper 1 cells and cytotoxic T cells. 1L-12R is also 
heterodimeric and comprises two subunits, IL-12Rpi and IL-12R(32. when IL-12 binds to IL- 
12R complex; it generates intracellular events that result in the expression of some genes such 
as those encoding IFN-y. IFN-y is released by NK and T cells and binds to macrophages 
resulting in a cell-mediated immune response to intracellular pathogens within the infected 
macrophage. The receptor for IFN-y also consists o f two subunits: IFN-yRl, the ligand-binding 
chain (also known as a chain), and IFN-yR2, the signal-transducing chain (also known as the (3 
chain or accessory factor 1). As the ligand-binding chains interact with IFN-y they dimerise and 
induce intracellular events that activate, via STATl, a wide range o f IFN-y-responsive genes. 
IFN-yR is also expressed on T cells and NK cells. An asterix denotes proteins that are encoded 
by mutated genes associated with the condition mendelian susceptibility to mycobacterial 
disease (MSMD). (Expert Reviews in Molecular Medicine, 2003)
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In addition to NK cells, IFN-y and IL-12, studies propose a critical role fro IFN- 
a/p and inducible nitric oxide synthase (N0S2). C57BL/6 mice with a disrupted N0S2 
gene (N0S2'^’), allowed rapid dissemination of the parasites and developed disease, 
even with 500-2000 parasites (Laskay et al., 1995; Diefenbach et al., 1998). N0S2'^' 
mice showed very slight increase in IFN-y mRNA expression after one day of infection 
compared to N0S2'^^  ^ animals (Diefenbach et al., 1998), because early production of 
IFN-y in L. major infected mice is mainly due to NK cells (Scharton and Scott, 1993; 
Laskay e? al., 1993; Reiner et al, 1994). These findings propose that nitric oxide 
synthase2 (N0S2) expression is essential for containment of parasites by NK cells- 
mediated pathway (see Figure 1.5). Furthermore, nitric oxide synthase 2 (N0S2) 
expression and Leishmania containment are reliant on IFN-a/p, as treatment with an 
anti IFN-a/p antibody led to rapid parasite spreading (Diefenbach et a l, 1998).
The above data taken together propose that the early containment is coordinated 
by the collective action of IFN-y, IFN-a/p, IL-12, N0S2 and NK cells.
During the infection by L. major, the activation of NK cells appears to depend 
on a sensitive balance between stimulatory and inhibitory cytokines. As mentioned 
before, NK cells response is crucial for the resistance of Z. major infection. IL-12 plays 
a major role in NK cell activation, since blocking IL-12 in vivo stopped the early NK 
cell activation (Scharton-Kersten et al, 1995). In susceptible mice, the early production 
of IL-12 is accompanied by the production of cytokines such as TGF-P, IL-4 and IL-10 
that inhibit IL-12 function (Solbach and Laskay, 1998). It has been shown that when Z. 
cto«ovfl«z-infected macrophages did not increase their IL-12 production, dendritic cells 
produced enough IL-12 to set the microenvironment necessary for the initial activation 
of NK cells (Gorak et al, 1998). But NK cells could not alone maintain control of Z. 
major control, the need for CD4^ T cell-derived IFN-y is crucial for the development of
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a Thl healing response. Interestingly, IFN-y from non T-cells did not affect the Thl 
development (Wakil et al., 1998).
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Figure 1.5. Inducible Nitric Oxide Synthase (iNOS). Macrophages are important for early 
immune responses to invading microorganisms, and the production of nitric oxide (NO) is 
central to this function. NO is generated by inducible nitric oxide synthase (iNOS, macNOS, 
Type II NOS) following exposure to certain cytokines, such as interferon-y (IFN-y). The IFN-y 
receptor signals through the Janus kinase (JAK) family and signal transducers and activators of 
transcription (STAT) proteins. Receptor occupation and dimerization induces the 
phosphoiylation of associated STATs. Activated STATs dimerize and translocate to the nucleus 
where they increase expression o f the transcription factor, IRF-1, that, in turn, binds to specific 
DNA elements in the iNOS gene promoter region to increase iNOS gene expression. iNOS is a 
soluble enzyme that, unlike cNOS and nNOS, does not require elevated intracellular Ca2+ 
levels for activation. SIGMA-ALDRICH
In humans, NK cells are also implicated in the early defense to Leishmania 
infection. Stimulation o f blood lymphocytes from naïve individuals (not exposed to 
Leishmania) with L. aethiopica antigens in vitro, resulted in IFN-y proliferation. The
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main activated cell types were CDS’, CD16\ CD56^ NK cells. But the same stimulation 
in individuals with ongoing L. aethiopica infection, CD4^ T cells were the major 
activated cells (Laskay et al, 1991; Akuffo et al., 1993). This indicates that NK cell 
mediated response is limited to the early stage of infection in naïve individuals. 
However healed patients showed a NK response similar to that of the naïve individuals, 
in addition to proliferation of CD8  ^cells (Maasho et al., 1998). This proposes that NK 
cells may have, in addition to their role in the early response, a role in the preservation 
of the healing process.
1,2.4, Adaptive Immune Response
1.2.4.1. General Aspects
If the previous innate mechanisms fail, T helper (Th) lymphocytes will be 
activated in order to control the multiplication of the parasites. Thl and Th2 are two 
functionally distinct subpopulations of CD4^ Th cells. These cells are differentiated by 
the different cytokines they produce upon an infection (Abbas et al., 1996; Mosmann 
and Fowell, 2002). Thl cells preferentially produce IFN-y and IL-2, while Th2 cells are 
characterized by their secretion of IL-4, IL-5, and IL-10 (see Figure 1.6). And because 
these cytokines play specific and different roles in the immune responses, the 
domination of one of the CD4^ Th subset will shape the outcome of infection. Thl cells, 
by their secretion of IFN-y (which activates macrophages) and IL-2 (which activates 
Cytotoxic T Lymphocytes, CTLs) are very important for the initiation of a cell- 
mediated immune response opposed to intracellular pathogens (Collins and Kaufmann, 
2002; Scott and Grencis, 2002). Th2 cells on the other hand are important for the 
induction of humoral immune responses since they secrete cytokines involved in the 
activation and differentiation of B cells into antibody- secreting cells (Scott and
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Grencis, 2002).
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Figure 1.6. Upon the entry of Leishmania metacyclic promastigotes into macrophages and 
dendritic cells, the production of IL-12 from infected cells induces NK activation and Thl 
differentiation which produce IFN-y. IFN-y stimulates macrophages to express iNOS and 
therefore to produce NO mediating parasite killing and consequently a healing response. On the 
contraiy, failure to produce IL-12 leads to Th2 differentiation and therefore to increased 
production o f lL-4, IL-10 and lL-13 leading to the dissemination o f the parasite and therefore to 
a non-healing response (Alexander and Bryson, 2005).
Both Thl and Th2 cells differentiate from a ThO precursor cell. Early after an 
infection, the eytokines secreted by the non-specifie immune system eells will stimulate 
the differentiation o f ThO into Thl or Th2. For example, the quiek secretion o f  IL-12 
and IL-18 by monoeytes/macrophages, and IFN-y by NK cells will lead to 
differentiation o f ThO cells into Thl cells. Whereas the secretion o f IL-4 early during 
the infeetion, direct the Th differentiation toward Th2 (Alexander and Bryson, 2005).
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1.2.4.2. Susceptible Versus Resistant Mice
Cell-mediated, but not antibody mediated immune responses protect the host 
against certain pathogens that produce chronic diseases such as leishmaniasis. Effective 
vaccination against such pathogens must therefore produce an immunological "imprint", 
so that, stable cell-mediated immunity is induced in all individuals after natural 
infection. BALB/c mice seem to be innately susceptible to Leishmania major since they 
mount an antibody response to the parasite after infection. Resistant mouse strains such 
as CBA/J mice, in contrast, respond to infection with a stable cell-mediated response 
(Bretscher et a/., 1992).
Many factors may play a role in shaping the course of infection, mainly the 
genetic background of the host, the early cytokine milieu, the way the antigen is 
presented to Th cells, the co-stimulatory molecules and the dose of the parasite. Each 
factor plays a certain role and to different extents depending on the circumstances and 
influences the role of others (Doherty and Coffman, 1996).
• Genetic background o f the host:
Several different host genes control the infection of distinct species of 
Leishmania. In cutaneous leishmaniasis, the susceptibility of inbred mice to L. major is 
controlled by Scl-1, Scl-2 (Blackwell et al, 1985a,b) and H-11 linked genes. Expression 
of Scl-1 results in a macrophage defect allowing increased parasite multiplication in 
vitro in skin macrophages and differences in the ability of those macrophages to process 
and present antigens. This might be due to the reduced level of MHC class II antigens 
expressed by infected BALB/c mice (Gorezynski and Mac Rae, 1982).
• Cytokine milieu:
The cytokine milieu affects the Th cells subsets and therefore outcome of 
infection. Although there are many cytokines that affect the immune response to L.
2 0
major (discussed in details below), IL-4, IL-12 and IFN-y seem to play a pivotal role in 
shaping this response. The high level of IL-4 mRNA during the first 16 hours post­
infection leads to the maturation of Th2 cells (Launois et al., 1998). This effect is 
supposed to be due to the state of unresponsiveness to IL-12 induced by IL-4 (Louis et 
al., 1998) since in the absence of IL-12 the susceptibility to L .major depends on the 
inability to promote a Thl response rather than the development of a Th2 response 
(Mattner et al., 1997). Furthermore, the treatment of resistant mice with anti-IL-12 or 
IFN-y antibodies leads to the early secretion of IL-4 and therefore to non-healing lesions 
(Launois et al., 2002). Since L. major multiplies in macrophages, IFN-y exerts its 
parasiticidal effect by inducing the production on NO by these cells (Green et al., 1991). 
However, resistant mice lacking the ligand-binding chain of IFN-y receptor are 
susceptible to L. major but still mount a Thl response since there is no expansion of IL- 
4-producing Th cells (Swihart et al., 1994). Susceptible mice mount Th2-like responses, 
and produce IgGl antibody whereas resistant mice mount a Thl-like response with the 
production of IgG2a antibody. Such a change in isotope production is expected because 
INF- y produced by Thl cells promotes a class switch IgG2a rather than IgGl 
(Bretscher et al., 1992).
• Antigen presentation:
Th cells have special receptors, T cell receptors (TCR) which can bind
specifically to leishmanial antigens. However, in order to activate the Th cells, the
leishmanial antigens must be presented by the products of the major histocompatability
complex II (MHC II) on the surface of special antigen presenting cells (AFC). Although
macrophages are known to play a central role in the course of infection since they are
the primary host cells and since they function as APC for the induction of the cell
mediated response (Will et al., 1992) other cells can also function as APC such as
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Langerhans cells (LC) (the dentritic cells of the skin), follicular dendritic cells and 
interdigitating reticulum cells of the paracortex of the lymph node (ElHassan et al., 
1995).
The T-cell is stimulated to proliferate and secrete lymphokines when there is 
complementarity between an antigen presented by a dendritic cell and the T-cell 
receptor. This process is called sensitization or more simply activation (Flechner et al.,
1988). Once the sensitization of the resting T-helper cells is accomplished, these 
sensitized Th2 cells interact with B cells in the production of antibody (Vitetta et al.,
1989). Sensitized Thl cells interact with antigen primed macrophages for more efficient 
phagocytosis and killing of the invading pathogens (Stout and Bottomby, 1989). The 
activation of Th cells is impossible without the epidermal Langerhans cells which, after 
the infection they move to the dermis and phagocytose fragments of the Leishmania or 
those which have escaped destruction. L. major amostigotes and not promastigotes 
efficiently enter LC which are induced to express increased amounts of MHC antigens 
and costimulatory molecules and to release other cytokines (as IL-12 p70) thus leading 
to a protective Thl cell immunity (Von Stebut et al., 1998). However, the LCs have 
been shown to internalise a small number of promastigotes which don’t differentiate 
into amastigotes and appear to be degraded (Konecny et al., 1999). It has been shown 
that LCs and monocytes produce large amount of IL-12p70 in a CD40 ligand (CD40L)- 
dependent manner (Marovich et al., 2000; McDowell et al., 2002). On the other hand, 
IL-4, if present in the initial stage of activation LCs, instructs those cells to produce IL- 
12 and promote Thl development. However, when present later, during the period of T 
cell priming, IL-4 induces Th2 differentiation and progressive disease in resistant mice 
(Biedermann et al., 2001). The expression of IL-4 receptor increases on infected LCs 
from susceptible mice but not on those from resistant mice (Moll et al., 2002). LCs have
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the ability to transport Leishmania major from the skin to the draining lymph nodes 
(LN). In contrast, no migration to the LN has been seen with Leishmania major infected 
macrophages (Moll et al., 1993; Moll et al., 1995). Also, in vitro studies have 
demonstrated that promastigotes inhibit the motility of LCs by up to 93% in a dose 
dependent and reversible manner (Jebbari et al., 2002). Furthermore, unlike 
macrophages, LC do not allow parasite replication and they do not release NO under the 
effect of IFN-y and LPS. Poute-Sucre et al. (2001) have shown that leishmania LPG 
impairs LC migration out of the skin and therefore modulates their immunostimulatory 
functions which require LC translocation from the skin to lymph nodes.
Migration places the LC, in the path of the recirculating T-cell pool and hence 
increases their probability of encountering an antigen-specific T-cell. TNF-a and IL-1 p 
have been shown to regulate the LC-mediated transport oi Leishmania. In vivo depletion 
of TNF-a significantly reduces the amount of infected LC and the parasite load in the 
draining lymph nodes. In contrast, the depletion of IL-1 p enhanced the parasite-induced 
LC migration (Amoldi and Moll, 1998). Finally, these motile antigen-bearing dendritic 
cells acquire the ability to temporarily bind T-cells in an antigen-independent fashion 
(Inaba et al., 1989). In resistant mice, the Th cells differentiate into Thl lymphocytes 
which secrete IFN-y needed to stimulate the DTH response (Reiner and Locksley, 
1995).
The differentiation of lymphocytes into Thl cells appears to need the 
interaction between CD 154 (from the TNF-a family) on the lymphocytes surface and its 
receptor CD40 on the DC surface and lymphocytes B. Thus, if the mice have a mutation 
in the CD40 or CD 154 genes, they will be unable to mount a protective cell mediated 
immune response (Kampbell et al., 1996). The binding of CD 154 to CD40 seem to
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stimulate the production of IL-12 which has a major role in the differentiation of T 
lymphocytes into Thl (Sypek et al., 1993). The elimination of the parasites appears to 
take place through two complementary mechanisms involving macrophages. The first 
one involves the destruction of the infected macrophages releasing the amastigotes to 
the extracellular medium. This mechanisms depends on the interaction between CD95L 
(from the TNF-a family) expressed on Thl lymphocytes and its receptor CD95. The 
involvement of this molecule induces the death of macrophages carrying it by apoptosis. 
Note here that the expression of CD95 on the infected macrophages is increased by 
IFN-y (Conceicao-Silva et al., 1998). The second mechanism involves the stimulation 
of the macrophages by IFN-y to produce the inducible nitrogen oxide synthase (iNOS) 
which catalyses the synthesis of nitrogen oxide (NO) which is toxic for the amasigotes 
(Bogdan et al., 2000). The production of iNOS by macrophages depends both on the 
secretion of IFN-y by the Thl lymphocytes and natural killer (NK) cells and the 
autocrine secretion of TNF-a by the macrophages. However, the effect of TNF-a on the 
production of iNOS seems to be mild since mice having a mutated gene of TNF-a or its 
receptor p55 are still able to limit the multiplication of the parasites (Filippi et al., 
2001). NO seems to modulate the immune response since it has been shown that at high 
concentration, NO inhibited IL-12 synthesis by activated macrophages, thus indirectly 
suppressing the expansion of Thl cells. On the other hand, at low concentrations, NO 
selectively enhanced the induction of Thl cells and had no effect on Th2 cells. NO 
exerts its effect in synergy with IL-12 during Thl cell differentiation and has no effect 
on fully committed Thl cells (Niedbala et al., 1999). The maintenance of a latent 
infection depends on the continuous production of NO. Thus, iNOS are detected at the 
site of infection and in the draining lymph nodes for many months after the infection.
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Furthermore, the administration of an iNOS inhibitor in cured mice leads to parasite 
multiplication and the appearance of new lesions. It is now established that the high 
level of iNOS sustained many months after the infection depends on the chronic 
activation of Th cells.
It seems also, that the maintenance of a protective immune response, needs the 
continuous production of IL-12 so that IL-12-deficient mice need continuous injections 
of recombinant IL-12 in order to limit the multiplication of parasites (Park et al., 2000). 
It is noteworthy that the chemokine monocyte chemoattractant protein-1 (MCP-1) is 
involved in determining the type of Th activated, since MCP-1-deficient mice are 
unable to mount Th2 responses. Lymph nodes cells from immunized MCP-1 (-/-) mice 
produce low amounts of IL-4, IL-5 and IL-10 with no effect on the levels of IFN-y and 
IL-2 preventing the immunoglobulin subclass switch that is characteristic of Th2 
responses (Gu et al., 2000).
As to the long term immunity, in vitro studies have shown that in the lymph 
nodes of disease recovered mice, both macrophages and dendritic cells harbor viable 
parasites. Only DC, however, are able to induce a T-cell immune response in the 
absence of exogenous antigen (Moll et al., 1995). In contrast to resistant mice, BALB/c 
mice are unable to mount a protective immune response and the disease exacerbates 
leading to the death of the animals.
As to the immune response against Leishmania major, BALB/c mice present 
many differences and at many levels. Although the neutrophils rapidly appear at the site 
of infection as in the case of resistant mice, their number remains high in susceptible 
mice as compared to resistant mice where their number decrease quickly (Tacchini- 
Cottier et al., 2000). Also, the number of macrophages at the site of infection is two 
times greater in resistant mice than in BALB/c mice where those macrophages lose their
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ability to produce IL-12 in response to LPS and IFN-y. Furthermore, the activity of NK 
cells is more significant in resistant mice than in BALB/c mice (Scharton-Kersten et al., 
1995). On the other hand, Th2 cells are activated in BALB/c mice after Leishmania 
major infection which leads to disease exacerbation. This infection induces the rapid 
expansion of Th cells in a LACK (Leishmania-activated C kinase) antigen dependent 
way leading to the production of IL-4 which will render T cells unresponsive to IL-12 
(Launois et al., 1995). This is crucial in determining the course of infection since the 
elimination of those cells from BALB/c mice leads to the development of the protective 
Thl response (Bix et al., 1998). Those Th cells in BALB/c mice lose also their ability to 
respond to IL-12 under the influence of IL-4 and TGF-p by diminishing the expression 
of IL-12 receptors (Himmelrich et al., 2000). Furthermore, since BALB/c mice have a 
very weak Thl response, the level of NOS in lymph nodes and lesions is decreased as 
compared to resistant mice. This is in accordance with the fact that the synthesis of 
iNOS by macrophages is increased by IFN-y and is inhibited by TGF-P, IL-4,11-10 and 
IL-13 (Vouldoukisetfl/., 1997).
• Co-stimulatory molecules:
The activation of T cells appears to require two signals: the antigen-MHC class
I or II association with TCR and a costimulatory signal involving the interaction of CD
28 (expressed on T cells) with B 7.1 (CD80) and B 7.2 (CD8 6 ) on APC (Lenschow et
a/., 1996). This interaction is especially important for the development of Th2 response
(Howland et al., 2000) so that without the CD28 costimulation a Thl response develops
leading to an IFN-y-dependent healing of the lesion. However, the absence of CD28-B7
interactions doesn’t change the course of the disease progression in mice treated with
high doses of L. major (Compton and Farrell, 2002). On the other hand, B 7.2 can also
bind to CTLA-4 having a negative regulatory effect on T-cell activity (Murphy et al.,
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1998).
• Dose o f the parasite:
The dose of infectious agent, interacting with the other factors, can deeply 
affect the type of immune response. BALB/c mice infected with low dose of L. major 
(around 1 0  ^organisms per mouse) are able to mount a protective cell-mediated immune 
response. Both BALB/c and CBA/J mice, when given a low dose of Leishmania major, 
either acquire systemic resistance or become more resistant to a large challenge of 
parasites given about two months after primary exposure (Bretscher et al., 1992). 
Although the lesion ultimately heals, those mice show significant pathology rather than 
a subclinical infection, and this protective response depends on the infectious dose and 
not the antigen dose (Doherty and Coffman, 1996). This outcome of the disease appears 
to be due to many overlapping mechanisms which rely on the fact that, although 
BALB/c mice might be genetically predisposed to mount a Th2 response to L. major, an 
early protective Thl response usually tends to develop suggesting that the initial 
conditions of the infection primarily determine the type of immune response. Thus, if 
sufficient IL-4, which is known to suppress IFN-y induction by inhibiting the release of 
IL-12 (Macatonia et al., 1995), is present during early stages of the infection, a Th2 
response predominates. However, if the early stimulation is weak, the initial IL-4 levels 
are too low to dominate over the Thl response (Doherty and Coffman, 1996). It is 
noteworthy to mention that IL-12 seems to play a crucial role in inducing this protective 
response since IL-12-deficient BALB/c mice develop a Th2 response even if infected 
with low inocula of L. major (Mattner et al., 1997). Mice made resistant after exposure 
to a low dose of parasites express a prolonged DTH responses after a normally 
pathogenic challenge, and their production of parasite-specific IgGl decreases by about 
eight fold (Bretscher et al., 1992).
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1.3. Cytokines
1.3.1. Definition
Cytokines are low-molecular-weight soluble proteins or glycoproteins 
produced by many types of cells especially white blood cells performing several 
functions in the regulation of immune response (Kroemer et al., 1993). The involvement 
of cytokines includes the development of cellular and humoral responses, initiation of 
inflammation, expression of adhesion molecules and the control of hematopoiesis and 
cellular proliferation and differentiation (Borish et al., 1996). The cytokines perform 
their functions by binding, in an antigen-nonspecific manner to specific receptors on the 
membrane of target cells initiating a signal transduction pathway that controls gene 
expression in those cells evoking particular biological activities (Henderson and Poole, 
1994).
1.3.2. General Features
Cvtokine mai or sources main cell tareetfsl main functions
Interleukin-2
(IL-2)
activated Thl, 
NK
T cells, B cells. 
Monocytes
activation of Th and Tc, 
enhancement of NK activity
Interleukin-3
(IL-3)
T cells stem cells, 
progenitors
pan-specific colony stimulating factor
Interleukin-5
(IL-5)
T cells B cells, eosinophils differentiation
Interleukin-7
(IL-7)
bone marrow, 
thymic stromal 
cells
progenitor B and 
T cells
differentiation into progenitor B and T 
cells, induction the expression of IL-2 
and its receptor
Interleukin-8 
(IL-8)
macrophages, 
skin cells
granulocytes, 
skin cells
chemotaxis
Interleukin-9
(IL-9)
Th cells Th cells, B cells, 
mast cells, 
thymocytes
growth factor
Interleukin-12 
(IL-12)
actiavted Thl 
cells
activated T cells, 
peripheral 
mononuclear cells, 
NK cells
induction of IIFN-y, IL-2, and TNF-a 
synthesis, reduction of IL-4, IL-5, IL- 
10, IL-13 synthesis, inhibitis IgE 
synthesis
Interleukin-18 
(IL-18)
Activated
macrophages
Thl, NK cells development of Thl and NKcells
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Tumor
Necrosis Factor 
(TNF)
macropahages,
lymphocytes
fibroblast,
endothelium
inflammation, cachexia, fibrosis; 
production of IL-1, IL-6, GM-CSF, 
adhesion molecules
Interferon-y
(IFN-y)
Thl cells, Tc, 
NK cells
T cells, B cells, 
macrophages, 
NK cells
inhibition of viral replication
and Th2 proliferation, enhancement of
macrophage activity
1.3,3. Role o f Cytokines in Cutaneous Leishmaniasis
1.3.3.1. Interleukin-2 (lL-2)
Interleukin-2 is a T-cell growth factor produced by Thl cells (Fishman and 
Perelson, 1994) thus playing an important role in the protection against the infection by 
Leishmania major. Lymphoid cells from BALB/c mice infected with this parasite 
produced significantly lower levels of IL-2 as compared to uninfected control (Cillari et 
al., 1986), protected BALB/c mice or to resistant mice (Cillari et al., 1986; Solbach et 
al., 1987). This suppression of IL-2 production is most probably mediated by 
macrophages due to the release of prostaglandins (Cillari et al., 1986). IL-2 can also act 
as a second signal with interferon-y (IFN-y) to induce macrophage leishmanicidal effect 
(Belosevic et al., 1988) with TNF-a being the possible effector molecule for resistance 
regulated by these two lymphokines (Belosevic et al., 1990). However, administration 
of IL-2 had no effect on the course of infection of BALB/c with Leishmania major 
(Lezama-Davila et al., 1992). IL-2 might also be involved in the development of Th2 
responses in BALB/c mice since IL-2 mRNA was detected at a comparable level in the 
spleen and lymph nodes of resistant, healer and non-healer mice during Leishmania 
major infection (Locksley et al., 1987). Much of this IL-2 mRNA seems to be derived 
from B cells (Heinzel et al., 1991). However, this is not the case of CD4^ T cells 
derived from susceptible non-healer mice which contain no detectable IL-2 (Heinzel et 
al., 1991). This might explain the fact that depletion of B cells from birth rendered 
genetically susceptible BALB/c mice resistant to Leishmania major infection (Sacks et
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al., 1984). On the other hand, when resistant mice are depleted from B cells, they 
become susceptible to infection (Scott et al., 1986). Furthermore, lymph nodes cells of 
BALB/c mice produced sixfold more IL-2 in culture than those of healing C57BL/6 
mice and this level is also increased in those mice made susceptible by IL-12 or IFN-y 
deficiency. But, this is not reflected by the IL-2 mRNA in vivo (Heinzel et al., 1998). In 
addition, IL-2 was shown to markedly suppress the activation of macrophages for 
intracellular killing. This suppressive effect seems to be mediated by TGB-p, which 
under the effect of IL-2 is produced 500-fold higher than normal levels which sufficient 
to block intracellular killing activities (Nelson et al., 1994). Thus, although IL-2 seems 
to be required for both the production of IL-4 and the differentiation of Th2 cells in 
susceptible mice, anti-IL-2 had no effect on the development of Thl response in 
resistant mice. However, four weekly injections of anti-IL-2 monoclonal antibody 
(mAb) cured more than 80% of BALB/c mice infected with Leishmania major as 
determined by diminished footpad swelling and decreased numbers of parasites in 
infected tissues. However, multiple doses of this mAb were required since one dose 
given at the time of infection was inefficient. This anti-IL-2 mediated cure was 
associated with increased IFN-y and decreased IL-4 production by regional lymph node 
cells (Heinzel et al., 1993).
1.3.3.2. Interleukin-3 QL-31
Interleukin-3 is produced by susceptible mice during Leishamnia major 
infection, but not by resistant mice (Lelchuk et al., 1988). This is in accordance with the 
increase of the number of IL-3-producing cells. Also, treating BALB/c mice with anti- 
IL-3 antibody significantly reduces the disease score (Saha et al., 1999). 
Administration of recombinant IL-3 also led to disease exacerbation (Feng et al., 1988).
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This might be due to the ability of IL-3 in combination with interleukin-4 (IL-4) to 
abrogate the macrophage activating capacity of interferon-gamma (IFN)-y (Liew et al.,
1989). Moreover, IL-3 can increase the number of immature monocytes in the 
developing lesion which might be “safe targets” in which the parasite can replicate 
(Mirkovich et al., 1886). Furthermore, it was observed that the intravenous (i.v.) 
immunization with leishmanial antigen induces protection whereas subcutaneous (s.c.) 
immunization leads to the exacerbation of the disease. This might be explained by the 
observation that spleen cells from BALB/c mice immunized by the s.c. route produced 
significantly higher levels of IL-3 and IL-3 mRNA than those from mice immunized by 
the i.v. route since IL-3 has been shown to to promote leishmanial infection (Lelchuk et 
al, 1989).
1.3.3.3. Interleukin-5 (IL-5)
BALB/c mice produce significantly more IL-5 during the first week of L. 
major infection as compared to resistant mice (Soares et a l, 1997). Furthermore, in 
murine leishmaniasis, and not in humans, the high IL-5 production accompanies the 
Th2 response which can exacerbate the disease (Rogers and Titus, 2004).
1.3.3.4. Interleukin-7 tIL-71
Previously, it was shown that treatment of murine macrophages infected with 
L. major with IL-7 without any other stimulus reduces the percentage of infected cells, 
as well as the parasite burden per cell, in a dose-dependent manner to a limited degree 
(45% reduction of the number of amastigotes per 100 macrophages). Simultaneous 
treatment of macrophages with IFN-y and IL-7 leads to nearly complete (> 99%) 
elimination of amastigotes. Addition of anti-IFN-y reverses the leishmanicidal effects of
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IL-7. In addition, the production of nitric oxide is induced in the presence of IL-7 
(Gessner et al., 1993). In contrast to this observation, other studies indicate that 
treatment of genetically susceptible BALB/c mice with IL-7 at the onset of the infection 
leads to enhanced lesion development and a significantly accelerated death of the 
animals. This was correlated with a 40-fold increased parasite burden in spleens and 
lymph nodes. One of the major changes appearing by the first week after infection in 
IL-7-treated mice was the increase of the total cell number in spleen and lymph nodes 
draining the local infection. Analysis of the cellular composition revealed that the 
enhanced cellularity was predominantly due to a rise in the B-cell compartment. Since 
antigen presentation by B cells has been implicated in the development of Th2 cells, the 
disease-aggravating activity of IL-7 is thought to be primarily due to augmentation of B 
lymphopoiesis (Gessner et al., 1995). Another study is consistent with this observation 
showing that IL-7-induced disease promotion was accompanied by an up to 10-fold 
higher parasite load in several issues of the mice. Furthermore, IFN-y production seen in 
untreated mice was suppressed in IL-7-treated mice with a significant increase in the 
total number of MHC Il-positive cells (Hoerauf et al., 1995).
1.3.3.5. Interleukin-8  fIL-81
IL-8 , which is mainly produced by human macrophages (Chensue, 2001) was 
shown that supernatants of moncytes infected with L  major have chemotactic activity 
for neutrophils and monocytes that was neutralized by anti-IL-8  antibodies. IL- 8  mRNA 
are induced within one hour of infection. This suggests that IL-8  may contribute to the 
cellular recruitment in leishmania lesions (Badolato et al., 1996). Furthermore, the 
infection with L  major promastigotes leads to the accumulation of polymorphonuclear 
leukocytes (PMN) which is amplified by the induction of IL-8  production in those cells
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(van Zandbergen et al., 2002). In addition to the chemotactic activity, IL-8  stimulatess 
the phagocytic activities of PMN (Baggiolini et aL, 1989) and may play a role in the 
development of a T-cell-mediated immune response to the parasite (Laufs et aL, 2002). 
However, whether the functional murine homologues of IL-8  (MIP-2 and KC) (Driscoll, 
1994) are involved in this process (Tacchini-Cottier et aL, 2000) needs further 
investigations.
1.3.3.6. Interleukin-9 fIL-91
It was shown that although no functionally active IL-9 was detected in sera of 
both BALB/c and C57BL/6 (resistant) mice, IL-9 is produced after in vitro antigenic 
restimulation and its mRNA was found to be expressed in lymph nodes and spleens 
during an immune response against L  major. Shortly after infection no principal 
differences in the kinetics of IL-9 expression could be observed, which has its 
maximum between day 5 and 7 after infection. The rate of production however is higher 
in the susceptible BALB/c mice. In athymic BALB/c nu/nu mice and in mice depleted 
of CD4+ T cells no IL-9 production is detectable in vivo at the level of mRNA and no 
IL-9 is produced after stimulation with L. major antigen in vitro. Treatment of infected 
mice with cyclosporin A ablates antigen-specific IL-9 production when tested in vitro 
without affecting its production after polyclonal T cell stimulation (Gessner et al,. 
1993). From 4 weeks after infection, IL-9 synthesis was observed only in BALB/c mice, 
correlating with the expansion of antigen-specific Th2 type T helper cells in these mice. 
Treatment of BALB/c mice with neutralizing anti-IL-4 mAh, a regimen known to lead 
to subsequent cure of infected BALB/c mice, suppresses late IL-9 synthesis (Nashed et 
aL, 2000). More recent studies suggest that IL-9 is able to promote Th2 response in 
BALB/c mice and that its neutralization reduces this detrimental response (Arendse et
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al., 2005).
1.3.3.7. Interleukin-12 fIL-12i
As to the infection with L. major, IL-12 prevents deleterious Th2 T cell 
responses and promotes curative Thl responses in an IFN-y-dependent fashion (Heinzel 
et aL, 1993). Within 1 day of infection with L  major, susceptible BALB/c mice 
produce a burst of IL-4 in their draining lymph nodes, resulting in a state of 
unresponsiveness to IL-12 in parasite-specific CD4+ T cells within 48 hours due to a 
rapid down-regulation of IL-12R beta2-chain mRNA expression in CD4+ T cells. In 
contrast, IL-12R beta2-chain mRNA expression is maintained on CD4+ T cells from 
resistant C57BL/6 mice (Himmelrich et aL, 1998). More recent researches show that 
even macrophages at an intermediate maturation stage can produce large amount of IL- 
12 p40 (Oliveira et aL, 2005). An important role is assigned for the regulation of the IL- 
12 receptor during the innate immune response after infection of mice with L  major. 
During the innate immune response, the lymph node cells of L. major-mÏQcXtà resistant 
mice upregulate the IL-12 receptor on CD4 (+), CD8 (+), and B cells. An increase in the 
ability of the lymph node cells to bind IL-12 correlates with 9.3- and 4.6-fold increases 
in the mRNA expression levels of the IL-12RP1 and -p2 subunits, respectively. In 
contrast, BALB/c mice, which are susceptible to L. major infection, show no increase in 
the ability of the lymph node cells to bind IL-12 and correspondingly smaller increase 
in the mRNA expression levels of the IL-12Rpl and -p2 subunits of 2- and 1.5-fold, 
respectively.
Since IL-12 is a major inducer of Thl cells which produce IFN-y that can 
activate macrophages to produce IL-12, it has been shown that NO can be an inhibitor 
of this feedback loop, preventing the excessive amplification of Thl cells (Huang et aL,
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1998). Type 2 NO synthase (N0S2)-derived NO is a prerequisite for cytokine signaling 
and function in innate immunity since in the absence of N0S2 activity, IL-12 is unable 
to prevent spreading of Leishmania parasites and did not stimulate NK cells for 
cytotoxicity or IFN-y release (Diefenbach et aL, 1999).
A major parasite cell surface molecule, phosphoglycan (PG), of Leishmania 
can selectively, in a dose-dependent manner, inhibit the synthesis of IL-12 (p40, p70) at 
the transcriptional level by activated murine macrophages (Piedrafita et aL, 1999). Also, 
dendritic cells have the capacity to promote protective Thl immune responses in 
Leishmania infection because in response to direct stimulation with Leishmania 
promastigotes, DC from both C3H ("resistant" to L. major infection) and BALB/c 
("susceptible") up-regulate production of IL-12 p40 (Konecny et aL, 1999).
IL-12 is shown to be required not only to initiate Thl cell development but also 
throughout infection to maintain a Thl cell response and resistance to L. major (Park et 
aL, 2000). As to the infection with low doses of L. major, it is shovm that the footpad 
swelling is observed after 6 weeks, coincident with the onset of parasite clearance and 
with production of high levels of IL-12 and IFN-y in draining lymph nodes (Lira et aL, 
2000). However, IL-12-deficient mice infected with only small numbers of parasites 
show the progressive lesion development and high parasite burden associated with a 
polarized Th2 response proving that IL-12 is indispensable for protective immunity 
against L. major (Mattner et aL, 1997).
1.3.3.8. Interleukin-18 HL-181
When BALB/c mice are injected daily with IL-18 and/or IL-12, neither IL-12 
(10 ng/mouse) nor IL-18 (1,000 ng/mouse) induce the healing of the lesion caused by L. 
major infection, while daily injection of IL-12 and IL-18 during the first week after
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infection strongly protects the mice from footpad swelling by induction and activation 
of Thl cells. Furthermore, these mice acquire protective immunity against L. major. In 
the absence of endogenous IL-18, the resistant mice show prolonged footpad swelling 
as well as diminished nitric oxide production. However, daily injection of IL-18 into IL- 
18(-/-) mice corrects their deficiencies, suggesting that these mice have Thl cells that 
produce IFN-y in response to IL-18. Indeed, these mice have normal levels of Thl cells. 
Thus, IL-18 is not responsible for inducing Thl cells but participates in host resistance 
by its action in stimulating Thl cells to produce IFN-y (Ohkusu et al., 2000). Also, IL- 
18-/- mice may develop larger lesions during early phase of infection but eventually will 
resolve them as efficiently as IL-18+/+ mice.
By 2 weeks after infection, although Ag-stimulated lymph node cells from L.
wîfl/or-infected IL-18+/+ and IL-18-/- mice produce similar levels of IFN-y, those from
IL-18-/- mice produce significantly more IL-12 and IL-4. By 10 weeks after infection,
both IL-18+/+ and IL-18-/- mice resolve L  major infection. At this time, lymph node
cells from both IL-18+/+ and IL-18-/- mice produce IL-12 and IFN-y but no IL-4.
Furthermore, administration of anti-IFN-y antibodies to IL-18-/- mice render them
susceptible to L. major indicating that despite the role IL-18 may play in early control
of cutaneous L  major lesion growth, this cytokine is not critical for development of
protective Thl response and resolution of L. major infection (Monteforte et al., 2000).
On the other hand, recent studies have shown that IL-18 can also induce T cells to
differentiate into Th2 cells, in the presence of TCR activation, either alone or together
with IL-4. This effect of IL-18 is inhibited in the presence of IL-12. BALB/c mice
infected with L. major and treated with recombinant IL-18 developed an exacerbated
disease and enhanced Th2 responses compared with untreated controls providing a
novel mechanism for Th2 cell development and suggesting that IL-18 is capable of
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inducing Th2 cell differentiation in the absence of IL-4 (Xu et aL, 2000).
1.3.3.9. Tumor Necrosis Factor-a tTNF-al
Previous researches using TNF-a specific antibodies show that TNF-a, mainly 
produced by CD4+ cells (Kemp et aL, 1999), plays an important role in mediating host 
protection against the infection with L. major (Liew et aL, 1990), especially through the 
induction of NO production (Green et aL, 1994; Moskowitz et aL, 1997) in the presence 
of IFN-y (Bogdan et aL, 1990). Some studies have shown that the membrane-anchored 
form of TNF-a present on the surface of CD4+ cells is more efficient than the soluble 
form of TNF-a (Brikland et aL, 1992). However, TNF-a seems not to be a decisive 
factor responsible for the resistance versus susceptibility in L. major infection since its 
bioactivity can be detected in both resistant and susceptible mice until 5 weeks of 
infection. Also, the neutralization of TNF-a doesn’t alter the course of infection neither 
in BALB/c mice nor in CBA mice although it leads to an increase in lesion size and a 
delay in the healing process in the latter type of mice (De Kossodo et aL, 1994). Also, 
the high level of PGE2 in infected BALB/c mice seems to depress the levels of both 
IFN-y and TNF-a (Milano et aL, 1996). TNF-a R p55 and TNF-a R p75 deficiency 
appear to affect the lesion size with no significant effect on macrophage leishmanicidal 
activity or nitric oxide production since the parasites are eliminated within the lesions 
(Vieira et aL, 1996; Nashleanas et aL, 1998; Nashleanas and Scott, 2000). On the other 
hand, TNF-a plays a role in the induction of LG migration since in vivo depletion of 
TNF-a reduces the number of LC and the parasite burden in the draining lymph nodes 
(Amoldi and Moll, 1998). Some studies suggest that TNF-a can signal through a third 
receptor so that abolishing the signaling through both TNFRl and 2 can be
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compensated, whereas absence of the ligand (TNF-a) is fatal (Wilhelm et aL, 2001).
1.3.3.10. Interferon-gamma (IFN-v^
IFN-y plays important roles in leishmaniasis including the activation of 
macrophages to kill L  major and the induction of increased surface expression of class I 
and II MHC molecules (Wang et aL, 1993; Swihart et aL, 1994). IFN-y partially inhibits 
the proliferation of Th2 cells in a dose-dependent manner (Femandez-Botran et aL, 
1988; Rafati et aL, 2002). In accordance with this finding, the in vivo injection of 
resistant mice with anti- IFN-y antibody results in a non-healing lesion and ultimately 
death (Belosevic et aL, 1989). However, in order to reach this result, the antibody 
should be administered within the first week of infection (Scott, 1991). On the other 
hand, BALB/c mice injected with L  major and treated with IFN-y mount a Thl 
response without modifying the progress of the disease (Sadick et al,. 1990). 
Furthermore, the presence of IFN-y is needed in order to convert the anti-IL-4 antibody 
treated BALB/c mice into healers (Coffman et aL, 1991).
IFN-y is able also to enhance iNOS transcription and NO release from 
stimulated mouse macrophages (Ding et aL, 1988) and that is why macrophages fi*om 
IFN-y and IFN-y-receptor gene knock-out mice have impaired NO production (Dalton et 
aL, 1993). However, the parasite killing by macrophages is independent of endogenous 
IFN-y production but is enhanced by exogenous IFN-y (Von Stebut et aL, 2002). 
Furthermore, the inoculation of BALB/c mice with a low dose of L. major leads to the 
generation of IL-4-producing cells without affecting the generation of IFN-y-producing 
cells (Lang et aL, 2003).
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1.3,4. Cytokines Involved in This Study
I.3.4.I. Interleukin-IB
IL-1 is well known as an important mediator of many immune responses 
including inflammation (Dinarello, 1996). The IL-1 family gene family exists both in 
humans and mice. This family consists of 3 genes encoding 3 distinct proteins, IL-1 
alpha, IL-1 beta and IL-1 receptor antagonist (IL-1 Ra). IL-1 Ra binds to the same 
receptors as IL-1 alpha or beta but does not induce any intracellular signal thus acting as 
an inhibitor (antagonist) of IL-1 activity (Dinarello, 1994). IL-1 beta consists of 153 
amino acids with a molecular weight of 17 kD (Auron et aL, 1984). IL-1 alpha consists 
of 159 amino acids with a molecular weight of 17 kD (March et aL, 1985).
Despite their structural similarities, IL-1 a  and IL-ip have different 
mechanisms of expression, synthesis and secretion (Dinarello, 1996). The transcription 
of both IL-1 a  and IL-lp is stimulated during inflammatory responses by immune 
complexes, certain coagulation and complement cascade proteins, substance P and viral 
and bacterial products (Dinarello, 1991). Also, this transcription is induced by many 
cytokines such as granulocyte-macrophage colony stimulating factor (GM-CSF) (Sisson 
and Dinarello, 1988), IFN-y (Collait et aL, 1986; Ucla et aL, 1990) and tumor necrosis 
factor-alpha (TNF-a) (Nawroth et aL, 1986). Furthermore, both cytokines induce their 
own production in endothelial cells and monocytes (Dinarello et aL, 1987). However, 
IL-1 self enhancement is inhibited by IFN-y by reducing the transcription of the IL-1 (3 
gene, whereas it increases the transcription induced by LPS (Schindler et aL, 1990). 
Certain Th2 cytokines, such as interleukin-4 (IL-4), interleukin-10 (IL-10) and 
interleukin-13 (IL-13), have a suppressive effect on IL-1 synthesis. These cytokines 
induce B lymphocyte expansion and immunoglobulin production, whilst inhibiting cell-
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mediated immunity. IL-4, IL-13 (Hart et aL, 1989; Vannier et aL, 1992) and IL-10 (De 
Waal Malefyt et aL, 1991; Wang et aL, 1994) inhibit IL-1 production in cultured cells. 
The effect of IL-10 has also been confirmed in vivo in volunteers who received an 
injection of this cytokine. Other cytokines such as TGF-B (Chantry et aL, 1989) and 
interleukin-6 (IL-6) (Schindler et aL, 1990) tend to suppress IL-1 production. Finally, it 
has been shown that submitting subjects to a diet rich in unsaturated fatty acids (omega- 
3) reduces their capacity to produce IL-1 (Endres et aL, 1989; Meydani et aL, 1993). 
There exists an endocrine feedback mechanism for IL-1 production. This cytokine 
stimulates, via the production of hypothalamic and hypophysial hormones, the 
production of corticosteroids which have, in turn, an inhibiting effect on the production 
of IL-1 and TNF-alpha (Besodovski et aL, 1986; Berkenbosch et aL, 1987).
IL-1 a  and IL-ip differ also as to localization, maturation and secretion since 
the former remains mainly intracellular while the main part of the latter is secreted after 
cleaving by a specific protease. Unlike pro-IL-lB, pro-IL-1 alpha is just as active as the 
mature form and remains intracellular for the main part and acts at this level (Mosley et 
aL, 1987). Moreover, IL-1 a  is only rarely found in the circulation or extra-cellular 
biological liquids and only in cases of serious illness when it may have its origin in 
lysed cells (Wakabayashi etaL, 1991).
As far as IL-IB is concerned, the greater part of pro-IL-lB also remains in the 
cytosol until it is cleaved and transported to the extracellular environment (Stevenson et 
aL, 1993). In fact, pro-IL-lB is not fully active biologically and is not secreted until it 
has undergone an intra-cellular cleaving into its mature form (Black et aL, 1988).The 
specific enzyme responsible for this cleaving is called the "IL-IB converting enzyme" 
(ICE) (Cerretti et aL, 1992; Thomberry et aL, 1992). ICE is highly specific to pro-IL-1 B 
and does not cleave pro- IL-1 a  (Howard et al., 1991). ICE activity is also regulated by
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the presence of a competitive inhibitor of the substrate consisting of a tetrapeptide 
whose presence reduces the maturation and secretion of IL-IB and encourages the 
accumulation of pro-IL-lB (Thombeny et aL, 1992). The over-expression of the ICE 
gene leads to increased apoptosis in cells transfected with this gene (Miura et aL, 1993; 
Faucheu et aL, 1995).
With respect to IL-lRa, it is called IL-1 inhibitor because it blocks the effect of 
IL-1 a  and IL-1 p. It is a protein with a molecular weight of 22 kD, the corresponding 
gene being homologous with that of IL-1 a  (18%) and IL-lp (26%) (Seckinger et aL, 
1988; Hannum et aL, 1990). Unlike the IL-1 genes, the IL-lRa gene possesses a signal 
sequence which allows the protein to be secreted in the extra-cellular environment. 
However, an alternative splicing of the messenger RNA may occur, which modifies the 
exon encoding for the signal sequence and leads to the translation of a protein which 
remains intra-cellular and which is, therefore, called icIL-lRa (Haskill et aL, 1991; 
Butcher et aL, 1994). Both the secreted and the icIL-lRa forms of IL-lRa have exactly 
the same biological activity. The icIL-lRa form is constitutively expressed in 
keratocytes and in digestive epithelial cells (Haskill et aL, 1991), i.e. in the same cells 
as those where large quantities of intra-cellular pro-IL-1 alpha are found. It has therefore 
been suggested that icIL-lRa plays a regulating role in the intra-cellular activity of IL- 
1 alpha (Arend, 1993). A second form of icIL-lRa, also generated by alternative splicing 
of the messenger RNA, has been described in different types of cells and is called icIL- 
IRa type 2 (Muzio et aL, 1995). The inhibiting activity of this icIL-lRa 2 is comparable 
to that of classical icIL-lRa but the biological significance of this second type of icIL- 
IRa is currently not understood.
Many observations have shovm that IL-lRa and IL-IB are produced by the 
same cells but are regulated in different ways. Namely, LPS is a powerful inducer of
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both IL-IB and IL-lRa (Vannier et al., 1992). Immune complexes and adherent IgG are 
also important inducers of IL-lRa, whilst they only very slightly stimulate the 
production of IL-IB (Arend et al., 1991; Poutsiaka et al., 1991). However, high 
concentrations of LPS reduce IL-lRa expression and secretion induced by adherent 
IgG, without impairing the production of IL-IB. Furthermore, interleukin-3 and GM- 
CSF increase the production of IL-lRa by monocytes (Jenkins and Arend, 1993), 
although this latter cytokine seems to be more a differentiating factor than a direct 
inducer of IL-lRa. IL-1 itself, whether alpha or beta, is also an inducer of IL-lRa, but 
its direct activity in this field is quite weak and it seems to be an enhancing agent for 
other stimuli (Arend, 1998). However, this influence of IL-1 activity on the production 
of IL-lRa could explain the effect of certain substances described as IL-Ra activators, 
but which activate IL-1. It has thus been shown that TGF-B induces the secretion of IL- 
lRa in monocytes via IL-1 synthesis since this activity is completely blocked by the 
presence of anti-IL-lB antibodies (Wahl et al., 1993).
On the other hand, the Th2 cytokines, considered classically to be anti­
inflammatory, such as IL-4 (Wong et al., 1993), IL-10 (Jenkins et al., 1994; Seitz et al.,
1995) and IL-13 (Muzio et al., 1994) are inducers and, more especially, enhancers of 
IL-lRa syntiiesis with a direct effect, since it is not modified by the presence of an 
inhibitor of protein synthesis such as cyclohexymine. It is interesting to note that the 
surface molecules of Th2 cells preferentially stimulate the production of IL-lRa, whilst 
those of Thl lymphocytes tend to induce IL-1 production (Chizzolini et al., 1997). In 
addition, a pro-inflammatory cytokine, TNF-a, and certain anti-inflammatory cytokines, 
such as IL-4 and IL-10, but not IL-13 and TGF-B, have a synergic effect on the 
production of IL-lRa by PMN (Marie et al., 1996).
The three members of the IL-1 family share the same receptors. An additional
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sub-unit called the IL-1 receptor accessory protein (IL-lR-AcP) was shown to be 
present in the mouse (Greenfeder, 1995). Therefore, the IL-1 receptors (IL-IR), 
constitute a family of 3 molecules belonging to the immunoglobulin superfamily: two 
true receptors, called IL-1 receptor type I (IL-IRI) and IL-1 receptor type II (IL-IRJI), 
and IL-lR-AcP. These receptors can exist in either a transmembrane or a soluble form, 
which allows them to play a major role in the regulation of the biological activity of IL- 
1. IL-IRI is a glycoprotein expressed at the surface of numerous types of cells, but 
preferentially on endothelial cells, fibroblasts, chondrocytes, smooth muscle cells and T 
lymphocytes (Shirakawa et al., 1987). IL-IRI is a transmembrane monomeric molecule 
(Sims et al., 1988). However, IL-IRI is the only one of the two IL-1 receptors capable 
of transmitting a signal when it is occupied by IL-1 (Stylianou et al., 1992; Sims et al,. 
1993; Labow et al., 1997). Furthermore, substances such as phorbol esters, 
prostaglandin E2 (PGE2), dexamethasone, vitamin D3, IL-2 and IL-4 are, however, 
capable of increasing the expression of IL-IRI at the cell surface (Dinarello, 1994) 
while TGF-B reduces the expression of IL-IRI (Dubois et al., 1990).
IL-lR-AcP presents some homology with IL-IRI and is a 570 amino acids 
protein with a molecular mass of approximately 66 Kda (Greenfeder et al., 1995). IL- 
IR-AcP plays a significant role in the initiation of all IL-1 biological responses since in 
the absence of IL-lR-AcP, IL-1 can bind to IL-IRI but no signal can be transduced. 
Furthermore, IL-lR-AcP seems to be required for IL-1-induced production of IL-6 and 
E-selectin (Cullinan et al., 1998). The second IL-1 receptor (IL-IRII) is a 68 kD 
glycoprotein whose intra-cytoplasmic portion only has 29 amino acids (McMahan et al., 
1991), that is why this receptor cannot transmit any signal (Sims et al., 1994). It is 
expressed in very small quantities on the same cells as IL-IRI, apart from endothelial 
cells, but it is distinctly predominant on B lymphocytes, monocytic cells,
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polymorphonuclear neutrophils and haematopoietic cells (McMahan et al, 1991). 
Finally, although T lymphocytes have always been considered to preferentially express 
receptor type 1, Th2 clones also express a considerable amount of IL-IRII (McKean et 
al, 1993).
Although IL-IRII does not transmit any signal, it is capable of binding IL-IB 
with great affinity and can compete with IL-IRI for binding the latter, which amounts to 
reducing the biological activities of IL-IB. For this reason it is called a "decoy receptor" 
and is considered to be a negative regulatory factor for IL-IB which remains trapped on 
this receptor preventing it from inducing a biological signal (Colotta et al., 1994).
IL-lRa can bind to IL-IRII, but with an affinity one hundred-fold weaker than 
for IL-IRI (Granowitz et al., 1991). Thus, there is little competition between the 
inhibiting activities of IL-lRa and IL-IRII at target-cell surface level. In fact, when IL- 
IRI expression increases, the biological activity of IL-1 increases, whereas when IL- 
IRII expression increases, the biological activity of IL-1 is inhibited (Re et al.,
1996).The increased expression of IL-IRII, observed in the presence of dexamethasone, 
IL-4 and IL-13, also confirms the anti-inflammatory effect of these substances (Colotta 
et al., 1993; Re et al., 1994; Colotta et al., 1996).
There are also soluble forms for the two types of receptors resulting from the 
proteolytic cleavage of the extra-cellular portion of membrane receptors (Symons et al., 
1991). Thus, we can note that IL-lsRI binds preferentially to IL-1 alpha and IL-lRa, 
whereas IL-lsRII has a greater affinity for IL-IB raising the issue of therapeutic use of 
these soluble forms of receptors. The soluble form of IL-lRacP inhibits the activity of 
IL-1 by increasing the affinity of binding of IL-1 to IL-1 RII (Smith et al., 2003).
To conclude, it is important to note that the complexity of the relationship 
between IL-1 and its different inhibitors explains the difficulties encountered in
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standardizing the different methods used to measure IL-1 in biological fluids at 
inflammatory sites and restrains the interpretation of these measurements in the absence 
of information concerning IL-1-specific receptors and inhibitors.
As to the infection with L. major, it was shown that the level of IL-1 p in the 
injected paw of BALB/c mice increases significantly at day 3 following the injection of 
the parasites to return back to the normal level at the end of the first week post­
injection. Then, this level increases again at the end of the second week post-injection 
and is maintained throughout the observation period (7 weeks) (Kanaan et al. 2000). 
This is in accordance with the observation that the macrophages from susceptible mice 
secrete large amounts of IL-1 in response to Leishmana major infection, while these 
firom resistant mice produce significantly lower levels (Cillari et al., 1989; Wagner et 
al., 1991). Treating mice with an anti-IL-1 receptor mAh inhibits the development of 
lesions in cutaneous leishmaniasis, but has little, if any effect, on the parasite number in 
the lesions as well as the cytokines that the animals produce in response to infection 
(Theodos et al., 1994). Although IL-1 is not required for mounting an immune response 
and antigen-dependent proliferation, it appears to be required for normal regulation of 
Thl/Th2 response (Satoskar et al., 1998) since IL-1 acts as a co-factor of the activation 
of Th2 cells (Kurt-Jones et al., 1987; Litchman et al., 1988) by stimulating Leishmania 
major infected macrophages to present antigens to Th2 cells and therefore inducing IL- 
4 synthesis (Chakkalath and Titus, 1994). Furthermore, IL-lp reduces the Langerhans 
cells (LC) mediated migration of Leishmania major to regional lymph nodes since the 
depletion of IL-lp enhances the parasite-induced LC migration, whereas treatment with 
recombinant IL-lp reduces the rate of infected LC in the lymph nodes (Amoldi and 
Moll, 1998). Consequently, IL-1 seems to exacerbate the leishmanial lesion in L. 
wq/or-infected BALB/c mice especially by the induction of prostaglandins synthesis
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(Ajdary 1997).
1.3.4.2. Interleukin-4 riL-43
IL-4 is a multifunctional cytokine of 129 amino acids (20 kDa) produced by 
Th2 cells that acts as an autocrine growth factor for Th2 cells (Fishman and Perelson, 
1994). The biological activity of IL-4 is mediated by a specific receptor which is 
expressed at densities of 100-5000 copies per cell. Also, the biological activities of IL-4 
are species-specific; mouse IL-4 is inactive on human cells and human IL-4 is in active 
on murine cells. IL-4 promotes the proliferation and differentiation of activated B-cells, 
the expression of class II MHC antigens and of low affinity IgE receptors. In activated 
B cells, this cytokine stimulates the synthesis of IgG 1 and IgE and inhibits the synthesis 
of IgM, IgG3 and IgG2a. This isotope switching is antagonized by INF-y. Pre-treatment 
of macrophages with IL-4 prevents the production of IL-1, TNF-a and prostaglandins. 
IL-4 can inhibit IL-2 and IFN-y production by naive cells and the activation of natural 
killers (NK) cells induced by IL-2 (Tanaka et a/., 1993) and this may complement the 
effects of IL-10 (discussed in 1.3.4.4), which acts on mature Thl cells (Biedermann at 
al., 2001).
Susceptible mice exhibit a peak of IL-4 mRNA in their spleens 90 min after 
intravenous injection of parasites and in the lymph nodes 16 hours after subcutaneous 
injection (Launois et al., 1997a). Moreover, the expression of IL-4 receptor on infected 
Langerhans cells increases in susceptible mice but not on those from resistant mice. 
Thus, this increase of IL-4 receptor expression of infected LC in addition to the 
inhibition of lipopolysaccharide-induced IL-12 (discussed in 1.3.3.7) response of those 
LC may contribute to the development of Th2 cells and therefore susceptibility to 
Leishmania major (Moll et al., 2002). Surprisingly, Biedermann et al. (2001) have
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shown that IL-4 instructs dentritic cells (DC) to produce IL-12, thus promoting a Thl 
response, if present during the initial activation of DCs. However, when present later, 
during the period of T cell priming, IL-4 induces Th2 differentiation and progressive 
leishmaniasis in resistant mice. However, a recent study shows that there is no 
relationship between early production of IL-4 by CD4 T cells and susceptibility to L. 
major in BALB/c mice suggesting that other unidentified factors might be responsible 
for the non-healing lesion (Lang et al., 2003).
1.3.4.3. Interleukin-6 (TL-6I
This cytokine is a protein of 185 amino acids. Several types of cells produce 
IL-6 including macrophages, dendritic cells and Th2 cells (Taga and Kishimoto, 1997). 
Among the physiological stimuli for the synthesis of IL-6 are IL-1 and TNF (Akira et 
al., 1993). IL-6 production can also be induced by all substances elevating intracellular 
levels of cyclic adenine monophosphate (cAMP) such as prostaglandin E2 (Akira et al., 
1993).
The IL-6 receptor is mainly expressed on T-cells, activated B-cells, peripheral 
monocytes. It is not expressed in resting B-cells but in resting T-cells (Bauer and 
Herrmann, 1991).
IL-6 is a pleiotropic cytokine influencing antigen-specific immune response 
and inflammatory reactions (Hirano, 1992). Also, IL-6 stimulates the synthesis of 
adeno-cortico tropic hormone (ACTH) in the pituitary and is a B-cell differentiation 
factor and a T-cell activation factor. In the presence of IL-2, IL-6 induces the 
differentiation of T-cells into cytotoxic T-cells. Furthermore, IL-6 is capable of 
inducing the final maturation of B-cells into immunoglobulin-secreting plasma cells 
pre-activated by IL-4 (Taga and Kishimoto, 1997).
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In accordance with its general biological roles, IL-6 is suggested to favour the 
outgrowth of Th2 cells (Rincon et al., 1997). In addition, when challenged with L. 
major, IL-6-deficient mice controlled infection and mounted Thl responses (Moskowitz 
et al., 1997). However, the IL-6 might have many diverse effects on CL; for example, 
IL-6 is required for the development of a Thl response (Yamamoto et al., 2000) and 
Th2 (Rincon et al., 1997) thus IL-6 is required for the development of both a Thl and 
Th2 response (Samoilova et al., 1998). On the other hand, when BALB/c IL-6-deficient 
mice were infected with L. major, no significant difference between the course of 
infection (lesion size and parasite burden) in those mice and wild type mice was found, 
but the IL-6-deficient mice expressed lower levels of Th2 and Thl associated cytokines 
(Titus et al., 2001).
The ability of IL-6 to induce Th2 differentiation is blocked by antibodies to IL- 
4, implying that IL-6 induces IL-4 which in turn induces Th2 differentiation. In 
contrast, IL-4 is active on CD4^ T cells fi*om IL-6-deficient mice demonstrating that 
Th2 induction by IL-4 don’t require IL-6. Rincon et al. (1997) suggest that IL-6 is a key 
component in a link between innate immunity and Th2 responses, which parallels the 
connection between the macrophage/NK response to intracellular pathogens and Thl 
induction.
1.3.4.4. Interleukin-10 TIL-103
IL-10 is a homodimeric protein with subunits having a length of 160 amino 
acids. The murine receptor is a protein of approximately 110 kDa that binds to murine 
IL-10 specifically. IL-10 is produced by the Th2 subset of CD4^ cells, but not by cells 
in the Thl subset (Fiorentino et al., 1989). Although IL-10 has multiple biological 
activities, the function addressed here is the inhibition of IFN-y and IL-2 synthesis by
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Thl cells at both mRNA and protein levels (Fiorentino et al., 1991). This effect is 
antagonized by IL-4. The net effect of IL -10 on Thl cells is to inhibit their 
proliferation, probably via reduced IL-2 synthesis, but Thl cells inhibited by IL-10 
retain the capacity to proliferate in the presence of externally added T-cell growth 
factors (IL-2 / IL-4) (Fiorentino et al., 1989). IL-10 reduces antigen-specific human T 
cell proliferation by diminishing the antigen-presenting capacity of monocytes and 
down-regulating class II MHC expression (De Waal Malefyt et al., 1991). IL-10 can 
also be produced by mast cells (Moore et al., 1990), monocytes (De Waal Malefyt et 
al., 1991), macrophages and B cells (Howard and O’Garra, 1992).
A role for IL-10 in leishmaniasis is indicated by the detection of IL-10 mRNA 
in CD4'  ^ T cells of infected, susceptible BALB/c mice. IL-10 is not detected in cells 
from resistant mice (Heinzel et al., 1991). Also, whereas normal BALB/c mice develop 
progressive non-healing lesions with numerous parasites within them, BALB/c mice 
lacking IL-10 control the disease progression and have relatively small lesions with 
1000-fold fewer parasites within them by the fifth week post-infection (Kane and 
Mosser, 2001). Kane and Mosser have also shown that the amastigotes of Leishmania 
use the host IgG to exploit the anti-inflammatory effects of Fc gamma (ciystallized 
fragment) R (receptor) to induce the production of IL-10, which prevents those 
macrophages activation and diminished their production of IL-12 and TNF-a. The 
removal of endogenous IL-10 by anti-IL-10 treatment, however, doesn’t alter the Th2 
cytokine pattern in non-healer mice nor modulates DTH reactivity, IgE production or 
fatal disease progression, but partially blocks the IFN-y inhibiting effect of recombinant 
IL-4 in healer mice.
During chronic infection, the levels of IL-10 are similar in both healer and non­
healer mice. However, at early stages of the infection, IL-10 production is significantly
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higher in the non-healer mice. Thus, IL-10 doesn’t seem to play a significant role in the 
T helper differentiation during L. major infection. But the high production of this 
cytokine early during infection in non-healer mice and inhibition of IFN-y production 
may contribute to drive the immune response towards a Th2 response (Chatelain et al.,
1999). IL-10 was also found to play an essential role in parasite persistence as sterile 
cure is achieved in IL-10-deficient mice and IL-4/IL-10 double deficient mice (Belkaid 
et al., 2001). Thl-DC interactions are not subject to IL -10 inhibition (Fishman and 
Perelson, 1994) although, a recent report indicates that while IL-10 does not inhibit DC- 
dependent Thl proliferation, it may inhibit DC-dependent IFN- y production 
(Macatonia et al., 1993). One possible hypothesis that may apply to a localized 
infection occurring in a tissue is that migrating DC would pick up the antigen, process 
and present it to resting T-cells in the draining lymph nodes, resulting in T-cell 
sensitization. The sensitized T-cells and macrophages will then accumulate at the site of 
infection, and the macrophages will process and present the antigen to both sensitized 
T-cells and activated T-cells that have returned to the resting state. IL-10 would 
influence these interactions and inhibit the ability of Thl activated by interacting with 
macrophages from secreting IFN-y (Fishman and Perelson 1994). Recently, an 
important role for IL-lO-producing CD4^ CD25^ regulatory T ( T r e g )  cells has been 
reported in leishmaniasis especially at the level of parasite persistence by moderating 
the activity of T effectors to maintain latent infection (Belkaid et al., 2002; Mendez et 
al, 2004)
1.3.4.5. Interleukin-13 fIL-133
Interleukin-13 (IL-13) is a 14 Kda glycoprotein containing around 132 amino 
acids and is structurally quite similar to IL-4, being globular in shape with 4 a  helices
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and a short P sheet and the whole structure is stabilized by disulphide bridges. 
Functionally, although IL-13 and IL-4 are close, they exert different effects on T 
lymphocyte functions: IL-13 doesn’t significantly inhibit the IL-2-induced T 
lymphocyte production of interferon-y (IFN-y). IL-13 is made principally by T helper 
lymphocytes type 2 (Th2 cells) and it can also be produced by Thl cells and CD8  ^T 
lymphocytes (Minty et al., 1997).IL-13 inhibits inflammatory cytokines production and 
synergises with IL-2 in regulating IFN-y synthesis.
IL-13, similarly to IL-4 and IL-10, has a suppressive effect on IL-1 synthesis 
and induces B lymphocyte expansion and immunoglobulin production (Hart et al., 
1989; Vannier et al., 1992). IL-13 receptor is believed to represent a heterotrimer 
containing IL-4R a, IL-2 R y and a unique IL-13 binding component (Borish and 
Rosenwasser, 1997). IL-13 has been shown to act through an IL-4 independent 
mechanism (Doherty et al., 1993; Kambayashi et al., 1996) which suggests that IL-13 
and IL-4 are not redundant Th2 mechanisms (McKenzie et al., 1998). On the other 
hand, IL-4R alpha chain is an essential component of both IL-4 and IL-13 receptors as 
proved by the reduced footpad swelling, parasite load, moderate histopathology in IL- 
4R alpha -/- BALB/c mice (Mohrs et al., 1999).
Macrophage migration inhibitor (MIF) was reported to kill Leishmania major 
especially by promoting TNF-a production by macrophages. In addition, this effect is 
blocked by IL-13, IL-10 and transforming growth factor-p (TGF-P) (also known as 
macrophage deactivating cytokines) (Juttner et al., 1998).
IL-13-mediated functions are shown not only to contribute to the susceptibility 
phenotype but also to play a protective role in chronic leishmaniasis (Brombacher,
2000). The over-expression of IL-13 in transgenic mice makes the normally resistant
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C57BL/6 mouse strain susceptible to L. major infection even in the absence of IL-4 
expression. This susceptibility correlates with a suppression of IL-12 and IFN-y 
expression. Furthermore, the IL-13-deficient BALB/c mice are resistant to L  major 
infection with an additive effect of deleting both IL-4 and IL-13 (Matthews et al., 
2000).
1.4. Inflammation and Pain
1.4.1. Definition
Inflammation is a physiological response of a host to invasion by a foreign 
body, pathogen or other tissue damage. The cardinal symptoms of inflammation are 
redness (erythema), swelling (edema), heat (fever) and pain. Usually, those symptoms 
are accompanied by the loss of function of the inflamed area. The increase in vascular 
diameter (vasodilation) at the site of infection leads to an increase in blood volume and 
therefore to heat and redness. Furthermore, the increase in vascular permeability leads 
to edema and contributes to the swelling and redness of the area (Dray, 1994).
Pain can be persistent or chronic and persistent pain can be subdivided into two 
classes: acute pain and neuropathic pain. The first results from the presence of a noxious 
stimulus that produces actual tissue damage and activation of nociceptors in the injured 
tissue, while the second results from direct injury to nerves in the peripheral or central 
nervous system. Acute pain is biologically useful because it signals injury or disease 
and subsides as healing progresses. In contrast, chronic pain is unlikely to resolve and 
lasts longer than the usual healing time and serves no useful biological roles since it 
limits normal functions of human.
Acute nociception refers to our ability to detect and react to potentially 
damaging stimuli, which are usually mechanical or thermal in nature. Under
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circumstances of tissue injury, stimuli that would not normally be considered painful 
become capable of elieiting intense pain.
This hypersensitivity to stimulation of injured tissue and surrounding uninjured 
tissue has been termed “hyperalgesia”. An example of classical hyperalgesia in humans 
is the unpleasant pricking pain evoked by a blunt probe applied adjacent to injured 
tissue. In other situations, a stimulus normally perceived as innocuous, such as a brush 
of the skin, becomes intensely painful: this phenomenon is termed “allodynia” 
(Markenson, 1996; Warfield and Bajwa, 2004 and Lewin et al., 2004) (Figure 1.7).
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Figure 1.7. Effects of tissue injury on pain sensitization. The curve on the right shows normal 
pain response as a function of stimulus intensity. After injury, the curve shifts to the left: 
noxious stimuli become more painful (hyperalgesia), and innocuous stimuli are experienced as 
pain (allodynia). (Gottschalk and Smith, 2001).
1,4,2, Nociceptors
The propagation of pain is initiated with the activation of physiological
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receptors, called nociceptors, widely found in the skin, mucosa, membranes, deep 
fascias, connective tissues of visceral organs, ligaments and articular capsules, 
periosteum, muscles, tendons, and arterial vessels. The receptors correspond to free 
nervous endings and represent the more distal part of a first-order afferent neuron 
consisting of small-diameter fibers, with little or unmyelinated, of the A-Delta (rapid) or 
C type (slow) (Bessou and Perl, 1969), respectively. Their receptor fields can consist of 
areas ranging from punctiform regions to regions measuring several millimeters in 
diameter, or even of more than one site in distant territories (Mense, 1983; Lynn, 1992).
The nociceptors found in the skin originate from small nervous stems that, 
when approaching the epidermis, lose their myelin, ramifying into extensive plexuses. 
Two types of free nervous endings exist: the ramified ones originating from 1 or 2 
myelinated fibers forming intraepithélial terminations and the nonencapsulated 
glomerular bodies, deriving firom a single unmyelinated fiber and organized in a densely 
spiral manner below the epidermis or the mucosa. In other organs, this organization may 
vary because the type of propagated stimulation, the form of propagation, and the 
quality of the painful sensation depend on the receptor nervous fiber complex and the 
innerved organ (Willis and Westlund., 1997; Millan, 1999).
Normally, painful sensation results fi*om specific activation of the nociceptors 
by mechanical, thermal, or chemical stimulus, and not by the hyperactivity of other 
sensory modality receptors. They present higher thresholds than the other receptors and 
respond progressively according to the intensity of the stimulus. However, the 
sensitization of the nociceptors causes reduction of the thresholds and, in some cases, 
spontaneous activity (Mense, 1983; Willis and Westlund., 1997; Millan, 1999).
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1.43, Peripheral Afferent Fibers
Peripheral afferent fibers (first-order afferent fibers) are classified into three 
types in terms of structure, diameter, and conduction velocity. In the presence of a 
noxious stimulus, the primary nociceptive afferents show differentiated patterns of 
propagation.
1.4.3.1. C-Fibers
C-type fibers are unmyelinated, ranging in diameter from 0.4 to 1.2 Dm and 
have a velocity of 0.5-2.0 m/s. They propagate information in a slower way, at times 
secondary to the action of the A-Delta afferents. Their prolonged potentials undergo 
summation along time and induce the manifestations of dull pain. Although widely 
used, this differentiation does not apply to all organs, being more evident in the skin 
(Casey et al., 2004). The C-type fibers present thermosensitive receptors reacting to 
heating and cooling, mechanoreceptors of low threshold and specific receptors for 
algogenic substances such as potassium ions, acetylcholine, proteolytic enzymes, 
serotonin, prostaglandin, substance P, and histamine. Many C fibers with high-threshold 
receptors respond equally to thermal and mechanical stimuli, or are sensitive to 
mechanical, thermal and chemical stimuli, and for this reason are called, polymodal. A 
special type of C fiber responds to high intensity thermal stimuli and, in association 
with polymodal fibers, seem to be responsible for the mediation of the flare response 
after tissue damage.
Another type of C fiber of slow conduction, mechanoinsensitive, and mediated 
by histamine is also recognized and is probably involved in the burning sensation. 
Finally, a new class of fibers is described having receptors that do not respond to 
noxious stimuli in general, called silent receptors, which are activated only in the
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presence of inflammation (Willis and Westlund, 1997; Millan, 1999).
1.4.3.2. A-Delta Fibers
A-Delta (AO) fibers are barely myelinated, ranging in diameter firom 2.0 to 6.0 
□m and have a velocity of 12-30 m/s. They propagate modally specific information, 
with marked intensity and short latency. They promote a quick sensation of first phase 
or acute pain, triggering withdrawal actions. The A-Delta fibers are classified into two 
groups. The first one, type I, corresponds to fibers with high-threshold 
mechanoreceptors that primarily respond to mechanical stimuli of high intensity and 
respond weakly to thermal or chemical stimuli and, after being sensitized, to harmful 
heat. Group II presents fibers with mechanothermal receptors for high temperatures 
(45-53 °C) and some receptors for intense cold (-15 °C) and can later be sensitized to 
vigorous mechanical stimuli at nonnoxious thresholds (Willis and Westlund, 1997).
1.4.3.3. A-BetaFibers
The A-Beta fibers are myelinated, with a diameter of more than 10 Dm and a 
velocity of 30-100 m/s, and do not propagate noxious potentials in normal situations; 
however, they are fundamental in the painful circuitry because they participate in the 
mechanisms of segmental suppression (Willis and Westlund, 1997).
1,4.4, Sensitization o f Nociceptors
The process of sensitization (or hyperalgesia) is familiar: a stimulus strong 
enough to cause tissue damage hurts more with time, and even after the stimulus has 
been removed, the damaged area is hypersensitive to touch and to temperature. This 
phenomenon can be attributed partly to changes in pain transmission in the spinal cord
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at higher levels, but an important component results from processes occurring at the site 
of injury. A large number of molecules released by tissue damage are known to act as 
mediators of hyperalgesia. Examples include neuropeptides, prostaglandins, histamine, 
platelet-activating factor, and bradykinin (Kress and Reeh, 1996). With so many 
different factors able to cause hyperalgesia, it is perhaps no surprise that more than one 
cellular mechanism is involved. One recently elucidated mechanism involves activation 
of protein kinase A. External inflammatory messengers such as prostaglandins, 
serotonin, and adenosine activate adenylate cyclase and consequently increase the level 
of cAMP, leading to activation of protein kinase A (Levine et al., 1993).
Four principle mechanisms of afferent-induced central sensitization can be 
proposed:
• Synaptic mechanisms'. These include all changes that occur after an action 
potential invades the presynaptic nerve terminal of primary afferent AD- or C-fibers up 
to the postsynaptic currents that are activated by binding of the neurotransmitter to their 
postsynaptic receptors. Synaptic transmission may be affected by changes in the content 
or the release of neurotransmitter (presynaptic mechanism), the diffusion or inactivation 
of neurotransmitter, the density or the binding affinity of neurotransmitter receptors, or 
changes in the conductance or gating behavior of ion channels in the postsynaptic 
membrane (postsynaptic mechanism).
• Membrane excitability: Changes of membrane properties in postsynaptic 
neurons may affect the transformation of excitatory postsynaptic currents (EPSCs) to 
the discharge of action potentials. Examples for such alterations in nociceptive neurons 
are changes in input resistance or resting membrane potential, changes in threshold for 
action potential firing, or changes in after hyperpolarization leading to changes in 
discharge fi*equency and discharge patterns.
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• Phenotypical changes: These include, but are not limited to, the expression 
of new neurotransmitters, neuromodulators or their receptors in primary afferent nerve 
fibers or in spinal or supraspinal neurons following tissue injury.
• Morphological reorganization: This includes all afferent-induced 
morphological changes in spinal cord or brain such as sprouting of primary afferent 
nerve terminals, e.g. following nerve injury or apoptotic or excitotoxic cell death in 
spinal dorsal horn following intense noxious stimulation (Sandkuhler et al., 2000).
1,4.5. Nociceptive Afferent Fibers End on the Dorsal Horn o f  the Spinal Cord
Nociceptive afferent fibers terminate predominantly in the dorsal horn of the 
spinal cord:
The dorsal horn can be subdivided into six different layers (laminae) on the 
basis of the cytological features of its resident neurons that convey distinct modalities 
terminating in distinct laminae of the dorsal horn. Thus there is a close correspondence 
between the functional and anatomical organization of neurons in the dorsal horn of the 
spinal cord.
Nociceptive neurons are located in the superficial dorsal horn, in the marginal 
layer (also called lamina I) and the substantia gelatinosa (lamina II). The majority of 
these neurons receive direct synaptic input from AS and C fibers. Many neurons 
respond exclusively to noxious stimulation (and thus are called nociceptive-specific 
neurons) and project to higher brain centers. Some neurons in this layer, called wide- 
dynamic- range neurons, respond in a graded fashion to both nonnoxious and noxious 
mechanical stimulation. The substantia gelatinosa (lamina II) is made up almost 
exclusively of intemeurons (both excitatory and inhibitory), some of which respond 
only to nociceptive inputs while others respond also to nonnoxious stimuli.
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Laminae III and IV are located ventral to the substantia gelatinosa and contains 
neurons that receive monosynaptic input from A(3 fibers. These neurons respond 
predominantly to nonnoxious stimuli and have quite restricted receptive fields that are 
organized topographically. Lamina V contains primarily wide-dynamic-range neurons 
that project to the brain stem and to regions on the thalamus. These neurons receive 
monosynaptic input from A5 and Ap fibers. They also receive input directly from C 
fibers, either directly from their dendrites, which extend dorsally into the superficial 
dorsal horn, or indirectly via excitatory intemeurons that themselves receive input 
directly from C fibers. Many neurons in the lamina V also receive nociceptive input 
from visceral stmctures.
Neurons in lamina VI receive inputs from large diameter afferents from 
muscles and joints. These neurons are sensitive to nonnoxious manipulation of joints. 
These neurons are though to contribute to the transmission of nociceptive messages. 
Finally neurons in the ventral horn laminae VII and VIII, many of which respond to 
noxious stimuli have more complex response properties because the nociceptive inputs 
to lamina VII neurons are polysynaptic (Christensen and Perl, 1970; Nashold and 
Ostdahl, 1979; Cervero and Iggo, 1980; Ruda et al., 1986).
1.4.6. Spinal Cord Tracts
Nociceptive signals transmitted from the spinal cord to the brain through five 
major ascending pathways: the spinothalamic, spinoreticular, spinomesencephalic, 
cervicothalamic, and spinohypothalamic tracts.
The spinothalamic tract is the major ascending nocicpetive pathway in the 
spinal cord. It consist of the axons of nociceptive specific and wide dynamic range 
neurons in laminae I and V-VII of the dorsal horn. These axons project to the
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contralateral side of the spinal cord and ascend in the anterolateral white matter, 
terminating in the thalamus. Electrical stimulation of the spinothalamic tracts results in 
pain.
The spinoreticular tract contains the axons of neurons in laminae VII and VIII. 
It goes up in the anterolateral quadrant of the spinal cord and ends in both the reticular 
formation and the thalamus. In contrast to the spinothalamic tract, it does not cross the 
midline.
The spinomesencephalic tract comprises the axons of neurons in laminae I and 
V. it projects in the anterolateral quadrant of the spinal cord to the mesencephalic 
reticular formation and periaqueductal gray matter, and via the spinoparabrachial tract, 
it projects to the parabrachial nuclei.
The cervicothalamic tract comprises the axons of neurons in lamina I, V, and 
VIII. It projects directly to supraspinal autonomic control centers and is thought to 
activate complex neuroendocrine and cardiovascular responses (Noordenbos and Wall, 
1976; Morgan and Heinricher, 1992).
1.4.7. Thalamic Nuclei Transmit Afferent Information to the Cerebral Cortex
Several nuclei in the thalamus process nociceptive information. Two are 
particularly important: the lateral and medial nuclear groups. The lateral nuclear group 
of the thalamus comprises the ventroposterior medial nucleus, the ventroposterior lateral 
nucleus, and the posterior nucleus. These nuclei receive input via the spinothalamic 
tract, primarily from nociceptive specific and wide dynamic range neurons in laminae I 
and V of the dorsal horn of the spinal cord. Neurons from these nuclei have small 
receptive fields, as do the spinal neurons that project to them. The lateral thalamus may 
therefore be mostly concerned with mediating information about the location of an
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injury, information usually conveyed to consciousness as acute pain.
The medial nuclear group of the thalamus comprises the central lateral nucleus 
of the thalamus and intralaminar complex. Its major input is from neurons in laminae 
VII and VIII of the dorsal horn. Many neurons in the medial thalamus respond 
optimally to noxious stimuli but also have widespread projections to the basal ganglia 
and many different cortical areas. They are therefore concerned not only with 
processing nociceptive information but also with stimuli that activate a nonspecific 
arousal system (Melzack, 1989; Talbot etal., 1991).
1.4.8. The Cerebral Cortex Contributes to the Processing o f Pain
Until recently most research on the central processing of pain has concentrated 
on the thalamus. However pain is a complex perception that is influenced by prior 
experience and by the context within which the noxious stimulus occurs. Neurons in 
several regions of the cerebral cortex respond selectively to nocicpetive input. Some of 
these neurons are located in the somatosensory cortex and have small receptive fields. 
Thus they may not contribute to the diffuse aches that characterize most clinical pain 
(Melzack, 1989; Talbot a/., 1991).
1.4.9. Factors Involved in Sensitization
Synaptic transmission between nociceptors and dorsal horn neurons is 
mediated by chemical neurotransmitter released by AS (glutamate) and C fibers 
(substance P). Upon repeated application of noxious mechanical stimuli, nearby 
nociceptors that were previously unresponsive to mechanical stimuli now become 
responsive a phenomenon called sensitization. The sensitization of nociceptors after 
injury or inflammation results from the release of variety of chemicals by the damaged
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cells and tissues in the vicinity of the injury (Greenspan, 1997). These are some of the 
important substances involved in sensitization and pain:
1.4.9.1. Prostaglandins
Prostaglandins are metabolites of arachidonic acid and are generated by the 
enzyme cyclooxygenase released from damaged cells. The major action of 
prostaglandins are sensitization of primary afferent nociceptors (PANs) to noxious 
stimuli (e.g., chemical, heat, mechanical) (Chahl and Iggo, 1977; Birrell et a l, 1991), 
probably via activation of cyclic adenosine monophosphate (cAMP) (Taiwo and Levine, 
1991) and sensitization of nerve afferents to bradykinin. Prostaglandins are not known 
to activate cutaneous afferents directly (Chahl and Iggo, 1977). On the other hand they 
activate nociceptors directly during inflammatory conditions (Birrell et al., 1991).
1.4.9.2. Bradvkinin
Bradykinin is released following tissue injury and is present during 
inflammation. It acts directly on PANs and causes pain (Whalley et al., 1987). 
Bradykinin carmot account alone for the hyperalgesia seen in inflammation (Marming et 
al., 1991), it acts synergistically with prostaglandin and cause release of arachidonic 
acid and conversion to prostaglandin E2 (PGE2). Subsequently, PGE2 directly stimulates 
PANs or sensitizes them to noxious stimuli (Chahl and Iggo, 1977).
1.4.9.3. Protons
Inflammation or tissue injury causes a decrease in pH of the extracellular space 
secondarilly to local hypoxia, resulting in activation, excitation and sensitization of 
PANs. Protons, which lower pH, selectively activate nociceptors and sensitize them to
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noxious stimuli (Steen et al., 1992).
1.4.9.4. Substance P
Located in the dorsal root ganglion neurons, substance P is transported to the 
periphery and released after PAN activation (Harmar and Keen, 1982; White and 
Helme, 1985). It intensifies pain by mechanisms involving inflammation, including 
prostaglandin release and cytokine stimulation (Saria, 1984; Lotz, 1987).
1.4.9.5. Nitric Oxide
The actual role of NO in nociception is unclear; it may be relevant for the 
actions of substance P and bradykinin in peripheral hyperalgesia. Inflammation leads to 
an upregulation of NO synthase in the dorsal root ganglion (DRG) and other cells. 
Ultimately neuropeptides may be released from nociceptive terminals, which can 
produce inflammatory hyperalgesia (Millan, 1999). Subcutaneous injection of NO 
produces pain (Holthusen and Arndt, 1994).
1.4.9.6. Cvtokines
Although the prostaglandins and sympathomimetic amines seem to be the final 
hyperalgesic mediators acting on primary sensory neurons (PSN) (Poole and woolf, 
1999), their release is usually preceded by the production of other mediators. The 
release of cytokines constitutes a link between the cellular injury and the production of 
those mediators responsible for the development of the inflammatory signs and 
symptoms.
Cytokines that are known to have major roles in initiating and sustaining 
inflammatory events and which are called the “pro-inflammatory cytokines”, include
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IL-1, IL-6, IL-8 and TNF-a. On the other hand, the cytokines which play a major role in 
modulating the immune response usually leading to the resolution of inflammation 
(called anti-inflammatory cytokines) include IL-1 receptor antagonist (IL-lra), IL-4, IL- 
10, IL-13 and transforming growth factor-p (TGF-p) (Henderson et al., 1994). 
However, it is more appropriate to consider, the right concentration in the right place, at 
the right time, for any cytokine to classify it as either a pro or anti-inflammatoiy 
cytokine since an absolute classification could be misleading. For example, IL-6, has 
many pro-inflammatory as well as anti-inflammatory actions (Dinarello, 1997).
• Interleukin-1 (IL-1):
Interleukin-1 (IL-1) is a proinfiammatory cytokine, produced by many types of 
cells, including immune cells in the periphery, as well as glia and neuron cells within 
the central nervous system (Dinarello, 1997), it induces prostaglandin PGE2 which 
activates PAN (Dayer et al., 1986). IL-1 shares many biological properties with other 
proinfiammatory cytokines, particularly with IL-18; both cytokines belong to the same 
gene family and share structural and functional similarities with each other (Dinarello, 
1999) and with TNF-a (Moldawer, 1994). In addition to its role in regulation of the 
inflammatory response, IL-1 plays a major role in immune-to-brain communication, in 
modulation of neural and neuroendocrine systems, and in behavioral changes during 
illness. Induction of IL-1 results in: (1) changes in several neurotransmitter systems, 
including the monoamines, acetylcholine, GAB A, and glutamate; (2) neuroendocrine 
alterations, including activation of the hypothalamus-pituitary-adrenal axis; (3) 
physiological changes, including fever, loss of body-weight, activation of the 
sympathetic nervous system, and suppression of peripheral immune response; (4) 
behavioural alterations, including anorexia, altered sleep patterns, fatigue, and reduction 
of locomotors, exploratory, social, and sexual behaviors (Besedovsky and del-Rey,
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1996; Maier and Watkins, 1998; Rothwell and Luheshi, 2000; Yirmiya et aL, 2000).
Mice with impaired IL-1 signaling display lower thermal and mechanical pain 
sensitivity, compared to their wild-type controls (Cullinan et al., 1998).
Interleukin-ip (IL-lp) has been observed to produce nociceptive effects when 
administered peripherally (Maier et al., 1993; Watkins et al, 1994; Safieh-Garabedian 
et al., 1995) or intracerebroventricularly (Oka et al., 1993; Watkins et al., 1994) and has 
also been implicated in the mediation of thymulin induced hyperalgesia in peripheral 
tissues (Safieh-Garabedian et al., 1997). It has been hypothesized that IL-ip may also 
serve as a mediator that sensitizes nociceptive neurons during inflammation and has 
been shown to play a central role in the generation of mechanical hyperalgesia (Watkins 
et al., 1994). The peripheral pro-nociceptive action of IL-ip may be mediated by a 
complex signaling cascade and secondary production of nitric oxide, bradykinin or 
prostaglandins (Poole et al., 1999).
IL-ip has also been implicated in modulation of pain sensitivity. Exogenous 
administration of IL-1 p usually produces hyperalgesia. Initial studies found that IL-ip 
produces hyperalgesia, following either peripheral or central administration (Oka et al., 
1993; Watkins et al., 1994). In peripheral nerves, IL-ip has been found in DRG neurons 
and in Schwann cells. In addition, expression of IL-1 receptor type I (IL-IRI) mRNA 
was detected in dorsal root ganglion neurons, suggesting a possible autocrine or 
paracrine action of IL-1 p on sensory processing (Copray et al., 2001). IL-ip also plays 
an important pain-modulatory role within the spinal cord. Intrathecal administration of 
IL-ip induces mechanical allodynia and thermal hyperalgesia (Tadano et al., 1999; 
Reeve et al., 2000; Falchi et al., 2001). It enhances the release of substance P in the 
spinal cord (Malcangio et al., 1996) and induces COX 2 expression (Newton et al., 
1997). Many studies have shown that the local release by IL-ip of COX products such
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as PGs contributes to the evoked hyperalgesia (Geng et al., 1995).
• Interleukin-1 receptor antagonist (IL-Ira):
Inflammatory hyperalgesia is prevented by experimental administration of 
endogenous IL-1 receptor antagonist (IL-lra), and neutralizing antibodies to IL-1 
receptors reduce pain associated behavior in mice with experimental neuropathy (Cunha 
et al., 2000).
IL-1 was also found to play an important role in mediating the hyperalgesic 
effects of various inflammatory stimuli. For example, treatment with IL-1 neutralizing 
antibodies or with IL-lra were found to attenuate or block the hyperalgesia produced by 
endotoxin (Maier et al., 1993), complete Freund’s adjuvant (Safieh-Garabedian et al., 
1995), nerve injury (Sommer et al., 1999) and carrageenin or bradykinin (Pool et al., 
1995; Cunha et al., 2000). Whereas blockade of IL-1 at the spinal cord level can prevent 
hyperalgesia induced by various inflammatory stimuli, including subcutaneous 
peripheral inflammation (Watkins et al., 1997; Samad et al., 2001).
IL-lra injection produced an almost complete reversal of the endotoxin (ET) 
induced hyperalgesia (mechanical), while hyperalgesia assessed by HP and TF tests was 
partially reduced (Safieh-Garabedian et al., 1997). Experiments in various animal 
models suggest that IL-1 is an important contributor to neuropathic pain. This lead to 
the suggestion that IL-lRa may serve an analgesic function under the appropriate 
conditions. Using a rodent L5 spinal nerve transaction model, it was shown that 
although administration of IL-1 Ra alone failed to reduce pain, it improved the ability of 
soluble TNF receptors to do so. This was associated with reduced expression of IL-6, 
but not IL-1, in the spinal cord (Sweitzer et al., 2001). Patients with fibromyalgia, a 
condition associated with chronic pain, have higher levels of circulating IL-lRa. In 
general, the majority of studies have shown that exogenously injected IL-ip is pro­
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nociceptive in animals but not clearly in man. This question can only be answered when 
and IL-1 receptor antagonist is used clinically, but the animals studies suggest that IL-1 
may be and important pain mediator in humans.
• Interleukin-6 (IL-6):
The pleiotropic cytokine IL-6 is markedly upregulated during various 
pathologic situations generally associated with increased pain and hyperalgesia 
(Sommer, 2001). It induces release of prostaglandin E (PGE) from mononuclear cells, 
which activate primary afferent nociceptors (PAN) (Cunha et al., 1992). Increased IL-6 
serum levels have been detected in patients with neuropathies, malignant tumors, 
musculoskeletal disorders, bum injury, autoimmune and chronic inflammatory 
conditions. All these disorders have in common a tenderness sensation and 
hypersensitivity of the affected tissues. Most experimental studies report pro- 
inflammatory and pro-nociceptive roles for IL-6. Intraplantar, intracerebroventricular or 
intrathecal injection of IL-6 induces hyperalgesia or allodynia in rats. IL-6-/- mice 
present with reduced thermal hyperalgesia after carrageenan inflammation or nerve 
injury. Antisera neutralizing endogenous IL-6 inhibit LPS-induced hyperalgesia (De 
Jongh et al., 2003; Sommer, 2001). It also induces allodynia and hyperalgesia via 
actions in the dorsal horn (De Leo et al., 1996). In addition, the intraplantar injection of 
IL-6 has been shown to produce hyperalgesia (Cunha et al., 1992).
Dinarello (1994, 1997) reported that IL-6 has more anti-inflammatory actions 
than proinflammatoiy ones. Two studies have examined the effect of exogenously 
administered IL-6 on nociception with some conflicting results. Oka et al. (1995) found 
that intracerebroventricular injection of IL-6 induced thermal hyperalgesia in naive rats 
in an IL-1 independent way. Whereas intracistemal IL-6 had anti-nociceptive effects in 
an acute orofacial pain model, as assessed by the nociceptive jaw opening reflex,
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hyperalgesic effects were observed in an inflammatory orofacial formalin pain model 
(Choi et al., 2003). A recent study by Flatters et al. (2004) reported that exogenous 
spinal IL-6 (100-500 ng) had no significant effect on electrically evoked neuronal 
responses in naive rats. In contrast, following neuropathy, spinal IL-6 produced a dose- 
related inhibition of the electrically evoked C-fiber. In addition, spinal IL-6 markedly 
inhibited mechanical neuronal responses in neuropathic rats. Higher doses of spinal IL- 
6 also inhibited the C-fibers but, to a lesser degree. This suggests that IL-6 is a potential 
modulator of neuropathic pain.
• Tumor Necrosis Factor-a (TNF-a):
There have been correlations between tissue levels of TNF-a and pain and 
hyperalgesia in a number of painful diseases (Barnes et al., 1992; Shafer et al., 1994 
and Tak et al., 1997; Lindenlaub and Sommer, 2003). It induces release of IL-I and IL- 
6 (Lindsay and Harmar, 1989).
TNF-a is widely considered the prototypic proinfiammatory cytokine due to its 
principal role in initiating the cascade of activation of other cytokines and growth 
factors in the inflammatory response. After injury or during inflammation, TNF-a is 
synthesized and released by a multitude of cell types. It has also been demonstrated that 
Schwann cells can produce TNF-a after injury, suggesting a possible role in neuropathic 
pain (Wagner and Myers, 1996; Sommer et al., 1998).
TNF-a induces production of IL-ip, IL-6 and IL-8. This cytokine cascade 
finally results in the activation of cyclooxygenase-2 dependent prostanoid release and 
the release of catecholamines fi*om sympathetic fibers (Poole et al., 1999).
• Interleukin-10 (IL-10):
IL-10 is known to inhibit inflammatory hyperalgesia (Poole et al., 1995; 
Kanaan et al., 1998; Opal and DePalo, 2000) by down-regulating the production of IL-
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1, TNF-a and Nerve growth Factor (Bogdan et al., 1991; Oswald et al., 1992; Jenkins et 
al., 1994; Saadé et al., 2000). Furthermore, IL-10 is able to inhibit the hyperalgesic 
responses to TNF-a and IL-6 but not to IL-8 and PGE2 (Poole et al., 1995). This is due 
to the fact that the hyperalgesic activities of TNF-a and IL-6 depend on the induction of 
cytokines (IL-1 (3 and IL-8, and IL-ip respectively), while IL-8 induces the production 
of sympathomimetic amines (Cunha et al., 1991). IL-10 was shown also to inhibit IL- 
ip-stimulated PGE2 production mainly through suppressing COX-2 (Poole et al., 
1995). Recent studied have shown that IL-10 potentiated and prolonged the analgesic 
effect of morphine (Johnston et al., 2004).
• Interleukin-IS (IL-13):
IL-13 has a suppressive effect on IL-1 synthesis and induces B lymphocyte 
expansion and immunoglobulin production (Hart et al., 1989; Vannier et al., 1992). 
Concerning the effect of IL-13 on the pain thresholds, Lorenzetti et al. (2001) suggested 
that IL-13, released by lymphocytes, limits the inflammatory hyperalgesia (due to E.coli 
endotoxin, LPS injection) by inhibiting the production of TNF-a, IL-ip and PGE2. 
Similarly, the pretreatment with IL-13 prevented, in a dose dependent manner, the 
hyperalgesia induced by UVB. This is in correlation with the concomitant down- 
regulation of the increased levels of TNF-a and IL-ip by UVB (Saadé et al., 2000).
1.5. Hypothesis and Aims
As a summary, in murine cutaneous leishmaniasis (CL) caused by Leishmania 
major, the outcome of infection depends on the activation of either CD4^ Thl or Th2 
cells, which differ by their pattern of cytokine production. When BALB/c mice are 
infected with a high dose of L. major, a Th2 response prevails leading to the
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exacerbation of the disease. This infection causes a persistent state of hyperalgesia 
which appears very early in infection even before any lesion develops. This 
hyperalgesia is accompanied by the up-regulation of some pro-inflammatory cytokines 
such as IL-lp. However, when BALB/c mice are injected with low dose of L  major, 
they mount a protective Thl immune response and acquire systemic resistance. 
Although the lesion ultimately heals, the mice show significant pathology. Therefore, 
we suggest that low dose of L  major can cause a hyperalgesic state early in infection 
accompanied by the up-regulation of some pro-inflammatory cytokines such as IL-ip 
and IL-6.
On the other hand, IL-10 and IL-13 are shown to have a hypoalgesic effect in 
many inflammatory models, mainly through down-regulating some pro-inflammatory 
cytokines, mainly IL-lp. Therefore, we hypothesize that those two cytokines are able to 
reduce the L  /wq/or-induced hyperalgesia in both high and low dose models. However, 
since IL-10 and IL-13 are produced mainly by Th2 cells, they might be able, if present 
early in infection, to change the cytokine milieu and therefore the course and outcome 
of the infection leading to an enhanced Th2 response in the high dose model and to the 
inhibition of the suspected Th2/Thl switch in the low dose model.
Therefore, since IL-10 and IL-13 have might many potential clinical uses 
especially as hypoalgesic agents, it is of major importance to determine whether their 
presence only reduces hyperalgesia or might have a drastic effect on the course and 
outcome of cutaneous leishmaniasis.
This thesis, therefore aims to answer the following questions:
• Does the low dose of L. major, as in the case of high dose, cause a state of 
hyperalgesia and for how long?
• Is the L. major -induced hyperalgesia accompanied by the up-regulation of
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the pro-inflammatory cytokines IL-lp and IL-6?
• Do IL-10 and IL-13 have a hypolagesic effect on the L. maJor-mducQd 
inflammation in both doses?
• Does the hypoalgesic dose of IL-10 arid IL-13 cause a major change in the 
course of L. major infection as assessed by the level of IL-4 in the paws, the parasite 
burden and the paw thickness of the infected paws?
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CHAPTER! 
MATERIALS AND METHODS
2.1. Experimental Animals
Adult female BALB/c mice, provided by the animal house at the Lebanese 
American University (20-30 g) were used in all the experiments performed in this study. 
The animals were housed under optimal conditions of light and temperature (12 hours 
light and 12 hours dark cycles; 22 ± 3°C) and received solid food and water ad libitum. 
During the period of the experiments, the mice were kept in groups of five, in clear 
plastic cages with solid floors covered with 3-6 cm of saw dust. All experimental 
procedures were carried out with strict adherence to the ethical guidelines for the study 
of experimental pain in conscious animals (Zimmerman, 1983).
2.2. Parasite Culture and Preparations
Leishmania major (MHOM/SU/73/5 ASKH) parasites (provided by the 
London School of Hygiene and Tropical Medicine) were grown at 22 ± 1°C to 25 ± 1°C 
in a standard biphasic medium and subcultured weekly. The solid medium (underlay) 
was made of bactoagar supplemented with 10% rabbit blood, while the liquid medium 
(overlay) consisted of Lock's solution (4g NaCl, 0.2g CaCli, 0.2g KCl and 0.2g glucose 
in 500 ml distilled water) supplemented with 10% heat-inactivated fetal calf serum (at 
56°C for 30 min.), 100 lU/ml of penicillin and 100 lU/ml of streptomycin (Sigma). The 
overlay solution containing the promastigote forms of the parasite were centrifuged for 
10 min at 2500 rpm and the parasites were resuspended in 1ml Lock's medium. The 
parasite count was determined in a trypan blue solution using a hemocytometer and
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readjusted to have 2.5x10^ parasites per 50pl Lock's medium for the high dose and to 
have 4x10^ parasites per 50pl Lock's medium for the low dose of L. major. All mice 
were injected subcutaneously (s.c.) with the parasite in the ventral side of their left hind 
paw.
2.3. Behavioural Measurments
2.3.1, Experimental Groups
The reported results are based on two sets of experiments each involving 
different groups of mice (n = 5-6 in each).
In the first set of experiments, four groups were subjected to different pain tests 
three days before any treatment, then one group received intraplantar injection (i.pl.) 
injection high dose of Leishmania major (2.5x10^ promastigote s/5 0 pi Lock’s 
medium/left hind paw), the second group received i.pl. injection low dose of 
Leishmania major (4 xl0^promastigotes/50pl Lock’s medium/left hind paw). The two 
remaining groups were used as control, one with no treatment and the other received i.pl 
injection of Lock’s medium (50pl /left hind paw). All groups were subjected to pain 
tests three times weekly following the injections for a period ranging between 24 to 32 
days.
In the second sets of experiments, seven groups of mice were subjected to 
different pain tests three days before any treatment, then three groups received i.pl. 
injection high dose of Leishmania major (2.5x10^ promastigotes/50pi Lock’s 
medium/left himd paw), one of which was left with no treatment while the other two 
groups received daily i.p. injections for six consecutive days of interleukin-10 (15 
ng/animal) and interleukin-13 (15 ng/animal) respectively. The other three groups 
received i.pl. injection low dose of Leishmania major (4 xlO  ^ promastigotes/5Opl
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Lock’s medium/left hind paw), one of which was left with no treatment while the other 
two groups received daily i.p. injections for six consecutive days of interleukin-10 (15 
ng/animal) and interleukin-13 (15 ng/animal) respectively. The seventh group consisted 
of naïve mice and was used as control.
2.3.2. Pain Tests
The hot plate (HP) and the tail flick (TF) tests were used to assess the thermal 
pain thresholds.
2.3.2.1. The Tail Immersion Test
The tails of the mice were immersed into a beaker of distilled water, the 
temperature of which being adjusted at T= 50°C (±0.5°C). The time interval between the 
immersion of the tail and the tail flicking reaction was recorded using a digital 
stopwatch with a 1/100 second precision. Each animal was subjected to this test three 
times with a three minutes interval between consecutive measurements and the average 
was recorded (Kanaan et al., 1996).
2.3.2.2. The Hot Plate Test
Each animal was placed on a heated pad with the temperature being adjusted at 
T = 51°C (±0.5°C). The latency of paw licking or jumping was taken a digital stopwatch 
with a 1/100 second precision as an index of pain threshold (Kanaan et al., 1996).
2.4. Immunoassays
2.4.1. Tissue Processing
The skin of both right (non-injected) and left (injected) hind paws of the
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infected mice, was removed under deep anesthesia with pentobarbital (50mg/kg). The 
removed parts of skin were stored at -82°C. Tissues were removed at days 2, 4, 6, 13,21 
post-infection from mice infected subcutaneously (s.c.) with Leishmania major (both 
high and low dose) alone and from those infected with the parasite and treated 
intraperitoeanlly (i.p.) with 15 ng/animal of IL-10 or IL-13 for 6 consecutive days. Both 
paws (treated and none treated) were individually homogenized for 1 minute at a speed 
of 20,000 r.p.m. in 1.2 ml of a phosphate buffered saline (PBS) based homogenization 
buffer. 100ml PBS contained 0.818g, NaCl, 0.02g KCl, 0.02g KH2PO4, 0.115g 
Na2HP0 4  and was made up by adding 100 ml double distilled water and regulating the 
pH in a range between 7.2 - 7.4. The homogenization buffer was prepared by adding: 
2.3376g of NaCl, 0.5g of bovine serum albumin (BSA), 50 pi of tween 20 and 2 tablets 
protease inhibitor to 100ml of PBS. The homogenized samples were centrifuged at 
13000 g for 60 minutes at 4°C; supernatants were removed and stored in 
pyrogen/endotoxin-free tubes at -82°C until further usage.
2,4,2. Interleukin-1 pAssay
A  mouse IL-ip (mlL-ip) kit was provided by The BioSource International, 
Inc. mlL-ip kit is a solid phase sandwich Enzyme Linked-lmmuno-Sorbent Assay 
(ELISA). A monoclonal antibody specific for mlL-ip (IgGl) has been coated onto the 
wells of the microtiter strips provided. 50 pi of control specimens and samples are 
added to their corresponding wells, followed by the addition of a 50 pi of biotinylated 
anti-lL-ip (Biotin Conjugate) into each well except the chromogen blanks. During the 
first incubation (for one hour and a half at 37°C), the mlL-ip antigen binds 
simultaneously to the immobilized (capture) antibody on one site, and to the solution 
phase biotinylated antibody (IgGl) on a second site, after removal of excess second
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antibody by washing four times, a 100 pi of Streptavidin-Peroxidase (enzyme) is added 
into each well except the chromogen blanks. This binds to the biotinylated antibody to 
complete the four member sandwich. After a second incubation (for 30 minutes at room 
temperature) and followed by washing four times to remove all unbounded enzyme, 100 
pi of stabilized chromogen (which is acted upon by the bound enzyme to produce 
colour) is added and incubated for 30 minutes at room temperature and in the dark, 
followed by adding stop solution (100 pi). The intensity of this coloured product is 
directly proportional to the concentration of mlL-lp present in the samples. The optical 
density was read by a plate reader using 450 nm filter.
2.4,3, Interleukin-6
A mouse lL-6 (mlL-6) kit is also provided by The BioSource International, Inc. 
mlL-6 kit is a solid phase sandwich ELISA. A monoclonal antibody (IgGl) specific for 
mlL-6 has been coated onto the wells of the microtiter strips provided. 100 pi of 
standard diluent is added to zero wells (Wells reserved for chromogen blank should be 
left empty) then 100 pi of samples are added to the other empty wells followed by 
incubation for 2 hours at room temperature. During the first incubation, the mlL-6 
antigen binds simultaneously to the immobilized (capture) antibody on one site, after 
washing four times a 100 pi of biotinylated anti-lL-6 (lgG2a) (biotin Conjugate) 
solution is added into each well except the chromogen blanks followed by incubation 
for 30 minutes at room temperature then washing wells four times. 100 pi of 
Streptavidin-HRP is added into each well except the chromogen blanks followed by 
incubation for 30 minutes at room temperature. This binds to the biotinylated antibody 
to complete the four member sandwich. After a third incubation and washing four times
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to remove all unbounded enzyme, a 100 pi of stabilized chromogen (which is acted 
upon by the bound enzyme to produce colour) is added and incubated for 30 minutes at 
room temperature and in the dark, followed by adding stop solution (100 pi). The 
intensity of this coloured product is directly proportional to the concentration of mlL-ip 
present in the samples. The optical density was read by a plate reader using 450 nm 
filter.
2.4.4. Interleukin-4 Assay
A mouse lL-4 (mlL-4) kit is also provided by The BioSource International, Inc. 
mlL-4 kit is a solid phase sandwich ELISA. A monoclonal antibody (lgG2b) specific 
for mlL-4 has been coated onto the wells of the microtiter strips provided. 100 pi of 
standard diluent is added to zero wells (Wells reserved for chromogen blank should be 
left empty) then 100 pi of samples are added to the other empty wells followed by 
incubation for 2 hours at room temperature. During the first incubation, the mlL-4 
antigen binds simultaneously to the immobilized (capture) antibody on one site, after 
washing four times a 100 pi of biotinylated anti-lL-4 (IgGl) (biotin Conjugate) solution 
is added into each well except the chromogen blanks followed by incubation for 30 
minutes at room temperature then washing wells four times. 100 pi of Streptavidin-HRP 
is added into each well except the chromogen blanks followed by incubation for 30 
minutes at room temperature. This binds to the biotinylated antibody to complete the 
four member sandwich. After a third incubation and washing four times to remove all 
unbounded enzyme, a 100 pi of stabilized chromogen (which is acted upon by the 
bound enzyme to produce colour) is added and incubated for 30 minutes at room 
temperature and in the dark, followed by adding stop solution (100 pi). The intensity of
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this coloured product is directly proportional to the concentration of mIL-ip present in 
the samples. The optical density was read by a plate reader using 450 nm filter.
2.5. Parasite Load
The reported results are based on two sets of experiments each involving 
different groups of mice (n = 5-6 in each).
In the first set of experiments, 16 groups of mice had their infected paws 
removed under deep anestesia with pentobarbital (50 mg/kg) at days 2, 7, 14 and 21 
post-infection. Eight groups were infected (s.c.) with high dose of L  major, out of 
which four groups were treated (i.p.) with 15 ng/animal of IL-10 for the first 
consecutive days. The other eight groups were infected (s.c.) with low dose of L. major 
and again out of which four groups were treated with 15 ng/animal of IL-10 for the first 
consecutive days.
In the second set of experiments, 16 groups of mice had their infected paws 
removed under deep anestesia with pentobarbital (50 mg/kg) at days 2, 7, 14 and 21 
post-infection. Eight groups were infected (s.c.) with high dose of Z. major, out of 
which four groups were treated (i.p.) with 15 ng/animal of IL-13 for the first 
consecutive days. The other eight groups were infected (s.c.) with low dose of L. major 
and again out of which four groups were treated with 15 ng/animal of IL-13 for the first 
consecutive days. The removed parts of the skin were stored at -80° C.
The paws of mice were inoculated into sterile plastic tubes containing 2 mL of 
Lock’s medium. Then, they were homogenized manually with a Teflon tip for 5 
seconds, then centrifuged at 1000 rpm (SIGMA 2K15) for 5 minutes. The supernatants 
containing the parasite cells were then removed and stained with trypan blue and 
counted using a Neubauer chamber (Haemocytometer).
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2.6. Paw Thickness
The paw thickness of mice was measured using a digital calliper on a weekly 
basis for 32 weeks post-infection.
In the first set of experiments, four groups had their paw thickness measured. 
One group received intraplantar injection (i.pl.) injection high dose of Leishmania 
major (2.5x10^ promastigotes/5Opl Lock’s medium/left hind paw), the second group 
received i.pl. injection low dose of Leishmania major (4 xlO  ^ promastigotes/50pl 
Lock’s medium/left hind paw). The two remaining groups were used as control, one 
with no treatment and the other received i.pl injection of Lock’s medium (50pl /left hind 
paw).
In the second sets of experiments, six groups of mice had their paw thickness 
three groups received i.pl. injection high dose of Leishmania major (2.5x10^ 
promastigotes/50pi Lock’s medium/left himd paw), one of which was left with no 
treatment while the other two groups received daily i.p. injections for six consecutive 
days of interleukin-10 (15 ng/animal) and interleukin-13 (15 ng/animal) respectively. 
The other three groups received i.pl. injection low dose of Leishmania major (4 xlO^ 
promastigotes/5 Dpi Lock’s medium/left hind paw), one of which was left with no 
treatment while the other two groups received daily i.p. injections for six consecutive 
days of interleukin-10 (15 ng/animal) and interleukin-13 (15 ng/animal) respectively.
2.7. Data Analyses
For the behavioural tests, the values obtained from individual animals in each 
experimental group were averaged for each time interval in each test and plotted against 
time. The degree of significance of differences between the values obtained for each 
time interval in the different groups was compared to the control values using one-way
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ANOVA followed by Bonferoni post-hoc test. For the immunoassays, the determination 
obtained for each cytokine at each time interval were averaged for each experimental 
group. Comparisons were made between the pairs of injected legs and naive for each 
time interval following injections. The degree of significance of differences between 
those measurments was calculated by one-way ANOVA followed by Bonferoni post- 
hoc test.
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CHAPTER 3 
EFFECT OF HIGH AND LOW DOSE OF LEISHMANIA 
MAJOR ON PAIN THRESHOLDS
3.1. Introduction
Subcutaneous injection of Leishmania major in the paw of susceptible mice 
such as BALB/c mice is characterized by a cutaneous inflammation leading to a moist 
lesion which appears 3- 4 weeks following the injection (Cony et al, 1994).
The injection of mice with Leishamnia major leads to hyperalgesia and to the 
increase of the level of pro-inflammatory cytokines Interleukin-1 p (IL-lp) and Nerve 
Growth Factor (NGF) even before any lesion appears (Kanaan et al., 2000). This up- 
regulation might explain this observed hyperalgesia in the light of recent evidence on 
the role of cytokines in the sensitization of nerve afferents and the subsequent 
hyperalgesia. On the other hand, if BALB/c mice are injected with low dose of 
Leishmania major, they show significant pathology rather than a subclinical infection, 
although the lesion will ultimately heal (Doherty and Coffinan, 1996). Therefore, it is of 
great importance to assess the occurrence of any nociceptive state in those mice and to 
determine the role of some pro-inflammatory cytokines such as IL-ip and lL-6 in this 
hyperalgesia.
3.2. Does Leishmania major Infection Induce Hyperalgesia in Mice Infected With 
High Dose As Well As Low Dose of the Parasite?
3.2.L The Effect o f Lock’s Medium Injection on the Induction o f Hyperalgesia
To ensure that the transport medium used in subsequent experiments did not 
have a detrimental effect on experimental outcome, mice were injected with 50 p,L of
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Lock’s medium per left hind paw. This had no effect on either the hot plate test or the 
tail flick test for pain thresholds as compared to untreated mice, the p value being 
greater than 0.5 in both cases and at all dates post-infection (Figures 3.1 A and 3.IB).
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Figure 3.1. Time course of the effect of intraplantar injection of Lock’s medium on the thermal 
hyperalgesia of mice as assessed by (A) the hot plate test and (B) the tail flick test. Mice were 
injected with 50 p,l of Lock’s medium per left hind paw or left untreated. They were tested 3-4 
times per week for hot plate and tail flick latency. Each result is the mean of 5 mice ± standard 
error of the mean (SEM).
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5.2.2. The Effect o f High Dose Leishmania major on the Induction o f Hyperalgesia
The hot plate (HP) and tail flick (TF) test were used to assess the extent of 
hyperalgesia produced by the intraplantar injection of Leishmania major (2.5 x 10^  
promastigotes/50 pi Lock's medium/left hind paw). As shown in Figure 3.2A, the 
injection of Leishmania major produced a significant decrease in the HP latency (as 
calculated with reference to untreated mice using one-way ANOVA followed by the 
Bonferroni post-hoc test). It dropped significantly at day one post-infection from 17.00 
± 0.16s in the untreated mice to 10.61 ± 0.95s (p= 0.0002) reaching a minimum of 8.43 
± 0.32s at day 10 post-infection as compared to 16.9 ± 0.26s in the untreated mice with 
a p value less than 0.001 (Figure 3.2A).
The TF latencies dropped significantly at day 1 post-infection (3.72 ± 0.12s) as 
compared to the control (5.037 ± 0.086s) (p= 0.0004) and reached a peak at day 10 
post-infection when the TF latency dropped from 5.17 ± 0.036s in the control mice to 
3.09 ± 0.027s (p< 0.001) sustaining this level throughout the experiment as shown in 
Figure 3.2B.
5.2.5. The Effect o f Low Dose Leishmania major on the Induction o f  Hyperalgesia 
Since high dose L. major was shown to induce hyperalgesia even before any 
lesion appears (Kanaan et al., 2000) and although mice infected with low dose might 
develop a lesion that ultimately heals, those mice show significant pathology (Doherty 
and Coffman, 1996). Therefefore, we assessed the pain thresholds in BALB/c mice 
injected with low dose of the parasite (4 x 10^  promastigotes/50 pi Lock's medium/left 
hind paw). As shown in Figure 3.3A, the injection of Leishmania major produced a 
significant decrease in the HP latency at day one post infection (9.24 ± 0.39s) as 
compared to the untreated mice (16.95 ± 0.16s) (p< 0.001) and sustained this level till
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day 13 post-infection when the hot plate latency started to increase to reach 13.1±0.096s 
as compared to 16.95 ± 0.084s for the naive (p< 0.001).
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Figure 3.2. The time course of the effect of intraplantar injection of Leishmania major (high 
dose) on the thermal hyperalgesia of mice as assessed by (A) the hot plate test and (B) the tail 
flick test. Mice were injected with 2.5 x 10^  promastigotes per 50 pi per left hind paw or left 
untreated. They were tested 3-4 times per week for hot plate and tail flick latency. Each result is 
the mean of 5 mice ± SEM and the degree of significance was calculated with reference to 
untreated mice.
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At day 17 post-infection the HP latency became 15.59 ± 0.64s as compared to 
the untreated mice (16.43 ± 0.443s) (p> 0.05) (Figure 3.3A).
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Figure 3.3. The time course of the effect of intraplantar injection of Leishmania major (low 
dose) on the thermal hyperalgesia of mice as assessed by (A) the hot plate test and (B) the tail 
flick test. Mice were injected with 4 x 10^  promastigotes per 50 p, per left hind paw or left 
untreated. They were tested 3-4 times per week for hot plate and tail flick latency. Each result is 
the mean of 5 mice ± SEM and the degree of significance was calculated with reference to 
untreated mice.
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The decrease in TF latencies was as significant as the decrease in HP latency. TF 
latency dropped significantly at day 1 post-infection from 5.04 ± 0.086s to 3.47 ± 
0.082s (p< 0.0001) and reached a minimum of 3.084 ± 0.081s at day 6 post-infection 
compared to 4.92 ± 0.073s (p< 0.0001) in the untreated mice. After that, the TF latency 
started to increase reaching a value of 4.64 ± 0.071s day 13 as compared to the 
untreated mice (5.075 ± 0.028s) (p= 0.0002). At day 17 post-infection the difference 
between the TF latency in the untreated mice and that of the mice injected with low 
dose of the parasite was no longer significant (p= 0.138) as shown in figure 3.3B.
3.3. Effect of Leishmania major Infection on the Levels of IL-lp
The level of IL-1 p was shown to increase in the paws of mice infected with high 
dose of L. major parallel to the observed hyperalgesia (Kanaan et al., 2000). In order to 
confirm this observation and to determine the role of IL-lp on the hyperalgesia induced 
by low dose of the parasite, the levels of this cytokine were assessed in the injected 
paws of BALB/c mice infected with high and low dose of L. major.
3.3.1. Effect of High Dose Leishmania major on the Levels of IL-1 p
The intraplantar injection of a high dose of Leishmania major (2.5 x 10  ^
promastigotes/50 pi Lock's medium/left hind paw) caused a significant change in the 
levels of IL-lp, as detected by the Sandwich ELISA, in the injected hind paw starting 
day 2 post-infection increasing from 147.06 ± 12.59 pg/hind paw in the untreated mice 
to 406.88 ± 29.39 pg/hind paw in the injected mice (p< 0.001). However, there was no 
significant difference between the level of IL-lp in the paws of untreated mice (147.06 
± 12.59 pg/hind paw) and levels in the right (non-injected) paws of the infected mice
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(170.60 ± 32.42 pg/hind paw) the p value being greater than 0.05 (Figure 3.4A). The 
levels of IL-lp reach a peak at day 4 post-infection when it was 434.64 ± 36.39 pg/hind 
paw in the injected paw which is significantly higher than the levels in the untreated 
mice (p< 0.001). Furthermore, the difference between the levels of IL-1 P in the paws of 
untreated mice (147.06 ± 12.59 pg/hind paw) and those of the non-injected paws of the 
infected mice (365.92 ± 50.17 pg/hind paw) became significantly different (p< 0.01) 
(Figure 3.4A). The difference between the levels of IL-lp in the injected paws and those 
in the paws of untreated mice remained significantly different throughout the period of 
the experiment despite decreasing by day 13 post-infection to 304.41 ± 38.36 pg/hind 
paw and increasing again at day 21 post-infection to become 328.73 ± 11.65 pg/hind 
paw (p< 0.001). On the other hand, the levels of IL-lp in the non-injected paws started 
to decrease from day 6 post-infection to become very close of the levels in the untreated 
mice at day 21 post-infection (146.73 ± 9.92 pg/hind paw) (p> 0.05).
3.3.2. Effect of Low Dose Leishmania major on the levels of IL -ip
The intraplantar injection of a low dose of Leishmania major (4 x 10^  
promastigotes/50 pi Lock's medium/left hind paw) also caused a significant change in 
the levels of IL-lp in the injected hind paw at 2 days post-infection, increasing from 
147.06 ± 12.59 pg/hind paw in the untreated mice to 384.88 ± 34.37 pg/hind paw in the 
infected mice (p< 0.001). However, there was no significant difference between the 
level of IL-lp in the paws of untreated mice (147.06 ± 12.59 pg/hind paw) and levels in 
the right (non-injected) paw of the infected mice (172.67 ± 52.64 pg/hind paw) (p> 
0.05) (Figure 3.4B). The levels of IL-1 p reach a peak at day 6 post-infection in both 
paws (injected and non-injected); however, this increase in the level of IL-lp in the
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injected paw (431.91 ± 85.94 pg/hind paw) was significantly different from the 
untreated mice (p< 0.01) while in the non-injected paw (280.28 ± 31.77 pg/hind paw) 
was not (p> 0.05). After that, the levels of IL-1 p in both injected and non-injected paws 
decreased to 211.42 ± 21.30 pg/hind paw and 148.92 ± 16.36 pg/hind paw in the 
injected and non-injected paws respectively by day 13, neither of which were 
significantly different from the levels of IL-lp in the paws of untreated mice (Figure 
3.4B) (p> 0.05). The levels of IL-ip in the injected paws of mice infected with low dose 
of Leishmania major and the levels of the injected paws of mice infected with high dose 
of the parasite was not significantly different (p> 0.05) on days 2-6. This decrease in the 
levels of IL-ip reached 199.61 ± 31.68 pg/hind paw in the injected paws of mice 
infected with low dose of Leishmania major and 192.66 ± 21.58 pg/hind paw in the 
non-injected paw at day 21 post-infection. At this time point the p value for the 
variation among the three groups was 0.2618. Interestingly, at this date, the levels of IL- 
ip  in the injected paws of mice infected with low dose of the parasite were significantly 
lower than the levels in the injected paws of the mice infected with high dose L. major 
(328.73 ±11.65) (p= 0.005).
3.4. Effect of Leishmania major Infection on the Levels of IL-6
IL-6 is markedly upregulated during various pathologic situations generally 
associated with increased pain and hyperalgesia (Sommer, 2001) and it plays major role 
in the modulation of the immune reactions (Kishimoto, 2003).
In order to determine the role of IL-6 in the hyperalgesia caused by the high and 
low dose of L. major, this assay was performed to assess the levels of IL-6 in the paws 
of BALB/c mice in both models.
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Figure 3.4. The effect of the injection of high dose (2.5 x 10  ^ promastigotes/50 pi Lock's 
medium/left hind paw) (A) and low dose (4 x 10  ^ promastigotes/50 pi Lock's medium/left hind 
paw) (B) Leishmania major on the levels o f IL-1 (3 in the left (injected) paw and the right (non- 
injected) paw at days 2,4,6,13 and 21 post infection. Each result is the mean o f 5 mice ± SEM 
and the degree of significance was calculated with reference to untreated mice.
3.4.1. Effect o f High Dose Leishmania major on the Levels o f IL-6
The intraplantar injection o f a high dose o f Leishmania major (2.5 x 10  ^
promastigotes/50 pi Lock's medium/left hind paw) caused a significant increase in the
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level of IL-6 at day 2 post-infection in the injected hind paw of the mice (85.45 ± 15.5 
pg/hind paw) (p< 0.01) compared to the level of lL-6 in the paws of untreated mice 
(29.06 ± 1.84 pg/hind paw). However, no significant change in the level of lL-6 was 
observed in the non-injected paws of the mice (p> 0.05) (Figure 3.5A). An increase in 
the level of this cytokine was also observed at day 4 post-infection in both the injected 
paw (47.42 ± 5.75 pg/hind paw) and the non-injected paw (48.7 ± 7.42 pg/hind paw) as 
compared to the control value, (p< 0.05 in both cases) (Figure 1.5A). At day 6 post­
infection, there was also a significant increase in the level of lL-6 in the injected paws 
(43.09 ± 5.51 pg/hind paw) compared to the control value the (p< 0.05), while the 
increase in the levels of lL-6 observed in the non-injected paws (37.09 ± 9.17 pg/hind 
paw) was not significant (p> 0.05) (Figure 3.5A). As is also shown in Figure 3.5A, the 
levels of lL-6 continued to decrease with time in the injected and non-injected paws to 
levels which were not significantly different from those in untreated mice by day 13 and 
day 21 (p> 0.05 in all cases).
3.4.2. Effect of Low Dose Leishmania major on the Levels of IL-6
The intraplantar injection of a low dose of Leishmania major major (4 x 10^  
promastigotes/50 pi Lock's medium/left hind paw) caused, at day 2 post-infection, a 
significant increase in the levels of lL-6 in the injected hind paws (61.75 ± 6.44 pg/hind 
paw) as compared to the levels of lL-6 in the paws of untreated mice (29.06 ± 1.84 
pg/hind paw) (p< 0.01) (Figure 3.5B). The increased levels of lL-6 in the non-injected 
paw (48.47 ± 16.72 pg/hind paw), however, were not significantly different from the 
levels in infected mice (p> 0.05). The levels of lL-6 in both injected and non-injected 
paws had decreased by day 4 post-infection (44. 98 ± 5.47 pg/hind paw; 39.36 ± 4.49 
pg/hind paw respectively) only the former only being significantly higher than the
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control value (p< 0.05).
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Figure 3.5. The effect of the injection of high dose (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) (A) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (B) Leishmania major on the levels of IL-6 in the left (injected) paw and the right (non- 
injected) paw at days 2,4,6,13 and 21 post infection. Each result is the mean of 5 mice ± SEM 
and the degree of significance was calculated with reference to untreated mice.
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At days 6, 13 and 21 post-infection, the levels of IL-6 in the injected and the 
non-injected paws showed no significant difference from the levels in untreated mice 
(p> 0.05 in all cases) (Figure 3.5B). Interestingly, the pattern of production of IL-6 
observed in the low dose infected mice did not differ significantly at any time point 
from the high dose infected mice (p> 0.05 in all cases).
3.5. Discussion
In accordance with previous studies (Kanaan et al., 2000), the infection with a 
high dose of L. major produced a significant decrease in thermal pain thresholds as 
assessed by the HP and TF tests suggesting an acute nociceptive-related behaviour 
organized both at the supraspinal and spinal levels. This hyperalgesia was accompanied 
by an up-regulation of the levels of IL-lp in the infected paws of BALB/c mice starting 
day two post-infection and throughout the whole period of the experiment providing a 
further evidence for a direct role of IL-1 P in hyperalgesia mainly through sensitizing the 
nociceptors at the site of infection (Watkins et al., 1994).
Our results showed also that the infection with a low dose of L. major 
produced a significant decrease in the pain thresholds during the first two weeks 
accompanied by an up-regulation of IL-1 p providing evidence about a direct role of IL- 
lp  in hyperalgesia. On the other hand, the levels of IL-6 were up-regulated during the 
first few days of infection with L. major in both, high and low dose models. However, 
the direct role of IL-6 in hyperalgesia is not critical at later stages of infection.
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CHAPTER 4
THE EFFECT OF IE-10 AND IE-13 ON PAIN 
THRESHOEDS AND PRO-INFEAMMATORY CYTOKINES
4.1. Introduction
Many cytokines play major roles in initiating and sustaining inflammatory 
events and are called the “pro-inflammatoiy cytokines”, such as IL-1, IL-6, IL-8 and 
TNF-a. On the other hand, other cytokines play a major role in modulating the immune 
response usually leading to the resolution of inflammation (called “anti-inflammatory 
cytokines”) and they include IL-1 receptor antagonist (IL-lra), IL-4, IL-10, IL-12, IL- 
13 and transforming growth factor-P (TGF-P) (Henderson et al, 1994). Many studies 
investigated the effect of IL-10 and IL-13 on hyperalgesia induced by many substances 
and models.
IL-10 is known to inhibit inflammatory hyperalgesia (Poole et al., 1995; 
Kanaan et al., 1998; Opal and DePalo, 2000) by down-regulating the production of IL- 
1, TNF-a and Nerve growth Factor (NGF) (Bogdan et al, 1991; Oswald et a l, 1992; 
Jenkins et al, 1994; Saadé et al, 2000). Furthermore, IL-10 is able to inhibit the 
hyperalgesic responses to TNF-a and IL-6 but not to IL-8 and prostaglandin E2 
(PGE2), (Poole et al, 1995). This is due to the fact that the hyperalgesic activities of 
TNF-a and IL-6 depend on the induction of cytokines (IL-lp and IL-8, and IL-lp 
respectively), while IL-8 induces the production of sympathomimetic amines (Cunha et 
al, 1991). IL-10 was shown also to inhibit IL-lp-stimulated PGE2 production which 
sensitises nociceptors (Ferreira, 1988) mainly through suppressing COX-2 (Poole et al, 
1995).
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IL-13 has been shown to have a suppressive effect on IL-1 synthesis and to 
induce B lymphocyte expansion and immunoglobulin production (Hart et al., 1989; 
Vannier et al., 1992). Concerning the effect of IL-13 on the pain thresholds, Lorenzeti 
et al., 2001 suggested that IL-13, released by lymphocytes, limits the inflammatory 
hyperalgesia (due to Escherichia coli endotoxin, LPS injection) by inhibiting the 
production of TNF-a, IL-ip and PGE2. Similarly, the pretreatment with IL-13 
prevented, in a dose dependent manner, the hyperalgesia induced by UVB irradiation. 
This is in correlation with the concomitant down-regulation of the increased levels of 
TNF-a and IL-ip by UVB (Saadé et al., 2000). It is of major interest, therefore, to 
determine the effect of both IL-10 and IL-13 on the Leishmania major-'mducQd 
inflammation with respect to hyperalgesia and the levels of pro-inflammatory cytokines 
which were increased during inflammation, using the hypoalgesic dose proved to be 
efflcient in other models.
4.2. Does InterIeukin-10 have Any Effect on L. major Induced Hyperalgesia?
Since IL-10 was shown to reduce hyperalgesia in some models {Escherichia 
coli endotoxin, LPS injection and UVB) and since L. major-inducQd inflammation in 
BALB/c mice can produce hyperalgesia, this assay was performed to assess the effect of 
daily injection of interleukin-10 (IL-10) during the first six days of infection on the pain 
thresholds of uninfected mice, mice infected with high dose of L. major and those 
infected with low dose of the parasite during and after the period of treatment.
4.2.1. Effect o f Interleukin-10 on the Pain Thresholds in Uninfected Mice
Mice were treated with interleukin-10 alone in order to control for any direct 
analgesic effects. Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six
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consecutive days produced no significant change in the pain thresholds neither during 
the treatment period nor after it, the levels being very close to those of the untreated 
mice (p> 0.05) in both the hot plate and the tail flick tests (Figure 4.1 A and 4. IB).
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Figure 4.1. The time course of the effect of the daily intraperitoneal injection of IL-10 on pain 
thresholds in mice as assessed by (A) the hot plate test and (B) the tail flick test. Mice were 
injected with 15 ng of IL-10 for 6 consecutive days or left untreated. Each result is the mean of 
5 mice ± SEM and the degree of significance was calculated with reference to untreated mice.
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4.2.2. Effect o f Interleukin-10 on the Pain Thresholds in High Dose L. major 
Infected Mice
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days produced a significant reduction of high dose L. major-mà\xcQà hyperalgesia 
during the period of treatment. The HP latencies increased to 10.85 ± 0.20s at day 1 as 
compared to the mice injected with L. major alone (8.62 ± 0.18s) (p< 0.001) and to the 
control (15.01 ± 0.075) (Figure 4.2A). However, the difference between the HP 
latencies of the treated mice and those of the control mice remained significant with a p 
value less than 0.001. The maximum effect was reached at day 3 through day 6 post­
infection. The HP latency at those dates increased from 7.89 ± 0.1 Is in the mice injected 
with a high dose of the parasite to 12.47 ± 0.33s in those treated also with IL-10 (p<
0.001). At day 8 post-infection, the levels started to decrease to reach a minimum of 
6.00 ± 0.12s at day 15 post-infection as compared to 7.40 ± 0.22s (p< 0.001) in the mice 
injected with high dose of L  major (Figure 4.2A). However, the difference between 
those two groups became insignificant by day 20 post-infection, both being significantly 
lower than the HP latency in the control mice. The HP latencies were 6.86 ± 0.25s and
6.26 ± 0.072s in the mice injected with a high dose of L. major alone and those also 
treated with IL-10 respectively, as compared to the control (15.20 ± 0.124s) the p value 
being less than 0.001 in both cases.
With respect to the tail flick latency, the daily treatment with 15 ng of IL-10 
per mouse increased this latency from 3.76 ± 0.18s to 5.17 ± 0.13s (p< 0.001) at day 1 
post-infection (Figure 4.2B). The difference between the latencies of the IL-lO-treated 
mice and the untreated mice was insignificant at that date (p> 0.05). This effect was 
sustained until day 8 (the injection of IL-10 stopped at day 6) when the TF latencies 
decreased to levels very close to those in IL-10 non-treated mice (Figure 4.2B).
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Figure 4.2. The time course of the effect of the daily intraperitoneal injection of IL-10 on L. 
major (high dose) induced hyperalgesia as assessed by (A) the hot plate test and (B) the tail 
flick test. Mice were injected with 2.5 x 10^  promastigotes per 50 pi per left hind paw and 
another group also with 15 ng of IL-10 for 6 consecutive days. Each result is the mean of 5 mice 
± SEM and the degree of significance was calculated with reference to IL-10 non-treated mice.
For example, at day 15 post-infection, the TF latency was 3.093 ± 0.0613s in 
the mice injected with a high dose of L  major and treated with IL-10 as compared with
3.26 ± 0.099s (p> 0.05) and in those infected with parasite but not treated with IL-10 
and to 5.137 ± 0.020s in the untreated mice (p< 0.001).
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4.2.3. Effect o f  Interleukin-10 on the Pain Thresholds in Low Dose L. major 
Infected Mice
The treatment with daily injections of IL-10 (15 ng i.p.) for six days reduced 
the low dose L. TMo/or-induced hyperalgesia at day 3 post-infection, increasing the HP 
latency from 10.04 ± 0.42s to 12.77± 0.47s (p< 0.05). This hypoalgesic effect persisted 
till day 8 post-infection (the IL-10 injection stopped at day 6). However, the difference 
between the IL-10 treated mice and the untreated mice remained significant (p< 0.001). 
Starting day 10, the HP latencies decreased and sustained low levels during the 
experiment being 6.81 ± 0.26 at day 24 post-infection as compared to 13.61 ± 0.20s (p<
0.001) for the mice injected with low dose of L. major (Figure 4.3A).
As to the tail flick latency, the daily treatment with 15 ng of IL-10 per mouse 
reversed the mild hyperalgesia especially at day 6 post-infection increasing the TF 
latency from 4.041 ± 0.17s to 4.69 ± 0.20s which is close to the TF latency in the 
untreated mice (p> 0.05). However, starting day 8 post-infection, the TF latencies 
decreased to reach 3.17 ± 0.059s at day 24 post-infection as compared to 5.28 ± 0.063s 
(p< 0.001) for the mice injected only with low dose of L. major (the untreated mice had 
a TF latency of 5.10 ± 0.06s at that day) (Figure 4.3B).
4.3. Does the Hypoalgesic Action of Interleukin-10 have Any Effect on the Levels 
of IL-1 p in L. /«fl/or-Induced Inflammation?
IL-10 is known to inhibit inflammatory hyperalgesia (Poole et a l, 1995; 
Kanaan et al, 1998; Opal and DePalo, 2000) by down-regulating the production of IL-1 
(Saadé et al, 2000) and inhibiting IL-lp-stimulated PGE2 production which sensitises 
nociceptors (Ferreira, 1988) mainly through suppressing COX-2 (Poole et a l, 1995). 
Therefore, in order to determine the role of IL-lp in the IL-lO-induced reduction of 
hyperalgesia, we assessed the effect of the daily injection (i.p.) of 15 ng of IL-10 for the
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first consecutive 6 days on the levels of IL-lp in the paws of uninfected mice, and those 
infected with high dose and low dose L. major.
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Figure 4,3. The time course of the effect of the daily intraperitoneal injection of IL-10 on L. 
major (low dose) induced hyperalgesia as assessed by (A) the hot plate test and (B) the tail flick 
test. Mice were injected with 4 x 10^  promastigotes per 50 pi per left hind paw and another 
group also with 15 ng of IL-10 for 6 consecutive days. They were tested 3-4 times per week for 
hot plate and tail flick latency. Each result is the mean of 5 mice ± SEM and the degree of 
significance was calculated with reference to IL-10 non-treated mice.
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4.3.1, Effect o f Interleukin-10 in the Level o f IL -ip in  Uninfected Mice
This assay was performed in order to detect any possible effect of IL-10 on the 
level of IL-lp in uninfected mice.
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days produced no significant change (p> 0.05) in the level of IL-1 p in the paws of mice 
neither during the treatment period nor after it as shown in Figure 4.4 A. Note that the 
uninfected mice used as control were the same in all experiments involving the levels of 
IL-1 p.
4.3.2, Effect o f Interleukin-10 on the Level o f IL -lp  in Mice Infected with High 
Dose o f L, major
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days produced no significant reduction in the levels of IL-1 p in the injected paws of 
mice infected with high dose L. major and treated with IL-10 (344.57 ± 27.91 pg/hind 
paw) as compared to the levels of IL-1 P in the paws of mice infected only with high 
dose of the parasite at day 2 post-infection (p> 0.05). However, the difference in the 
levels of IL-1 p in the former case and that of the control value (147.06 ± 12.59 pg/hind 
paw) was significant (p< 0.001) (Figure 4.4B). The effect of IL-10 became more 
obvious at day 4 post-infection when the levels of IL-1 p reached 180.10 ± 55.61 
pg/hind paw in the infected paws of mice treated with IL-10, compared to 434.64 ± 
36.39 pg/hind paw in the infected paws of mice not treated with IL-10, (p< 0.01) 
(Figure 4.4B). Essentially, treatment with IL-10 reduced the level of IL-1 □ in the high 
dose infected mice close to (p> 0.05) those observed in the untreated mice. At day 6 
post-infection, the reduction of the levels of IL-1 P caused by the injection of IL-10 
remained significantly different (p< 0.05) as compared to the level of IL-1 p in the
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injected paws of IL-10 non-treated mice.
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Figure 4.4. Effect of the daily intraperitoneal injection of IL-10 on the level of IL-1 (3 in the 
paws of untreated mice (A) mice infected with high dose (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) (B) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (C) L. major. Mice were injected with 15 ng of IL-10 (i.p.) for 6 consecutive days and the 
levels of IL-1 (3 were assessed at days 2, 4 ,6 , 13 and 21 post-infection. Each result is the mean 
of 5 mice ± SEM and the degree of significance was calculated with reference to IL-10 non- 
treated mice.
101
Furthermore, the difference between the value in the treated mice and the 
control value remained insignificant (p> 0.05). This effect of reducing IL-lp levels was 
no longer observed on days 13 and 21.
4,3.3, Effect o f Interleukin-10 on the Level o f  IL -ip  in Mice Infected with Low Dose 
o f L, major
Treatment of mice infected with a low dose of L. major with IL-10 only 
showed a decrease in IL-ip levels in the paws compared to L. major infected mice at 
day 6 (<0.001) (Figure 4.4C). By day 13 post-infection, when the levels of lL-1 P in the 
injected paws of the IL-lO-non-treated mice (211.42±21.30 pg/hind paw) were no 
longer significantly different than the control value (p>0.05), the injection of IL-10 
caused a comparatively significant increase in the levels of lL-1 p in the injected paws 
of IL-10 treated mice (422.075±85.95 pg/hind paw) as compared both to the control 
value and the levels of lL-1 p in the injected paws of the IL-lO-non-treated mice (p<
0.001) (Figure 4.4C).
Similar results were observed at day 21 post-infection when the levels of lL-1 
p in the injected paws of the IL-lO-non-treated mice (199.61 ± 31.68 pg/hind paw) 
remained not significantly different than the control value (p> 0.05), while a significant 
increase in the levels of lL-1 p in the injected paws of IL-10 treated mice (392.912 ± 
26.715 pg/hind paw) was observed as compared both to the control value and the levels 
of lL-1 p in the injected paws of the IL-lO-non-treated mice (p< 0.001) (Figure 4.4C).
4.4. Effect of Interleukin-10 on the Levels of IL-6 in L, /wo/or-Induced 
Inflammation
IL-10 is able to inhibit the hyperalgesic responses to lL-6 (Poole et al., 1995)
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mainly by inhibiting IL-ip (Cunha et al., 1991).
In order to determine the role of IL-6 in the IL-lO-induced reduction of 
hyperalgesia, we assessed the effect of the daily injection (i.p.) of 15 ng of IL-10 for the 
first consecutive 6 days on the levels of IL-lp in the paws of uninfected mice, and those 
infected with high dose and low dose L. major.
4.4.1. Effect o f Interleukin-10 in the Level o f IL-6 in Uninfected Mice
This assay was performed in order to detect any possible effect of IL-10 on the 
level of IL-6 in uninfected mice. Treatment with daily injections of IL-10 (15 ng
i.p./mouse) for six consecutive days resulted in no significant change (p> 0.05) in the 
level of IL-6 in the paws of mice compared to untreated controls neither during the 
treatment period nor after it as shown in Figure 4.5A.
4.4.2, Effect o f Interleukin-10 on the Level o f IL-6 in Mice Infected with High Dose 
o f L, major
Daily treatment with IL-10 (15 ng i.p./mouse) of mice infected with high dose 
L. major for 6 consecutive days did not result in significant differences in IL-6 
production (as detected in the injected paws) compared to those infected with L. major 
alone or to untreated control mice at any of the time points (all p values > 0.05) apart 
from days 6 and 21. At these time points, the addition of IL-10 resulted in a significant 
increase in IL-6 levels (p< 0.05 and p< 0.001 respectively as compared to untreated 
mice) (Figure 4.5B).
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Figure 4.5. Effect of the daily intraperitoneal injection of IL-10 on the level of IL-6 in the paws 
of untreated mice (A) mice infected with high dose (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) (B) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (C) L. major. Mice were injected with 15 ng of IL-10 (i.p.) for 6 consecutive days and the 
levels of IL-6 were assessed at days 2, 4 ,6 , 13 and 21 post-infection. Each result is the mean of 
5 mice ± SEM and the degree of significance was calculated with reference to untreated mice.
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4.4.3, Effect o f Interleukin-10 on the Level o f IL-6 in Mice Infected with Low Dose 
o f L, major
Daily treatment with IL-10 (15 ng i.p./mouse) of mice infected with low dose 
L. major for 6 consecutive days produced no significant change in the levels of IL-6 in 
the infected paws of IL-10 treated mice neither at day 2 nor at day 4 post-infection 
compared to the injected paws of the IL-10 non-treated mice (p>0.05), (Figure 4.5C). At 
day 6,13 and 21 post-infection, the levels of IL-6 in the paws of IL-10 treated mice 
significantly increased (54.63 ± 5.69, 45.055 ± 5.69 and 57.93 ± 12.55 pg/hind paw 
respectively) compared to the untreated mice (p< 0.05) (Figure 4.5C).
4.5. Does Interleukin-13 also Have A Hypoalgesic Effect on L, major Induced 
Hyperalgesia?
Since previous research (Saadé et al, 2000; Lorenzetti et al., 2001) suggested 
that IL-13 limits the inflammatory hyperalgesia (due to E.coli endotoxin, LPS 
injection), these assays were performed to assess the effect of daily injection of 
interleukin-13 (IL-13) during the first six days of infection on the pain thresholds of 
untreated mice, mice infected with high dose of L. major and those infected with low 
dose of the parasite during and after the period of treatment.
4,5,1, Effect o f Interleukin-13 on the Pain Thresholds in Untreated Mice
In order to discount the possible analgesic effects of direct injection of IL-13 
on uninfected mice, we assessed the pain thresholds in uninfected mice treated with IL- 
13. Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive days 
produced no significant change in the pain thresholds neither during the treatment 
period nor after it, the levels being very close to those of the untreated mice (p> 0.05) in 
both the hot plate and the tail flick tests (Figure 4.6A and 4.6B).
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Figure 4.6.The time course of the effect of the daily intraperitoneal injection of IL-13 on pain 
thresholds in mice injected with (IL-13) as assessed by (A) the hot plate test and (B) the tail 
flick test. Mice were injected with 15 ng of IL-13 for 6 consecutive days or left untreated. Each 
result is the mean of 5 mice ±SEM and the degree of significance was calculated with reference 
to untreated mice.
4,5.2, Effect o f Interleukin-13 on the Pain Thresholds in High Dose L, major 
Infected Mice
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive 
days produced a significant reduction of high dose L  7wq/or-induced hyperalgesia 
during the period of treatment. The mean HP latencies increased to 14.29 ± 0.239s at 
day 6 as compared to mice infected with L. major alone (7.88 ± 0.21s) (p< 0.001) and as
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compared to the untreated mice which was 15.01± 0.075 (p> 0.05) (Figure 4.7A). At 
day 8 post-infection, the levels started to decrease to reach a plateau close to the levels 
of the infected mice not treated with IL-13. For example, at day 20 the HP latency of the 
mice treated previously with IL-13 was 6.90 ± 0.28s as compared to 6.86 ± 0.25s (p>
0.05) for the mice injected only with high dose of L  major and to 15.33 ± 0.13s (p<
0.001) in the untreated mice (Figure 4.7A).
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Figure 4.7. The time course of the effect of the daily intraperitoneal injection of IL-13 on L. 
major (high dose) induced hyperalgesia as assessed by (A) the hot plate test and (B) the tail 
flick test. Mice were injected with 2.5 x 10^  promastigotes per 50 pi per left hind paw and 
another group also with 15 ng of IL-13 for 6 consecutive days. They were tested 3-4 times per 
week for hot plate and tail flick latency. Each result is the mean of 5 mice ± SEM and the 
degree of significance was calculated with reference to IL-13 non-treated mice.
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With respect to the tail flick latency, the daily treatment with 15 ng of IL-13 
per mouse resulted in an increase from 3.76 ± 0.18s to 5.09 ± 0.1 Is (p< 0.001) at day 1 
post-infection compared to untreated mice with a TF latency of 5.037 ± 0.086s (Figure 
8B). This increase was sustained until day 8 (the injection of IL-13 stopped at day 6) 
followed by a decrease to levels very close to those in L. major infected mice which had 
not been treated with IL-13 (Figure 4.7B). This was a significantly lower value than that 
seen in untreated mice (3.14 ± 0.022s as compared to 5.10 ± 0.059s at day 24 post­
infection, the p value being less than 0.001). No significant difference was observed 
later (p> 0.05) between the TF latency of the mice injected with a high dose of the 
parasite and those treated with IL-13 (Figure 4.7B).
4.5,3, Effect o f  Interleukin-13 on the Pain Thresholds in Low Dose L, major 
Infected Mice
Since we showed here that the infection of BALB/c mice with low dose of L. 
major induced hyperalgesia for the first 10 days of infection, and since IL-13 is known 
to reduce hyperalgesia in other models including the high dose of this parasite, we 
performed this assay to assess the effect of IL-13 on the low dose L. major-màuccà low 
pain thresholds.
The effect of the treatment with daily injections of IL-13 (15 ng i.p.) for six 
consecutive days was to cause a reduction of the low dose L. wq/or-induced 
hyperalgesia as observed by an increase in the HP latency at day 1 post-infection from 
10.04 ± 0.40s to 13.08 ± 0.28s (p< 0.001). This effect increased at day 3 post-infection 
when this latency became very close to that of the untreated mice (15.02 ± 0.16s as 
compared to 15.21 ± 0.058s). The hypoalgesic effect of IL-13 persisted till day 8 post­
infection (the IL-13 injection stopped at day 6) when the HP latencies started to
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decrease reaching 6.52 ± 0.24s at day 24 post-infection as compared to 13.61 ± 0.20s 
(p< 0.001) for the mice injected with low dose of L  major (Figure 4.8A).
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Figure 4.8. The time course of the effect of the daily intraperitoneal injection of IL-13 on L. 
major (low dose) induced hyperalgesia as assessed by (A) the hot plate test and (B) the tail flick 
test. Mice were injected with 4x 10^  promastigotes per 50 pi per left hind paw and another 
group also with 15 ng of IL-13 for 6 consecutive days. They were tested 3-4 times per week for 
hot plate and tail flick latency. Each result is the mean of 5 mice ± SEM and the degree of 
significance was calculated with reference to IL-13 non-treated mice
With respect to the tail flick latency, the daily treatment with 15 ng of IL-13
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per mouse reversed the mild hyperalgesia throughout the period of IL-13 injection (6 
days). The TF latencies were increased at day 6 post-infection from 4.041 ± 0.17s in the 
mice injected with a low dose of L. major to 5.10 ± 0.095s (p< 0.01) in those injected 
with a low dose of the parasite and treated with IL-13. staring day 8 post-infection, 
however, the TF latencies decreased to reach 3.19 ± 0.049s at day 24 post-infection as 
compared to 5.28 ± 0.063s (p< 0.001) for the mice injected only with low dose of L. 
major which is close to the TF latency of the untreated mice at that day (5.10 ± 0.06s) 
(Figure 4.8B).
4.6. Does IL-13 affect the Levels of IL-lp in L. m^or-Induced Inflammation
IL-13 was shown to limit the inflammatory hyperalgesia (due to E.coli 
endotoxin, LPS injection) by inhibiting the production IL-ip (Lorenzetti et al., 2001). 
Furthermore, the pre-treatment with IL-13 prevented, in a dose dependent manner, the 
hyperalgesia induced by UVB accompanied by a down-regulation of the increased level 
IL-ip (Saadé et al., 2000). Also, as we have shown previously in this study, the 
hypoalgesic effect of IL-10 involved a reduction in the level of IL-ip. Therefore, and in 
order to determine the role of IL-lp in the IL-13-induced reduction of hyperalgesia, we 
assessed the effect of the daily injection (i.p.) of 15 ng of IL-13 for the first consecutive 
6 days on the levels of IL-lp in the paws of uninfected mice, and those infected with 
high dose and low dose L. major.
4.6.1. Effect o f Interleukin-13 in the Level o f  IL-1 p  in Uninfected Mice
In order to discount the possible effect of IL-13 on the level of IL-ip in 
uninfected mice, the level of IL-1 p in the paws of uninfected mice treated with IL-13
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was investigated.
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive 
days produced no significant change (p> 0.05) in the level of IL-1 P in the paws of mice 
neither during the treatment period nor after it as shown in Figure 4.9A.
4.6.2. Effect o f Interleukin-13 on the Level o f IL -ip  in Mice Infected with High 
Dose o f L. major
Treatment of mice infected with a high dose of L. major with IL-13 (15 ng
i.p./mouse) for 6 consecutive days resulted in significant decreases in the levels of IL- 
lp  detected in the injected paw at all the time points tested (p< 0.001) compared to 
mice infected with high dose of the parasite but not treated with IL-13 (Figure 4.9B).
4.6.3. Effect o f Interleukin-13 on the Level o f IL -ip  in Mice Infected with Low Dose 
o f L. major
Treatment of mice infected with a low dose of L. major with IL-13 (15 ng
i.p./mouse) for 6 consecutive days resulted in significant decrease in the levels of IL-1 P 
detected in the injected paws at day 2 post-infection (208.55 ± 53.23 pg/hind paw) 
compared to mice infected only with low dose of the parasite (384.44 ± 34.37 pg/hind 
paw), the p value being less than 0.05 (Figure 4.9C). The effect of IL-13 was also 
observed at days 4, 6 and 13 post-infection (p< 0.001, p< 0.01, p< 0.05 respectively). 
Thereafter, there was no significant difference among the three groups (p> 0.05) (Figure 
4.9C).
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Figure 4.9. Effect of the daily intraperitoneal injection of IL-13 on the level of IL-1 p in the 
paws of untreated(A) mice infected with high dose (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) (A) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (B) L. major. Mice were injected with 15 ng of IL-13 (i.p.) for 6 consecutive days and the 
levels of IL-1 p were assessed at days 2, 4 ,6 , 13 and 21 post-infection. Each result is the mean 
of 5 mice ± SEM and the degree of significance was calculated with reference to IL-13 non- 
treated mice.
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4.7. Effect of Interleukin-13 on the Levels of IL-6 in L. wayor-Induced 
Inflammation
Since IL-6 was shown to induce the production of IL-lp which seems to play 
an important role in hyperalgesia (Cunha et al., 1991) and since IL-13 was shown here 
to have a hypoalgesic effect, it is of major importance to determine the role of IL-6 in 
the IL-13-induced reduction of hyperalgesia. Therefore, we assessed the effect of the 
daily injection (i.p.) of 15 ng of IL-13 for the first consecutive 6 days on the levels of 
IL-ip in the paws of uninfected mice, and those infected with high dose and low dose L. 
major.
4.7.1. Effect o f Interleukin-13 in the Level o f IL-6 in Uninfected Mice
This assay was performed in order to detect any possible effect of IL-13 on the 
level of IL-6 in uninfected mice. Treatment with daily injections of IL-13 (15 ng
i.p./mouse) for six consecutive days had no significant effect on the level of IL-6 in the 
paws of uninfected mice neither during the treatment period nor after it (p> 0.05) as 
shown in Figure 4.10A.
4.7.2. Effect o f Interleukin-13 on the Level o f IL-6 in Mice Infected with High Dose 
o f L. major
Treatment of mice infected with a high dose of L. major with IL-13 (15 ng
i.p./mouse) for 6 consecutive days produced, at day 2 post-infection, no reduction in the 
levels of IL-6 in the injected paws (73.74 ±3.31 pg/hind paw) compared to the levels of 
IL-6 in the paws of mice infected only with high dose of the parasite (85.45 ± 15.50 
pg/hind paw) (p> 0.05) (Figure 4.1 OB). At day 4 post-infection, the level of IL-6 in the 
paws of IL-13 treated mice showed a significant and very large increase compared to 
the untreated mice reaching 83.98 ± 7.64 pg/hind paw (p< 0.001).
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Figure 4.10. Effect of the daily intraperitoneal injection of IL-13 on the level of IL-6 in the paws 
of untreated mice (A) mice infected with high dose (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) (B) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (C) L. major. Mice were injected with 15 ng of IL-13 (i.p.) for 6 consecutive days and 
the levels of IL-6 were assessed at days 2, 4,6, 13 and 21 post-infection. Each result is the mean 
of 5 mice ± SEM and the degree of significance was calculated with reference to untreated 
mice.
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Similar results were observed at day 6 post-infection (p< 0.01), but the 
difference between the level of IL-6 in the IL-13 treated mice and the IL-13 non-treated 
mice became insignificant (p> 0.05) (Figure 4.1 OB). However, no significant difference 
in the levels of IL-6 was observed at day 13 post-infection among the three 
experimental groups, the p value being 0.3704.
As shown also in Figure 4.1 OB, the levels of IL-6 in mice infected with a high 
dose of L. major treated with IL-13 increased again at day 21 post-infection to become 
42.36 ±3.81 pg/hind paw, which is quite higher than the levels of IL-6 in the paws of 
untreated mice (29.069 ± 1.84 pg/hind paw) (p< 0.05).
4,7.3. Effect o f Interleukin-13 on the Level o f  IL-6 in Mice Infected with Low Dose 
o f L. major
Treatment of mice infected with a low dose of L. major with IL-13 (15 ng
i.p./mouse) for 6 consecutive days produced, no significant change in the levels of IL-6 
at day 2 post-infection (54.64 ± 5.81 pg/hind paw) compared to the injected paws of the 
IL-13 non-treated mice (61.75 ± 6.44 pg/hind paw) (p> 0.05) (Figure 4.IOC). At day 4 
post-infection, the IL-6 levels in the paws of IL-13 treated mice showed a significant 
increase as compared to the untreated mice reaching 53.57 ± 4.85 pg/hind paw (p< 
0.01). However, no significant difference was observed between the two infected 
groups of mice, treated and non-treated with IL-13 (p> 0.05). Similar results were 
observed at day 6 post-infection. However, at days 13 and 21 post-infection, the levels 
of IL-6 in the infected paws of IL-13 treated mice increased significantly (73.96 ± 4.69 
and .61 ± 2.56 pg/hind paw respectively) compared to the IL-13 non-treated mice (p< 
0.001) (Figure 4.10C).
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4.8. Discussion
4.8.L How Can IL-10 Exert its Hypoalgesic Effect on L. major-induced 
Hyperalgesia?
IL-10 is known to play a role in inhibiting delayed-type hypersensitivity 
reactions (Howard and O'Garra, 1992) and in the suppression of macrophage functions 
such as MHC class II expression (De Waal Malefyt et al., 1991), adhesion (Fiorentino et 
al., 1991), the synthesis of proinflammatory cytokines such as IL-1 p and TNF-a 
(Mariana et al., 2003), and the expression of COX-2 and iNOS (Bogdan et al., 1991; De 
Waal Malefyt et al., 1991; Fiorentino et al., 1991; Oswald et al., 1992; Niiro et al., 
1995; Poole et al., 1995; Niiro et a/., 1997). In addition, IL-10 was shown to reduce 
hyperalgesia by inhibiting hyperalgesic cytokines (Saadé et a l, 2000) and by blocking 
COX-2 induction in macrophages (Poole et al., 1995). Our data provides further 
evidence about the hypoalgesic effect of IL-10 which was restricted to the period of its 
injection, since hyperalegisa was restored immediately after stopping IL-10 treatment. 
Furthermore, IL-10 seems to exert its hypoalgesic effect through reducing the levels of 
IL-ip starting day 3 days post-infection and was sustained till day 6 post-infection, 
when the injections of IL-10 were stopped. Thereafter, the levels of IL-1 p started to 
increase reaching values very close to levels of this cytokine in the paws of mice 
infected with high dose of L. major but not treated with IL-10. This time course of the 
levels of IL-1 P correlates well with that of the observed hyperalgesia in the mice 
infected with high dose of the parasite and treated for six consecutive days with IL-10, 
when the hyperalgesia was reversed only during the treatment period. These results 
provide further evidence about a possible direct or indirect role of IL-1 p in the high 
dose L. major-inducQd hyperalgesia in BALB/c mice. In conclusion, and as shown in 
other models (Milligan et al., 2005; Kopp et al., 2005), IL-10 is suspected to exert an
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additive hypoalgesic effect, during the period of treatment, through reducing the levels 
of IL-1 p and/or C0X2 and iNOS (Johnston et al., 2004).
With regards to the level of IL-6, our results suggest that IL-10 has no 
significant effect on the levels of this cytokine in the injected paws of mice infected 
with high dose of L. major during the period of treatment. Furthermore, at day 6 post­
infection, IL-6 levels were increased while IL-10 had its greatest effect in reducing 
hyperalgesia. In addition, at day 13 post-infection, when the mice were showing a 
persistent state of hyperalgesia, the levels of IL-6 in their infected paws were reduced to 
the control value. Taken together, and in contrast to previous studies stating that IL-6 is 
directly involved in pain (Obreja et al., 2005), our data suggests that IL-6 has no direct 
effect on hyperalgesia, suggesting again that IL-6, among other factors, may play a role 
in the induction of hyperalgesia via the stimulation of IL-lp production which remained 
significantly high in parallel with the observed hyperalgesia which is in agreement with 
other recent studies (Chessell et al. 2005; Cunha et al., 2005).
The hypoalgesic effect of IL-10 in the low dose model was consistent with our
results in the high dose model during the days of treatment, providing further evidence
that similar pro-inflammatory substances, one of which is IL-lp, were produced during
the first two weeks of infection in both models. IL-10 was able to reduce the levels of
IL-ip in the infected paws of mice in an additive way having its greatest effect at the
last day of treatment. This is in accordance with our results using the high dose model
of L. major confining a major role for IL-ip in the low dose L. wo/or-induced
hyperalgesia. Interestingly, the low pain thresholds observed during this early period of
infection in mice injected with low dose of L. major were not reversed in mice treated
with IL-10 as in the case of IL-10 non-treated infected mice. On the contrary, those
mice showed a state of hyperalgesia similar to that observed in mice infected with high
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dose of the parasite. This suggests that IL-10 caused a change in the course of infection 
leading to the persistence of the high level of some pro-inflammatory substances 
causing hyperalgesia, IL-ip being a major one since its the levels were increased after 
stopping the injection of IL-10 to become significantly higher than its levels in the low 
dose injected paws. The most probable explanation is that IL-10 whose receptor is 
highly expressed on NK and Thl cells, the major IFN-y producers, inhibits the synthesis 
of this cytokine which has a crucial role in preventing the dissemination of the parasite 
(Fiorentino et al., 1991) and therefore, IL-10 seems to be able to inhibit the microbicidal 
functions of macrophages but not their ability to multiply and therefore, their presence 
increases the hypemociceptive state mainly through their production of IL-1 P and TNF- 
a  (Mariana et al., 2003).
As in the case of the high dose model, IL-10 had no significant effect on the 
levels of IL-6 in the infected paws of mice during the treatment period, which argues 
against a direct role for IL-6 in hyperalgesia (which was reduced during this period). 
However, starting day 6 post-infection, the effect of IL-10 was to significantly increase 
the levels of IL-6 as compared both to the naïve values and the levels of this cytokine in 
the injected paws of mice infected with low dose of L. major. Thus, although IL-6 
doesn’t seem to play crucial role in hyperalgesia observed during early stages of 
infection, its up-regulation in the paws of mice treated with IL-10 in parallel to the 
persistent hyperalgesia, suggests that it might contribute in initiating a cascade of 
substances causing ultimately those low pain thresholds. However, IL-lO-induced 
increase in the level of IL-6 in parallel to the induced persistent low pain thresholds, 
suggests a possible role for IL-6 either in the hyperalgesia itself or in the cytokine 
milieu favouring this hypemociceptive status. This increase in the level of IL-6 has been 
suggested to be due to the ability of IL-10 to enhance the production of IL-4/IL-13
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(Mariana et al., 2003). This hypothesis is further supported by the fact that in human 
osteoblasts, the expression of IL-4R, IL-13R and IL-13Ra, has been demonstrated to 
play a role in the IL-4 and IL-13 induced IL-6 formation (Frost et al., 2001) in the 
presence of IL-1 and TNF (Silfversward et al., 2004). In our model, however, IL-13 
seems to play a more important role, since the level of IL-4 was not elevated in parallel 
with the high level of IL-lp neither in the high dose nor in the low dose models. Note 
that the high level of IL-1 p during the first 4 days of infection in mice treated with IL- 
10 while hyperalgesia was partially reduced suggests that IL-10 acts mainly at the level 
of COX-2 rather than at the level of IL-lp production.
4.8.2. How Can IL-13 Exert its Hypoalgesic Effect on L. major-induced 
Hyperalgesia?
As in the case of IL-10, IL-13 had a significant hypoalgesic effect in the treated 
mice during the injection period in both pain tests with no effect observed later on. This 
suggests that IL-13 exerts its hypoalgesic effect through reducing the levels of some 
pro-inflammatory substances which were elevated due to the infection with L. major. 
The effect of IL-13 as assessed by the HP test, however, was more profound than the 
effect of IL-10, since during the injection period (when the HP latency in the treated 
mice was significantly higher than in the IL-lO-treated mice) the former value was very 
close of that of the control mice. This is in agreement with previous reports indicating 
that, using the same doses, IL-13 is more efficient in reducing hyperalgesia than IL-10 
(Saadé et al., 2000).
Many studies suggest that, as is the case with IL-10, IL-13 exhibits its 
antinociceptive effects through the inhibition of the release of cytokines that mediate 
nociception by macrophages (such as TNF-a and IL-ip) and also by the inhibition of
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the expression of COX-2 and iN0S2 (Poole et al., 1995; Niiro et al., 1995; Onoe et al, 
1996; Niiro et al., 1997; Weiss et al., 1997; Lorenzetti et al., 2001). Furthermore, IL-13 
is known to enhance the secretion of IL-1 receptor antagonist (IL-l ra) and the release of 
the decoy IL-IRII, both of which possess anti-inflammatory properties by their ability 
to antagonize IL-1 activities. (Minty et al, 1993; de Waal Malefyt et al, 1993; Muzio et 
al, 1994; Colotta et al, 1994; Muzio et al, 1994; Cash et al, 1994; Vannier et al, 
1996) On the other hand, IL-10 and IL-13 analgesic effect was shown not to involve 
any significant role for endogenous opioids (Mariana et al, 2003). Many mechanisms 
might be involved in this process, one of which is the ability of both cytokines to inhibit 
the expression of iNOS leading to a decreased production of NO. This mechanism 
leads to an enhanced iron uptake by macrophages and, therefore, to a decrease in 
macrophage effector functions, of which one is IL-ip production. Surprisingly, and in 
contrast to IL-10, the injection of mice with IL-13, reduced the levels of IL-lp not only 
during the treatment period but this effect persisted till the end of the experiment. 
However, hyperalgesia was only reduced during the treatment period suggesting a role 
of another substance in mediating hyepralgesia. IL-6 seems to have no direct role in 
provoking hyperalgesia since, when IL-13 was injected, the levels of IL-6 were not 
reduced while hyperalgesia was reversed and after stopping the injection of IL-13, the 
levels of IL-6 were decreased while hyperalgesia was still observed. Therefore, IL-6 is 
not a hyperalgesic agent but it might be a part of the hyperalgesia molecular cascade 
either directly at early stages of the infection or by inducing (synergistically with IL-lp) 
the production of IL-2 (Houssiau et al., 1989). Thus, our results have demonstrated that 
the hypoalgesic effect of IL-13 is not mediated by its effect on the levels of IL-6 in the 
paws of mice infected with high dose of L. major and treated with IL-13. However, as 
mentioned previously, Silfversward et al. (2004) showed that IL-4/13 synergistically
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potentiates IL-1 and TNF-a induced secretion of IL-6 in human osteoblast-like cells. 
Our results showed that IL-13 has no major effect on the level of IL-6 in the paws of 
infected mice while at the same time the level of IL-1 p was significantly reduced. This 
suggests that IL-13 has a deeper impact on the level of TNF-a rather than IL-lp. 
Furthermore, the increased level of IL-6 at day 4, 6 and 21 post-infection in the paws of 
IL-13-treated mice whilst the level of IL-lp was reduced and the hyperalgesia was 
persistent, suggests that IL-6 is initially produced by macrophages and/or dendritic cells 
(no effect of IL-13 on IL-6 secretion by macrophages) and by Th2 cells starting day 4 
post-infection which leads to a high level of this cytokine. It is quite probable however, 
that at later stages the main source of IL-6 is Th2 cells which started to be differentiated 
during the first week of infection.
Taken together, our results suggest that BALB/c mice show an IL-ip- 
independent hyperagesia favouring a major role for the sympathomimetic amines, their 
production being stimulated by IL-8 which in its turn was stimulated by TNF-a (Cunha 
et al., 1992). This is in accordance with many studies stating that IL-13 induces the 
production IL-8 by human neutrophils (Girard et al., 1996). On the other hand, IL-13 
seems to reduce the levels of IL-lp by stimulating the production of another substance, 
most probably IL-4, which was not down-regulated throughout the whole experimental 
period and which is known to reduce the levels of IL-lp (Mariana et al., 2003) but not 
IL-8 (Cunha et al, 1991). This would suggest that IL-13 prevents the production of a 
factor that down-regulates IL-4, most probably IL-12 (or IFN-gamma) which always 
has the tendency to be secreted in the first few days of infection before either Thl or 
Th2 cells prevail. At day 7 post-infection, however, when IL-13 was no more injected 
and IL-12 was still produced, the level of IL-4 decreased. Thereafter, when Th2 cells
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became dominant (and therefore IL-12 level decreased) the level of IL-4 increased to 
become close to the control value. This suggests that IL-13 exerts this effect only during 
the period of treatment through inhibiting the production of IL-12. Conversely, IL-10 
was only able to reduce the levels of IL-lp during the treatment period, suggesting that 
this cytokine is not able to stimulate the secretion of IL-4 to the same extent as IL-13. 
Another possible scenario is that IL-13 can stimulate its own production and therefore 
inhibit the production of IL-12. This would favour a Th2 cell proliferation and result in 
an increase in the production of IL-13. Secreted IL-13 is able to down-regulate IL-ip 
but not TNF-a and/or IL-8 which could cause the observed hyperalgesia. It is worth 
noting that these conditions favour the dissemination of the parasite causing more 
production of TNF-a, mainly by mast cells.
On the other hand, and as assessed by the HP test, IL-13 was also more 
efficient than IL-10 in reducing the low dose L. wq/or-induced hyperalgesia during the 
period of treatment. Furthermore, the hypoalgesic effect of IL-13 was obvious in the 
Tail Flick test too. This hypoalgesic effect of IL-13 provides further evidence that 
similar pro-inflammatory substances were produced during the first two weeks of 
infection in both models. Interestingly, as in the high dose model, very low pain 
thresholds were observed after stopping the injections (at day 6) while the mice infected 
with low dose of the parasite, but non-treated with IL-13, showed increased latencies 
starting the second week of infection. This suggests that IL-13 caused a change in the 
course of infection which led to the persistence of the high level of some pro- 
inflammatory substances causing hyperalgesia. Here also, the level of IL-ip was 
reduced in parallel to the reduction in hyperalgesia due the injection of IL-13, indicating 
a possible role for this cytokine in early hyperalgesia and giving further evidence that
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IL-13 inhibits its production. The persistence of hyperalgesia while the level of IL-lp 
was decreased, however, suggests again that another factor plays a major role in 
inducing this hyperalgesia in an IL-1 p-independent fashion. TNF-a and/or IL-8 seem to 
be the best candidates, the effects of which lead to the production of sympathomimetic 
amines. Since IL-13 is known to inhibit both IL-lp and TNF-a but not IL-8, its 
hypoalgesic effect seems to be mediated by the inhibition of TNF-a during the period of 
injection with no later effect in evidence knowing that this latter cytokine is not only 
produced by macrophages (inhibited by IL-13) but by mast cells whose functions are 
most probably not affected by IL-13.
The results of this chapter have demonstrated that the hypoalgesic effect of IL- 
13 is not mediated by its effect on the levels of IL-6 in the paws of mice infected with 
low dose of L. major and treated with IL-13, since the level of IL-6 was significantly 
high when the hyperalgesia was reduced. However, an important role of IL-6 in 
hyperalgesia might be suspected since at days 13 and 21 post-infection, when 
hyperalgesia was still observed, the level of IL-6 in the infected paws of IL-13-treated 
mice was significantly higher than its level in the infected paws of IL-13-non-treated 
mice and that of the naïve mice which showed a reduced hyperalgesia. It is worth noting 
that at this time, the level of IL-lp was reduced in the paws of IL-13-treated mice. 
These results suggest that, in the low dose model, IL-13 plays an important role in 
driving the pathway of hyperalgesia through TNF-a which induces the production of 
IL-6 in an IL-1 p-independent pathway in addition to IL-8. IL-12, which is supposed to 
decrease IL-6, is inhibited by IL-13 which is in agreement with previous studies 
indicating that IL-13 potentiates the production of IL-6 in vivo (Di Santo et al., 1997).
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CHAPTER 5
THE EFFECT OF IL-10 AND IL-13 ON THE 
TH2/TH1 SWITCH
5.1. Introduction
A Thl mediated immune response is very important against intracellular 
pathogens such as Leishmania major (Collins and Kaufmarm, 2002; Scott and Grencis, 
2002). On the other hand, Th2 responses are important for the induction of humoral 
immunity, since they secrete cytokines involved in the activation and differentiation of 
B cells into antibody- secreting cells (Scott and Grencis, 2002). IL-10 inhibits the 
proliferation of Thl cells (Fiorentino et al., 1991) and IL-10 mRNA is detected in 
Leishmania mq/or-infected BALB/c mice but not in resistant mice (Heinzel et al., 
1991). Furthermore, whereas normal BALB/c mice develop progressive non-healing 
lesions, BALB/c mice lacking IL-10, control the disease progression and have relatively 
small lesions (Kane and Mosser, 2001). The high production of IL-10 early during 
infection in non-healer mice may contribute to driving the immune response towards a 
Th2 response (Chatelain et al., 1999).
IL-13 is made principally by Th2 cells and its functions are shown to 
contribute to the susceptibility to chronic leishmaniasis in mice (Brombacher, 2000). 
The over-expression of IL-13 in transgenic mice makes the normally resistant C57BL/6 
mouse strain susceptible to L. major infection even in the absence of IL-4 expression. 
This susceptibility correlates with a suppression of IL-12 and IFN-y expression. 
Furthermore, the IL-13-deficient BALB/c mice are resistant to L. major infection with 
an additive effect of deleting both IL-4 and IL-13 (Matthews et al., 2000).
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It is, therefore, of major interest to assess the role of both IL-10 and IL-13 in 
shaping the course of infection if present early in infection especially in BALB/c mice 
infected with low dose of Leishmania major which are suspected to become resistant to 
the parasite.
5.2. What Is the Effect of Leishmania major Infection on the Levels of IL-4?
IL-4 is produced by Th2 cells and acts as an autocrine growth factor for Th2 
cells (Fishman and Perelson, 1994). In leishmaniasis, the progression of the disease was 
associated with high level of IL-4 mRNA during the first 16 hours post-infection 
leading to the maturation of Th2 cells (Launois et al., 1998). This effect of IL-4 is 
suspected to depend on the suppression of IL-12RP2 expression on T cells (Himmelrich 
et al., 1998) and therefore rendering them unresponsive to IL-12 (Launois et al., 1995). 
Thus, although a Th2 response and mainly IL-4 were thought to be major factors needed 
for the exacerbation of cutaneous leishmaniasis, many studies have shown that IL-4 can 
enhance the production of IL-12 and therefore a Thl response (Biedermann et al., 
2001), and that a Th2 response can develop independently of IL-4 (Jones et al., 1998; 
Mohrs et al., 2000). These assays were performed to assess the effect of the infection 
with high dose and low dose of Leishmania major on the levels of IL-4 in the paws of 
BALB/c mice as an indication of the type of cells prevailing knowing that IL-4 is 
considered a typical representative of cytokines produced by Th2 cells.
5.2. i. Effect of Leishmania major Infection on the Levels of IL-4 in Mice Infected
with High Dose of Leishmania major
Since many contradictory studies have been published about the role of IL-4 in 
Leishmania wîq/or-induced inflammation (Kopf et al., 1996; Noben-Trauth et al., 1996;
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Mohrs et al., 2000), and in order to assess the effect the IL-10 and IL-13 in cutaneous 
leishmaniasis, we performed this assay to determine the level of IL-4 in the injected 
paws of BALB/c mice infected with high dose of Leishmania major. The intraplantar 
injection of a high dose of Leishmania major (2.5 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) caused no significant change in the levels of IL-4 in the injected 
hind paw except at days 4 and 7 post-infection where they decreased from 135.55 ± 
7.65 pg/hind paw in the untreated mice to 66.41 ± 8.74 pg/hind paw at day 4 post­
infection and 88.27 ± 10.29 pg/hind paw at day 7 post-infection in the infected mice, (p 
< 0.01 and 0.05 respectively) (Figure 5.1 A). Thereafter, the levels of IL-4 in the injected 
paws of infected mice returned to levels comparable with those in the paws of the 
untreated mice.
5.2.2. Effect o f Leishmania major Infection on the Levels o f IL-4 in Mice Infected 
with Low Dose o f the Parasite
Since we have shown previously that Leishmania major infection caused no 
significant increase in the level of IL-4 in the paws of mice infected with high dose of 
the parasite and since it has also been shown that IL-4 is not an indicator of 
susceptibility (Scott et al., 1996), we performed this assay to determine the level of this 
cytokine in BALB/c mice infected with low dose of Leishmania major and therefore 
suspected to become resistant to the parasite. The intraplantar injection of a low dose of 
Leishmania major (4x10^ promastigotes/50 pi Lock's medium/left hind paw) caused no 
significant change in the levels of IL-4 in the injected hind paw as compared to its level 
in the paws of untreated mice at any date post-infection (Figure 5. IB).
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Figure 5.1. The effeet of the injeetion of high dose (2.5 x 10 promastigotes/50 pi Lock's 
medium/left hind paw) (A) and low dose (4 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) (B) Leishmania major on the levels of IL-4 in the left (injected) paw at days 2, 4 ,7 , 13 and 
21 post infeetion.Each result is the mean of 5 mice ± SEM and the degree of significance was 
calculated with reference to untreated mice.
5.3. What Would Be the Effect of Interleukin-10 On the Levels of IL-4 In 
Leishmania ma/or-Induced Inflammation?
Since IL-10 plays an important role is shaping the course o f  infection by
127
driving the immune response toward a Th2 response (Chatelain et al., 1999) and since 
Thl cells inhibited by IL-10 retain the capacity to proliferate in the presence of IL-4 
(Fiorentino et al., 1989), we performed the assay to assess the effect of the daily 
injection (i.p.) of 15 ng of IL-10 for the first consecutive 6 days on the levels of IL-4 in 
the paws of mice, either non-infected or infected with high dose and low dose 
Leishmania major.
5.3.1. Effect of Interleukin-10 on the Levels of IL-4 in Non- Infected Mice
This assay was performed in order to discount the possible effect of IL-10 on 
the level of IL-4 in uninfected mice. Treatment with daily injections of IL-10 (15 ng 
i.p./mouse) for six consecutive days produced no significant change (p> 0.05) in the 
level of IL-4 in the paws of mice neither during the treatment period nor after it as 
shown in Figure 5.2 A.
5.3.2. Effect of Interleukin-10 on the Levels o f IL-4 in Mice Infected with High Dose 
of Leishmania major
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days produced, at day 2 post-infection, a significant increase in the levels of IL-4 in the 
injected paws of mice infected with high dose Leishmania major and treated with IL-10 
(197.97 ± 6.30 pg/hind paw) as compared to the levels of IL-4 in the paws of mice 
infected only with high dose of the parasite (127.42 ± 3.86 pg/hind paw) (p< 0.001). 
This increase reached a peak of 214.76 ± 12.044 pg/hind paw at day 7 post-infection 
which is significantly higher than the level of IL-4 in the injected paws of non-treated 
mice (p< 0.001).
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Figure 5.2. Effect of the daily intraperitoneal injection of IL-10 on the level of IL-4 in the paws 
of untreated mice (A) mice infected with high dose (2.5 x 106 promastigotes/50 pi Lock's 
medium/left hind paw) (B) and low dose (4 x 103 promastigotes/50 pi Lock's medium/left hind 
paw) (C) Leishmania major. Mice were injected with 15 ng of IL-10 (i.p.) for 6 consecutive 
days and the levels of IL-4 were assessed at days 2, 4 ,7 , 13 and 21 post-infeetion. Each result is 
the mean of 5 mice ± SEM and the degree of significance was calculated with reference to IL- 
10 non-treated mice.
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After that, the levels of IL-4 in the paws of all three groups of mice (namely 
untreated, infected and infected with IL-10 treatment) decreased to similar levels in all 
groups (p> 0.05 for all comparisons) (Figure 5.2B).
5.3.3. Effect o f Interleukin-10 on the Levels o f IL-4 in Mice Infected with Low Dose 
o f Leishmania major
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days produced a significant increase in the levels of IL-4 in the paws of IL-10 treated 
mice infected with low dose of Leishmania major (4 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) at 2 days post-infection (168.99 ± 6.43 pg/hind paw) in 
comparison to untreated mice and infected mice with no IL-10 treatment (p< 0.05) 
(Figure 5.2C). Thereafter, the level of IL-4 in the injected paws of IL-lO-treated mice 
decreased becoming similar to levels in the untreated mice at days 4 and 7 post­
infection and reaching a minimum of 73.54 ± 5.32 pg/hind paw by day 14. This level 
was significantly lower than the levels of IL-4 in the paws of untreated mice and mice 
infected with L. major but not treated with IL-10 (p< 0.01 and 0.05 respectively). The 
level of IL-4, by day 21 however, was not significantly different from the other groups 
(p> 0.05) (Figure 5.2C).
5.4. Does Interleukin-10 affect the Parasite Burden in Leishmania major Infected 
Paws in BALB/c Mice?
In order to assess the course of infection induced by the early presence of IL- 
10, these assays were performed to determine the effect of the daily injection (i.p.) of 15 
ng of IL-10 for the first 6 days on the parasite burden in the injected paws of mice, 
either infected with high dose or low dose Leishmania major.
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5.4.1. Effect o f Interleukin-10 on the Parasite Burden in Mice Infected with High 
Dose o f Leishmania major
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days showed no significant change in the parasite load in the injected paws of IL-lO- 
treated mice as compared to the IL-10-non-treated mice neither at day 2 nor at day 7 
post-infection (p> 0.05). However, at day 14 post-infection, the parasite load in the 
injected paws of IL-lO-treated mice increased to 7.27 ± 0.70 x 10^  parasites/hind paw as 
compared to 3.54 ± 0.62 x 10^  parasites/hind paw in the IL-10-non-treated infected mice 
(p< 0.05) (Figure 5.3A). The effect of IL-10 became more profound at day 21 post­
infection when the load in the injected paws of IL-lO-treated mice was to 14.14 ± 0.75 x 
10^  parasites/hind paw as compared to 5.75 ± 0.71 x 10^  parasites/hind paw in the IL- 
10-non-treated infected mice (p< 0.001) (Figure 5.3A).
5.4.2. Effect o f Interleukin-10 on the Parasite Burden in Mice Infected with Low 
Dose o f Leishmania major
Treatment with daily injections of IL-10 (15 ng i.p./mouse) for six consecutive 
days resulted in a significantly higher parasite load at all the time points studied in the 
injected paws of IL-lO-treated mice as compared to the IL-10-non-treated mice (p<
0.001) (Figure 5.3B).
5.5. Does the Increase of Parasite Burden Affect the Paws Thickness of 
Leishmania /wuyor-infected and IL-lO-treated BALB/c Mice?
Since IL-10 might shape the course of infection in leishmaniasis, we assessed 
the paw thickness of BALB/c mice injected with high and low dose of Leishmania 
major as an indicator of the extent of the inflammation response and therefore the 
progression of the disease as well as in infected mice treated with IL-10 as another sign
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of the type o f immune response prevailing.
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Figure 5.3. Effect o f the daily intraperitoneal injection o f IL-10 on the parasite burden in the 
paws o f mice infected with high dose (2.5 x 10  ^ promastigotes/50 pi Lock's medium/left hind 
paw) (A) and low dose (4 x 10  ^ promastigotes/50 pi Lock's medium/left hind paw) (B) 
Leishmania major. Mice were injected with 15 ng o f IL-13 (i.p.) for 6 consecutive days and the 
parasite loads were assessed at days 2, 4 ,7 , 13 and 21 post-infection. Each result is the mean o f 
5 mice ±  SLM and the degree o f significance was calculated with reference to IL-10 non-treated 
mice.
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5.5.L Effect o f High Dose Leishmania major on the Paws Thickness o f  Mice
The intraplantar injection of a high dose of Leishmania major (2.5 x 10^  
promastigotes/50 pi Lock's medium/left hind paw) caused a significant change in the 
paw thickness of the injected paw of infected mice starting at week 6 post-infection. 
Paw thickness increased from 2.64 ± 0.029 mm for the right non-injected paw to 3.051 
±0.16 mm for the injected paw (p< 0.05).
The paw thickness continued to increase throughout the period of the 
experiment reaching 5.65 ± 0.41mm at week 38 post-infection for the injected paw as 
compared to 2.74 ± 0.099 mm for the non-injected paw (p< 0.001) (Figure 5.4A).
5.5.2. Effect o f Low Dose Leishmania major on the Paws Thickness o f Mice
The intraplantar injection of low dose of Leishmania major (4 x 10^  
promastigotes/50 pi Lock's medium/left hind paw) caused no significant change in the 
injected paw thickness as compared to the non-injected paw throughout the whole 
experimental period (p> 0.05 in all cases) (Figure 5.4B).
5.5.5. Effect o f the Re-Injection o f High Dose o f Leishmania major on the Paws 
Thickness o f Mice Initially Infected with Low Dose o f  the Parasite
This test was performed to assess the course of infection, as to paw thickness, 
in mice infected initially with low dose of Leishmania major and re-infected with high 
dose of the parasite after 5 weeks. The intraplantar injection of high dose of Leishmania 
major (2.5 x 10^  promastigotes/50 pi Lock's medium/left hind paw) in the paws of mice 
previously infected with low dose of the parasite caused no significant change in the 
injected paw thickness of infected mice throughout the whole experimental period (38 
weeks) (Figure 5.4C).
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Figure 5,4. Effect of Leishmania major infection on the paw thickness in mice infected with 
high dose (2.5 xlO* promastigotes/50 pi Lock's medium/left hind paw) (A) low dose (4 x 10^  
promastigotes/50 pi Lock's medium/left hind paw) (B) low dose and then re-infected with high 
dose (C) of the parasite. Each result is the mean of 5 mice ± SEM and the degree of significance 
of the difference was calculated with reference to the non-injected paw.
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5.5.4, Effect o f Interleukin-10 on the Paw Thickness o f Mice Infected with Low 
Dose o f Leishmania major and then Re-Infected with High Dose
In order to detect any change in the course of infection induced by IL-10, this 
assay was performed to assess the effect of the daily injection (i.p.) of 15 ng of IL-10 on 
the paw thickness of mice re-infected with high dose of Leishmania major after 5 weeks 
of their initial infection with low dose of the parasite and therefore suspected to become 
resistant.
Treatment of mice, initially infected with low dose of Leishmania major, with 
daily injections of IL-10 resulted in no significant difference in the injected paw 
thickness of infected mice when re-injected with high dose of Leishmania major (2.5 x 
10^  promastigotes/50 pi Lock's medium/left hind paw) until week 30 post-infection 
(Figure 5.5). The paw thickness in IL-lO-treated mice then rose to 3.02 ± 0.13 mm 
which was significantly higher than the paw thickness of IL-lO-non-treated mice (2.52 
± 0.097 mm) (p< 0.05).
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Figure 5.5. Effect of the daily intraperitoneal injection of IL-10 on the paw thickness of mice
infected with low dose (4 x 103 promastigotes/50 pi Lock's medium/left hind paw) and then re­
injected with high dose (2.5 x 106 promastigotes/50 pi Lock's medium/left hind paw) 
Leishmania major. Mice were injected with 15 ng of IL-10 (i.p.) for 6 consecutive days and the 
paw thickness was recorded at weekly intervals post re-infection. Each result is the mean of 5 
mice ± SEM and the degree of significance of the difference was calculated with reference to 
the non-injected paw.
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As shown also in Figure 5.5, this increase in the thickness of infected paw of 
IL-lO-treated mice continued to rise to 4.01 ± 0.21 mm at week 38 as compared to the 
IL-lO-non-treated mice (2.51 ± 0.093 mm) (p< 0.01) (Figure 5.5).
5.6. What Would Be the Effect of Interleukin-13 on the Levels of IL-4 in 
Leishmania mayor-induced Inflammation?
lL-13 is very similar to lL-4 and contributes to the L. major susceptibility
phenotype in mice (Brombacher, 2000). However, it has been shown to act through an
lL-4 independent mechanism (Doherty et al., 1993; Kambayashi et al., 1996) and that
the over-expression of lL-13 in transgenic mice makes the normally resistant C57BL/6
mouse strain susceptible to L. major infection even in the absence of lL-4 expression.
Therefore, as a sign of a Th2 prevailing response, we performed those assays to assess
the effect of the daily injection (i.p.) of 15 ng of lL-13 for the first consecutive 6 days
on the levels of lL-4 in the paws of mice, either non-infected or infected with high dose
and low dose Leishmania major.
5.6.1. Effect o f IL-13 on the Levels o f IL-4 in Non- Infected Mice
This assay was performed in order to discount the possible effect of IL-13 on 
the level of lL-4 in uninfected mice. Treatment with daily injections of IL-13 (15 ng
i.p./mouse) for six consecutive days produced no significant change (p> 0.05) in the 
level of lL-4 in the paws of mice neither during the treatment period nor after it as 
shown in Figure 5.6A.
5.6.2. Effect o f IL-13 on the Levels o f IL-4 in Mice Infected with High Dose o f  
Leishmania major
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive
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days produced no major change in the level of IL-4 in the injected paws of IL-13-treated 
mice neither at day 2 nor day 4 post-infection as compared to the levels in the paws of 
untreated mice (p> 0.05). However, at day 4 post-infection, the level of lL-4 in the 
injected paws of IL-13-treated mice (133.21 ± 5.92 pg/hind paw) was significantly 
higher than the level in the injected paws of infected mice not treated with IL-13 (66.41 
± 8.74 pg/hind paw) (p< 0.01). At day 6 post-infection, when level of lL-4 in the 
injected paws of IL-13-non-treated mice was still significantly lower than the control 
value (88.23 ± 10.29 pg/hind paw as compared to 135.55 ± 7.65 pg/hind paw), the 
injected paws of IL-13-treated paws also showed a significant decrease the level of lL-4 
as compared to the control value to become 60.30 ± 7.86 pg/hind (p< 0.01) (Figure 
5.6B). After that, the levels of lL-4 in paws of all three groups of mice were veiy 
similar to each other (p> 0.5 for all cases) (Figure 5.6B).
5.6.3. Effect o f IL-13 on the Levels o f IL-4 in Mice Infected with Low Dose o f  
Leishmania major
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive 
days produced a significant decrease in the levels of lL-4 in the paws of the treated mice 
infected with low dose of Leishmania major (4 x 10^  promastigotes/50 pi Lock's 
medium/left hind paw) at day 4 post-infection (46.90 ± 5.95 pg/hind paw) as compared 
to the level of this cytokine both in the injected paws of the L. major infected mice 
(135.75 ± 5.19 pg/hind paw) as well as of untreated mice (p< 0.001) (Figure 5.6C). 
However, the level of lL-4 in the injected paws of IL-13-treated mice increased back to 
similar levels to the control value and that in the injected paws of IL-13-non-treated 
mice at day 7 post-infection (p> 0.05).
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Figure 5.6. Effect of the daily intraperitoneal injection of IL-13 on the level of IL-4 in the paws 
of untreated (A) mice infected with high dose (2.5 x 106 promastigotes/50 pi Lock's 
medium/left hind paw) (B) and low dose (4 x 103 promastigotes/50 pi Lock's medium/left hind 
paw) (C) Leishmania major. Mice were injected with 15 ng of IL-13 (i.p.) for 6 consecutive 
days and the levels of IL-4 were assessed at days 2, 4 ,7 , 13 and 21 post-infeetion. Each result is 
the mean of 5 mice ± SEM and the degree of significance was calculated with reference to IL- 
13 non-treated mice.
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IL-13 had a profound effect on the level of IL-4 in the injected paws of mice at 
later stages of infection reducing it from 116.35 ± 7.31 pg/hind paw and 122.34 ± 12.34 
pg/hind paw to 71.57 ± 3.76 pg/hind paw and 84.38 ±8.16 pg/hind paw at days 14 and 
21 post-infection respectively, the p values being less than 0.05 as compared with IL- 
13-non-treated infected mice (Figure 5.6C).
5.7. Does Interleukin-13 affect the Parasite Burden in Leishmania major Infected 
Paws in BALB/c Mice?
In order to assess the course of infection induced by the early presence of IL-
13, these assays were performed to determine the effect of the daily injection (i.p.) of 15
ng of IL-13 for the first 6 days on the parasite burden in the injected paws of mice,
either infected with high dose or low dose Leishmania major.
5.7.1, Effect o f Interleukin-13 on the Parasite Burden in Mice Infected with High 
Dose o f Leishmania major
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive
days resulted in significant increases in the parasite load in the injected paws of IL-13-
treated mice compared to the infected mice not treated with IL-13 at all time points
(day 2 p< 0.05, day 7 p< 0.001, day 14 p< 0.05 and day 21 p< 0.001) (Figure5.7A).
5.7.2. Effect o f Interleukin-13 on the Parasite Burden in Mice Infected with Low 
Dose o f Leishmania major
Treatment with daily injections of IL-13 (15 ng i.p./mouse) for six consecutive
days produced a significant increase in the parasite load in the injected paws of IL-13-
treated mice [(2.46 ± 0.38) x 10^  parasites/hind paw] as compared to the IL-13-non-
treated mice at all time points (day 2 p< 0.01, day 7 p< 0.05, day 14 p< 0.01 and day 21
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p< 0 .001) (Figure 5.7B).
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Figure 5.7. Effect of the daily intraperitoneal injection of IL-13 on the parasite burden in the 
paws of mice infected with high dose (2.5 x 106 promastigotes/50 pi Lock's medium/left hind 
paw) (A) and low dose (4 x 103 promastigotes/50 pi Lock's medium/left hind paw) (B) 
Leishmania major. Mice were injected with 15 ng of IL-13 (i.p.) for 6 consecutive days and the 
parasite loads were assessed at days 2, 4 ,7 , 13 and 21 post-infection. Each result is the mean of 
5 mice ± SEM and the degree of signifrcanee was calculated with reference to IL-13 non-treated 
mice.
5.8. Effect of Interleukin-13 on the Paw Thickness of Mice Infected with Low 
Dose of Leishmania major and Then Re-Infected with High Dose
This assay was performed to assess the effect o f  the daily injection (i.p.) o f 15
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ng of IL-13 for the first 6 days on the course of infection with respect to paw thickness 
(as an indicator of the extent of the inflammatory response) in mice infected initially 
with low dose of Leishmania major and re-infected with high dose of the parasite after 5 
weeks. The treatment of mice, initially infected with low dose of Leishmania major, 
with daily injections of IL-13 (15 ng i.p./mouse) for the first six days resulted in a 
significant increase in the injected paw thickness of infected mice when re-injected with 
high dose of Leishmania major (2.5 x 10^  promastigotes/50 pi Lock's medium/left hind 
paw) starting at week 24 post-infection when the paw thickness in IL-13-treated mice 
became 2.74 ± 0.052 mm (p< 0.01) (Figure 5.8). This increase in the thickness of 
infected paw of IL-13-treated mice continued to rise and was still significantly different 
at week 30 post-infection (3.5 ± 0.13 mm) as compared to the IL-13-non-treatd mice 
(2.47 ± 0.063 mm) (p< 0.001).
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Figure 5.8. Effect of the daily intraperitoneal injection of IL-13 on the paw thickness of mice 
infected with low dose (4 x 103 promastigotes/50 pi Lock's medium/left hind paw) and then re­
injected with high dose (2.5 x 106 promastigotes/50 pi Lock's medium/left hind paw) 
Leishmania major. Mice were injected with 15 ng of IL-13 (i.p.) for 6 consecutive days and the 
paw thickness was recorded at weekly intervals post re-infection. Each result is the mean of 5 
mice ± SEM and the degree of significance of the difference was calculated with reference to 
the non-injected paw.
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The difference in the paw thickness between the two groups increased so that 
at week 38 post-infection the IL-13-treated mice showed a paw thickness of 4.67 ± 0.23 
mm as compared to 2.48 ± 0.078 mm for the IL-13-non-trated mice with a p value less 
0.001 (Figure 5.8).
5.9. Discussion
5.9.1, Do IL-6 and/or IL-4 Play An Important Role in Shaping the Course o f  
Leishmania major-induced Inflammation?
Since the results in Chapter 4 indicate that both IL-10 and IL-13 cause a 
change in the course of infection, a number of parameters were assessed to determine 
whether the balance of the T helper cell response (Th2/Thl) in mice infected with low 
dose of Leishmania major was altered, due to the induced change of the cytokine milieu 
during the first six days of infection. These parameters were the level of IL-6 (as 
measured in chapter 4) and IL-4, the parasite burden in the injected paws of mice and 
their paw thickness.
IL-6 is known to be an inducer of IL-4 and therefore might be assessed as an 
indication of a Th2 response. Thus, it was crucial to determine the role of IL-6 in 
Leishmania /wq/or-induced inflammation in both high and low dose models and then to 
investigate the effect of IL-10 and IL-13 on the level of IL-6 in both models. Although 
IL-6 is suggested to favour the outgrowth of Th2 cells (Rincon et al., 1997), it might 
have many diverse effects on Cutaneous Leishmaniasis; for example, IL-6 is required 
for the development of a Thl response (Yamamoto et al., 2000). Thus, IL-6 is required 
for the development of both a Thl and Th2 response (Samoilova et al., 1998). Our data 
in chapter 4 provides evidence that IL-6 is not able by itself to direct the outcome of the 
disease since in both, the high and the low dose models, the levels of IL-6 increased
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significantly during the first 6 days and then gradually decreased to become very close 
to the level of IL-6 in the paws of naïve mice. This suggests that IL-6, in a specific 
cytokine milieu, might play a role in inducing other Th2 cytokines most probably IL-13, 
in the absence of Thl cells cytokines such as IL-12 and/or IFN-y. In this chapter, our 
study proceeded to determine any effect of the early rise of IL-6 on the level of IL-4 in 
the paws of infected mice and therefore to assess the general role of IL-4 in shaping the 
course of infection. Many previous studies stated that IL-4, produced by Th2 cells, is 
associated with susceptibility to L. major infection in BALB/c mice (Reiner and 
Locksley 1995; Kopf et al., 1996). When BALB/c mice were infected by Leishmania 
major, a burst of IL-4 mRNA was observed in the draining lymph nodes after 16 hours 
(Launois et al., 1995) which is essential for a second burst of IL-4 mRNA fi’om day 5 
onward. Studies revealed that the first burst of IL-4 caused a state of insensitivity of 
CD4^ T cells to IL-12 (Launois et al., 1997b). This state of unresponsiveness to IL-12 
was due to a rapid down-regulation of the p2-chain of the IL-12 receptor (Himmelrich 
et al., 199%).
These data confirm that the basic determinant for resistance to Leishmania 
major is the ability of the host to remain responsive to IL-12 and to maintain expression 
of the P2 chain of the IL-12 receptor for more than 16 to 48 hours post infection. 
Therefore, when T cells become unresponsive to IL-12 the host will develop a Th2 
response which leads to susceptibility. In contrast with the previous studies, our data has 
shown that the high dose of L. major did not lead to an increase in the level of IL-4 but 
on the contrary, a decrease in its level was evident at days 4 and 6 post-infection. 
However, our results might correlate with many studies suggesting that IL-4 receptor-a 
(IL-4Ra) rather than IL-4 itself plays a pivotal role in shaping the course of infection 
since IL-4Ra-deficient animals were shown to be more resistant to L. major than IL-4-
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deficient mice (Mohrs et al. 1999; Noben-Trauth et al. 1999) and IL-4-defîcient mice, 
on a BALB/c background, remained susceptible to L. major (Noben-Trauth et al. 1996). 
Furthermore, the expression of IL-4 receptor on infected Langerhans cells increases in 
susceptible mice but not on those from resistant mice. Thus, this increase of IL-4 
receptor expression of infected Langerhans cells in addition to the inhibition of induced 
IL-12 response of these cells may contribute to the development of Th2 cells and 
therefore susceptibility to Leishmania major (Moll et al., 2002).
The early decrease in the level of IL-4, therefore, might have no major effect 
on the progression of the disease which is in accordance with the study performed by 
Lang et al. (2003) which suggested that there is no relationship between early 
production of IL-4 by CD4 T cells and susceptibility to L. major in BALB/c mice 
suggesting that other unidentified factors might be responsible for the non-healing 
lesion. On the other hand, this decrease might help the development of a Th2 response 
since a previous study showed that IL-4, if present during the initial activation of DCs, 
instructs them to produce IL-12 and thus promoting Thl response (Biedermann et al., 
2001; Alexander and Biyson, 2005) and, however, if present later, during the period of 
T cell priming, IL-4 induced Th2 differentiation and progressive leishmaniasis in 
resistant mice (Biedermann et al., 2001). The maintenance of constant level of IL-4 in 
the paws of low dose of Leishmania 7wq/or-infected mice, however, favours the first 
hypothesis which suggests that this cytokine plays no significant role in shaping the 
course of infection.
In addition, the finding that IL-4/13-deficient animals have enhanced resistance 
to infection reinforces the notion that these cytokines act in combination to produce 
robust Th2 responses and inhibit Thl differentiation and parasite killing (Matthews et 
al. 2000). Furthermore, IL-4 and IL-13 which are homologous proteins are the only two
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cytokines that have been shown to physiologically activate the STAT6 transcription 
factor (Hou et al., 1994; Rolling et al., 1996; Izuhara et al., 1996).
Our data suggests, therefore, that IL-4 does not play a crucial role in the 
development of Th2 response in cutaneous leishmaniasis which is in line with previous 
studies (Dent et al., 1999); however, Leishmania major infection can stimulate the 
production of IL-4 receptors which might be activated by other factors, most probably 
IL-13 which in its turn causes a down-regulation of the p2-chain of the IL-12 receptor. 
Consequently, T cells become unresponsive to IL-12 and the host will develop a Th2 
response pathways in an IL-4 independent pathway leading to susceptibility.
5.9.2. Does the Early Injection o f Interleukin-10 Affect the Course o f Leishmania 
major-induced Inflammation?
IL-10 is a regulatory cytokine which suppresses Thl responses by acting on 
macrophages/monocytes, and also natural killer cells (Moore et al., 1993) and appears 
to be important in preventing Delayed Type Hypersensitivity responses (Fiorentino et 
al., 1989; Mosmann and Moore, 1991). It is mainly produced by Th2 cells, but can also 
be produced by other cells such as macrophages (Lang et al., 2002). IL-10 has been 
shown to be an important mediator of susceptibility to Leishmania major in mice (Kane 
and Mosser, 2001; Noben-Trauth et al., 2003). Also, recently it has been shown that IL- 
10 leads to higher parasite persistence in a resistant mouse model of Leishmania major 
infection (Da Costa et al, 2002) and plays an important role in rendering the Thl 
responses ineffective at controlling infection in the skin (Anderson et al., 2005).
In chapter 4 we suggest that IL-10 is able to induce the production of IL-6. 
However, our results show that IL-10 has no direct effect on the level of IL-6 in the 
paws of high dose Leishmania wq/'or-infected mice during the first four days of
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infection. But, the cumulative effect of IL-10 caused a significant increase at day six 
post-infection suggesting that specific factors were able to inhibit IL-lO-induced IL-6 
production during the first few days of infection. One of the suspected factors is IL-12 
and/or IFN-y, which continued to be secreted after stopping the injection of IL-10 at day 
six post^infection and therefore inhibiting IL-6 production till day 13 post-infection. 
Thereafter, when a Th2 response becomes prevalent, the low level of IL-12 was not able 
anymore to suppress IL-6 production and that is why the level of IL-6 is significantly 
increased at day 21 post-infection. Thus, IL-10 is suggested to induce, in a cumulative 
manner, either its own production and/or the production of IL-13 which inhibit the 
production of IL-12 which is always produced in Leishmania wq/or-induced 
inflammation early during the infection. In addition, macrophages stimulated by the 
immune complexes formed by the combination of IgG with the parasite were shown to 
produce IL-10 and thus inducing both macrophages (Sutterwala et al., 1999) and 
dendritic cells (Anderson et al., 2004) to switch off their production of IL-12.
As in the case of the high dose model, IL-10 had no significant effect on the 
levels of IL-6 in the low dose-infected paws of mice during the first four days of 
infection. However, at day 6 post-infection, the effect of IL-10 started to be significant 
in increasing the levels of IL-6 as compared both to the naïve values and the levels of 
this cytokine in the injected paws of mice infected with low dose of L. major. These 
results suggest that IL-10 had a crucial effect on the cytokine milieu in the injected 
paws which makes it very similar to that of the high dose model suggesting a change in 
the whole course of infection. The only difference between the two models is at day 13 
post-infection when the level of IL-lO-induced IL-13 was more efficient in reducing the 
level of IL-12 and/or or IFN-y leading to an increased level of IL-6.
In order to determine whether this IL-lO-induced increase in the level of IL-6
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is due to a change in the course of infection we assessed the effect of IL-10 on the level 
of IL-4 in the injected paws of mice treated with this cytokine as a sign of an enhanced 
Th2 response in the high dose model and an inhibited Th2/Thl switch in the low dose 
model, knowing that we showed here that IL-4 were not increased neither in the low nor 
in the high dose model. Our results have shown that IL-10 induced the production of IL- 
4 only during the period of treatment. However, another parameter measured indicated a 
more exacerbated disease, namely the parasite load in the infected paws of mice. This 
was significantly increased at days 14 and 21 post-infection due to the effect of IL-10. 
This can be explained by the fact that Leishmania major infection causes NK cells to 
produce IFN-y after activation by both parasite antigens and IL-12, which in turn 
prevented parasite dissemination (Laskay et al., 1995). In addition, inducible nitric 
oxide synthase (N0S2) seems to play a critical role in the containment of the parasite, 
since C57BL/6 mice with a disrupted N0S2 gene (N0S2'^'), allowed rapid 
dissemination of the parasites and developed disease, even with 500-2000 parasites 
(Laskay et al., 1995; Diefenbach et al., 1998). However, in susceptible mice, the early 
production of IL-12 is accompanied with production of cytokines such as TGF-P, IL-4 
and IL-10 that inhibit IL-12 function (Solbach and Laskay, 1998). Furthermore, it has 
been shown that treatment with anti-IL-10-receptor antibody enhances early parasite 
clearance in ear-vaccinated mice (Tabbara et al., 2005). Therefore, the cumulative effect 
of IL-10 leads to a decreased IFN-y production by NK cells through inhibiting IL-12 
function and consequently N0S2 induction will be reduced causing the dissemination of 
the parasite. In addition, CD40-CD40 ligand-mediated signaling on induction of the 
microbicidal effect was shown to depend on host genotype and the cytokine milieu. 
Since increased IL-10 production was restricted to susceptible macrophages, increased 
parasite replication was observed in those mice. This was demonstrated by preventing
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the replication by a neutralizing anti-IL-10 antibody. However, in the presence of IFN- 
gamma, CD40 engagement induced Leishmania killing by macrophages (Nunes et al., 
2005).
The effect of IL-10 is even more profound in changing the course of infection 
in the low dose model, since the parasite load in the paws on IL-lO-treated infected 
mice were significantly higher than that of the IL-lO-non-treated infected mice starting 
day two post-infection. This could be because the level of Th2 cells-produced cytokines 
(mainly IL-4) is not high enough to inhibit IL-12 and IFN-y activity. The effect of IL- 
10 in inhibiting the activity of those substances was so obvious, even at day 2 post­
infection and throughout the whole experimental period. Furthermore, IL-10 is known 
to inhibit the production of NO, which in addition to the above factors leads to the 
dissemination of the parasite. Also, the persistence of Leishmania major is related to the 
continuous expression of N0S2 in the draining lymph nodes and in the site of infection. 
Persistence of Leishmania major was found to be within macrophages and dendritic 
cells but not in granulocytes and endothelial cells and 60-70 % of those macrophages 
and dendritic cells lacked expression of N0S2 (Stenger et al., 1996). Therefore, we 
suggest that IL-10 is able to change the whole course of infection since, even after 
stopping IL-10 injection, the mice were not able to inhibit the parasite dissemination. In 
order to further clarify the status of the suspected Th2/Thl switch in the low dose 
model, we assessed the paw thickness of the IL-lO-treated infected mice after re­
injecting them with high dose of Leishmania major. Our results provide clear evidence 
that injecting BALB/c mice with IL-10 for the first six days of infection can cause a 
drastic effect on the course of infection so that when the mice were re-injected with high 
dose of Leishmania major after 5 weeks of the first injection, they were not able the 
control the dissemination of the parasite. This led to the appearance of a lesion 30
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weeks post-infection suggesting that the suspected Th2/Thl switch was impaired by the 
early presence of IL-10. This effect doesn’t seem to involve IL-4 which showed no 
significant increase except at day 2 post low dose infection. This suggests that another 
factor, most probably IL-13 was prevailing at the time of the high dose infection 
inhibiting the production of Thl cells cytokines such as IL-12 and/or INF-y.
5.9.3. Is Interleukin-13 as Efficient as Interleukin-10 in Shaping the Course o f  
Leishmania major-induced Inflammation?
Interleukin-13 (EL-13) which belongs to the T helper 2 cytokine family shares a 
number of structural characteristics and immunomodulatory functions with IL-4 and 
belongs to the same a-helix protein family (De Saint et al., 1998; McKenzie et al., 
1998; McKenzie et al., 1999). IL-4 and IL-13 can cross-compete for the IL-4Ra, but 
only IL-4 binds directly to this receptor chain (Zurawski et al., 1993). The evidence for 
this came from competition studies between IL-4 and IL-13 and the ability of IL-4 
antagonists to inhibit both IL-4 and IL-13-induced responses on the same cell type 
(Kruse et al., 1992; Aversa al, 1993). Matthews et al. (2000) demonstrated for the 
first time that IL-13 is an important component for the generation and maintenance of 
immune responses to L. major infection. The over expression of IL-13 resulted in 
C57BL/6 mice becoming susceptible to L. major, and significantly, this was 
independent of IL-4 expression. Conversely, IL-13-deficient BALB/c mice were 
resistant to L. major and BALB/c mice doubly deficient for IL-4 and EL-13 were 
significantly more resistant to L. major infection than either of the single cytokine- 
deficient animals or even the resistant C57BL/6 mouse strain (Matthews et al., 2000). 
Our results provide further evidence that the presence of IL-13 during the first six days 
of infection can affect the cytokine milieu and therefore, the course of infection since in
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both, high and low dose models, the level of IL-6 were significantly increased during 
the period of treatment. However, in the low dose model, the level of IL-6 was 
increased even after stopping the injection of IL-13. The most probable explanation for 
this difference is that IL-13 has been shown to inhibit the production of IL-12 by 
macrophages and to inhibit L. major parasite killing in vitro (Oswald et al., 1992; 
Doherty et al., 1993). Since IL-6 is mainly produced by macrophages, however, the 
increased production of IL-12 in the low dose model counteracts the effect of IL-13 in 
inhibiting the functions of macrophages and therefore their production of IL-6 lasts for a 
longer period of time. Furthermore, the suspected newly differentiated Th2 might be 
contributing to the high level of IL-6 (Rincon et al., 1997; Diehl and Rincon 2002).
These results suggest that IL-6 among other factors, favours the development 
of Th2 cells (Rincon et al., 1997). Consequently, the high level of other Th2 cells 
differentiation factors induced by the high dose of Leishmania major, such as IL-13, 
down-regulates IL-6 production; however, in the low dose model, where Thl cytokines 
prevail early in the infection, IL-6 is up-regulated for a longer period of time. This was 
further supported by assessing the effect of IL-13 on the level of IL-4 in the paws of 
infected mice. In the high dose model, although IL-13 had no significant effect on the 
level of IL-4 in the injected paws in BALB/c mice, it inhibited its down-regulation at 
day 4 post-infection suggesting that IL-13 prevents the production of the factor that 
down-regulates IL-4, most probably IL-12 (or IFN-gamma) which always has the 
tendency to be secreted in the first few days of infection before either Thl or Th2 cells 
prevail. However, at day 7 post-infection, when IL-13 was no longer injected and IL-12 
was still produced, the level of IL-4 decreased. Thereafter, when Th2 cells became 
dominant (and therefore IL-12 levels decreased) the level of IL-4 increased to become 
close to the control value. This suggest that IL-13 exerts this effect only during the
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period of treatment through inhibiting the production of IL-12 and that IL-4 has no 
major role in shaping the course of infection.
On the other hand, since IL-12 is produced in higher amounts in mice infected 
with low dose of Leishmania major, IL-13 was not able to significantly reverse its effect 
in decreasing the level of IL-4 at day 4 post-infection. The cumulative effect of IL-13, 
however, seems to inhibit the effect of IL-12 at day 7 post-infection; but thereafter, in 
the absence of IL-13, IL-12 was able to inhibit the production of IL-4 throughout the 
whole experimental period. Other Th2 cell differentiation factors might be up-regulated 
and, as mentioned above, IL-6 seems to play an important role at this level in addition 
to a suspected up-regulation of IL-13. Actually, IL-13 reduces IL-4 production at early 
time points and enhances IL-12 production and NK cell cytolytic activity (Flesch et al., 
1997).
To further assess the effect of IL-13 on the course of Leishmania major- 
induced inflammation, we determined the parasite burden in the paws of infected mice. 
Our data are in agreement with previous studies indicating that IL-13 inhibits the 
production of nitric oxide by LPS-activated mouse macrophages and mesangial cells, 
and inhibits superoxide anion production by human monocytes (Doherty et al., 1993; 
Doyle al., 1994; Sozzani et al., 1995; Saura et al.; 1996; Wright et al., 1997). In 
addition, IL-13 may be acting directly on the macrophage by inhibiting parasite killing 
mechanisms. It is also possible that the decrease in IL-12 production may be due to the 
increased parasite load suppressing normal macrophage function (Matthews et al. 
2000). The inhibition of NO production by IL-13 causes an enhanced iron uptake by 
mouse macrophages, which leads to a decrease in macrophage effector functions (Weiss 
et al., 1997). This might explain the increased dissemination of the parasite, since the 
containment functions of the host are consequently greatly reduced. On the other hand,
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IL-13 had a drastic effect on the parasite burden in the paws of mice infected with low 
dose of Leishmania major and this observation is in accordance with many studies 
suggesting that IL-13 enhances the production of Macrophage-Derived Chemokine 
(MDC) by monocytes and dendritic cells. This production may contribute to the 
amplification of Th2 responses since MDC preferentially attracts Th2 cells (Andrew et 
fl/., 1998; Bonecchi 1998).
Once again, to further assess the course of infection of these mice, the paws 
thickness was measured after re-injecting them with high dose of Leishmania major. 
We demonstrate here that IL-13 had a similar effect to IL-10 but seemed to be more 
powerful in shaping the course of infection, since a lesion appeared 24 weeks post­
infection which correlates with the high parasite burden in the injected paws of mice.
In conclusion, we demonstrate in this chapter that the hypoalgesic dose of both 
IL-10 and IL-13 can cause a drastic change in the cytokine milieu and therefore, shapes 
the course and outcome of Leishmania major-màuceà inflammation in BALB/c mice. 
This effect is suspected to be mainly due to the ability of those two cytokines to favour 
a Th2 response through up-regulation other factors which we suggest to be IL-13 itself, 
IL-5 or IL-9.
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CHAPTER 6 
CONCLUSIONS
In conclusion, our study is in agreement with many previous studies but raises 
many other points that need further investigation and will be discussed below.
In accordance with previous studies performed by Kanaan et al. (2000), our 
results showed that the infection with a high dose of L. major produced a significant 
decrease in thermal pain thresholds accompanied by an up-regulation in the levels of IL- 
Ip in the infected paws of BALB/c mice, providing a further evidence for a direct role 
of this cytokine in hyperalgesia. On the other hand, our results also showed that the 
infection with a low dose of L. major produced a significant decrease in the pain 
thresholds during the first two weeks, similar to that observed in the mice injected with 
high dose of the parasite accompanied by a significant increase in the levels of IL-lp in 
the injected hind paw. Thus, IL-lp might be mediating a complex signalling cascade 
within the spinal cord involving a secondary production of nitric oxide, bradykinin or 
prostaglandins (Cunha et al., 2005) in addition to substance P (Malcangio et al., 1996) 
and COX-2 (Samad et al., 2002). Therefore an assessment of the level of those 
substances in the injected paws as well as in the spinal cord of both models would be 
required to unveil the details of this process.
Although the levels of IL-6 were up-regulated during the first few days of 
infection with L. major in both high and low dose models, IL-6 doesn’t seem to play a 
direct role in hyperalgesia at later stages of infection, suggesting that IL-6, among other 
factors, may play a role in the induction of hyperalgesia via the stimulation of IL-ip 
production. It would be of major importance, therefore, to assess the effect of both, IL-
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IR antagonist and anti-IL-6 antibody to provide further information about the molecular 
pathway leading to the L. major-màuceà hyperalgesia.
Our data has also shown that IL-10 has a hypoalgesic effect on L. major- 
induced hyperalgesia, restricted to the period of injection and accompanied by a 
significant reduction in the levels of IL-ip. We would expect IL-10 to exert its 
hypoalgesic effect through reducing the levels of IL-1 p and/or C0X2 and iNOS, since 
IL-10 is known to play a role in the suppression of the synthesis of IL-lp and TNF-a 
(Mariana et al., 2003) and the expression of COX-2 and iNOS (Bogdan et al., 1991; De 
Waal Malefyt et al., 1991; Fiorentino et ai., 1991; Oswald et al., 1992; Poole et al., 
1995; Niiro et al., 1995; Niiro et al, 1997). This requires further investigation involving 
the effect of IL-10 on the levels of PGE2, COX-2 and iNOS during L. major infection. 
Our results also suggest that IL-10 has no significant effect on the levels of IL-6 in the 
infected paws of mice infected with high dose of L. major, even during the period of 
treatment and that it has no direct effect on hyperalgesia.
IL-10 was also shown to have a similar hypoalgesic effect in the low dose 
model accompanied by a significant reduction in the" levels of IL-ip in the infected 
paws of mice. Interestingly, the low pain thresholds observed during this early period of 
infection were not reversed in mice treated with IL-10 suggesting that IL-10 caused a 
change in the course of infection leading to the persistence of the high level of some 
pro-inflammatory substances causing hyperalgesia: mainly IL-ip whose levels in the 
infected paws were increased after stopping the injection of IL-10. This hypothesis 
might be assessed by injecting the mice with IL-lRa either to confirm or to deny any 
direct role for IL-ip in this observed hyperalgesia.
Although IL-6 doesn’t seem to play a crucial role in the hyperalgesia observed
154
during early stages of infection, the IL-lO-induced increase in the level of IL-6 is in 
parallel to the induced persistent low pain thresholds, suggesting a possible role for IL-6 
either in the hyperalgesia itself or in the cytokine milieu favouring this hypemociceptive 
status. This increase in the level of IL-6 is hypothesised to be due to the ability of IL-10 
to enhance the production of IL-13 (Mariana et al., 2003) suggesting a future study 
involving the assessment of the effect of IL-10 on the level of IL-13 in the infected 
paws of mice during L. major-induced inflammation.
As in the case of IL-10, IL-13 had a significant hypoalgesic effect in the treated 
mice during the injection period accompanied by a significant reduction in the level of 
IL-lp. However and in contrast to IL-10, the injection of mice with IL-13, reduced the 
levels of IL-lp not only during the treatment period but this effect persisted until the 
end of the experiment. Hyperalgesia was only reduced, however, during the treatment 
period suggesting a role for another substance in mediating hyperalgesia. Since IL-13 
did not affect the levels of IL-6 in the paws of infected mice while hyperalgesia was 
reversed after stopping the injection of IL-13, no major role for IL-6 in hyperalgesia can 
be suspected. This suggests that IL-13 might have a deeper impact on the level of TNF- 
a  rather than IL-ip or IL-6 and therefore requiring the assessment of the levels of TNF- 
a  in the infected paws during L. major-induced inflammation.
Taken together, our results suggest that BALB/c mice might show an IL-ip- 
independent hyperalgesia which favours a major role for the sympathomimetic amines, 
their production being stimulated by IL-8 which in its turn was stimulated by TNF-a. 
Therefore, it would be of major interest to study the time course of the levels of IL-8 
and sympathomimetic amines in the paws of mice during L. major infection.
IL-13 was also more efficient than IL-10 in reducing the low dose L. major-
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induced hyperalgesia during the period of treatment. Interestingly, and as in the high 
dose model, very low pain thresholds were observed after stopping the injections, 
suggesting that IL-13 caused a change in the course of infection. The level of IL-lp 
was decreased, however, not only during the treatment period, but throughout the the 
whole experiment suggesting that another factor plays a major role in inducing this 
hyperalgesia in an IL-1 P-independent mechanism. TNF-a and/or IL-8 seem to be the 
best candidates leading to the production of sympathomimetic amines.
Our results have shown also that the hypoalgesic effect of IL-13 is not 
mediated by its effect on the levels of IL-6 in the paws of mice infected with low dose 
of L. major. However, an important role of IL-6 in hyperalgesia might be suspected at 
later stages of the infection. These results suggest that in the low dose model, IL-13 
plays an important role in driving the pathway of hyperalgesia through TNF-a which 
induces the production of IL-6 in an IL-1 P-independent pathway in addition to IL-8. 
Therefore, it would be of considerable interest to assess the effect of IL-10 and IL-13 on 
the level of TNF-a, IL-8 and IL-13 itself in the paws of infected mice in addition to the 
effect of anti-IL-6 antibody, in order to determine the effect of IL-10 and IL-13 on the 
molecular pathway of L. major-mduced inflammation in BALB/c mice.
Since both IL-10 and IL-13 seem to cause a change in the course of infection,
three parameters were assessed to determine whether the suspected Th2/Thl switch in
mice infected with low dose of L. major was altered due to the induced change of the
cytokine milieu during the first six days of infection. These parameters included the
level of IL-6 and IL-4 and the parasite burden in the injected paws of mice in addition to
their paw thickness. Our data provides evidence that IL-6 is not able, by itself, to direct
the outcome of the disease, since in both the high and the low dose models, the levels of
IL-6 increased significantly during the first 6 days and then gradually decreased. This
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suggests that IL-6, in a specific cytokine milieu, might play a role in inducing other Th2 
cytokines (most probably IL-13) in the absence of Thl cells cytokines such as IL-12 
and/or IFN-y. We therefore suggest the assessment of the time course of the production 
of these cytokines especially in the presence of anti-IL-6 antibody in order to get a 
clearer picture about the interplay of cytokines during L. major infection.
In contrast to many previous studies, our data has shown that the high dose of 
L. major did not lead to an increase in the level of IL-4 which might correlate with some 
studies suggesting that IL-4 receptor-a (IL-4Ra) rather than IL-4 itself plays a pivotal 
role in shaping the course of infection (Mohrs et al. 1999; Noben-Trauth et al., 1999). 
Our data, therefore, suggests that IL-4 doesn’t play a crucial role in the development of 
Th2 response in cutaneous leishmaniasis which is in agreement with previous studies 
(Dent et al., 1999). L. major infection can stimulate the production of IL-4 receptors 
which might be activated by other factors, most probably IL-13 which in its turn causes 
a down-regulation of the (32-chain of the IL-12 receptor. Consequently, T cells become 
unresponsive to IL-12 and the host will develop a Th2 response leading to 
susceptibility. Here also the assessment of the level of IL-13 in the paws o f L. major- 
infected mice seems to be important for the determination of that factor.
Our results have shown that IL-10 has no direct effect on the level of IL-6 in 
the paws of high dose L. wq/or-infected mice and therefore, IL-6 has no direct effect on 
hyperalgesia suggesting once again, that IL-6, among other factors, may play a role in 
the induction of hyperalgesia. However, the effect of IL-10 was significant in increasing 
the levels of IL-6 (after stopping IL-10 treatment) in the injected paws of mice infected 
with low dose of L  major suggesting that IL-10 had a crucial effect on the cytokine 
milieu and therefore on the course of infection. Thus, the factor which was suspected to 
inhibit the production of IL-6, was itself suppressed by the early presence of IL-10. One
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of the suspected factors is IL-12 and/or IFN-y, whose levels time course should be 
assessed through L. major infection.
Evidence for this suspected inhibition in the Th2/Thl switch induced by the 
early treatment with IL-10 was further provided through the observation that IL-10 
induced the production of IL-4 only during the period of treatment, and that the parasite 
load in the paws on IL-lO-treated infected mice were significantly higher than that of 
the IL-lO-non-treated, infected mice. This might be due to the increased production of 
Th2 cells-produced cytokines, such as IL-4 during early infection and most probably IL- 
13 at later stages. Furthermore, our results provide clear evidence that injecting 
BALB/c mice with IL-10 for the first six days of infection can cause a drastic effect on 
the course of infection so that when the mice were re-injected with high dose of L. 
major after 5 weeks of the first injection, they were not able the control the 
dissemination of the parasite. This led to the appearance of a lesion 30 weeks post­
infection suggesting that the suspected Th2/Thl switch was impaired by the early 
presence of IL-10. This effect doesn’t seem to involve IL-4 which showed no 
significant increase, suggesting that another factor, most probably IL-13 was prevailing 
at the time of the high dose infection inhibiting the production of Thl cells cytokines 
such as IL-12 and/or INF-y.
Our results give further evidence that the presence of IL-13 during the first six 
days of infection can affect the cytokine milieu and therefore, the course of infection 
since in both high and low dose models, the levels of IL-6 were significantly increased 
during the period of treatment. However, in the low dose model, the level of IL-6 was 
increased even after stopping the injection of IL-13 due to its ability to inhibit the 
production of IL-12 by macrophages which is suspected to enhance L. major parasite 
killing (Oswald et al., 1992; Doherty et al., 1993).
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Our data also suggests that in both the high and low dose models, IL-13 had no 
major effect on the level of IL-4 in the injected paws in BALB/c mice, and therefore, 
other Th2 cell differentiation factors might be up-regulated and as mentioned above, IL- 
13 might be a good candidate.
Our data indicates that IL-13 can lead to an increased parasite burden, 
especially in the low dose model giving further evidence for the Th2/Thl switch 
inhibition and this was further supported by the increased paws thickness of mice 
initially infected with low dose of L. major and treated with IL-13 and then re-injected 
with high dose of the parasite.
Finally, we conclude that the hypoalgesic dose of both IL-10 and IL-13 can 
cause a drastic change in the cytokine milieu and therefore, shaping the course and 
outcome of L. wq/or-induced inflammation in BALB/c mice. This effect is suspected to 
be mainly due to the ability of those two cytokines to favour a Th2 response through up- 
regulation other factors which we suggest to be IL-13 itself, IL-5 or IL-9. These data 
provide new insights into the course of L  major infection confining a less direct role for 
IL-lp and IL-6 in hyperalgesia and for IL-4 in shaping the course of infection. 
Therefore, these data may contribute to medical research involving the treatment of L. 
wq/or-induced hyperalgesia and the use of IL-10 or IL-13 in a clinical setting for 
persons infected with this parasite, since both are seen, to drastically alter the course of 
infection.
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